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ABSTRACT The four possible isomers of each of 3-methoxy- and 3-benzyloxyestra-1,3,5(10)-
trien-17-ols (5–8 and 9–12) were converted through 16-p-tosyloxymethyl- or 16-bromomethyl 
derivatives into their 3-methoxy- and 3-benzyloxy-16-azidomethylestra(1,3,5(10)-triene 
derivatives (13–16 and 17–20). The regioselective Cu(I)-catalyzed 1,3-dipolar cycloaddition of 
these compounds with different terminal alkynes afforded novel 1,4-disubstituted diastereomers 
(21a–f, 22a–f, 23a–f, 24a–f and 25a–f, 26a–f, 27a–f, 28a‒f). The antiproliferative activities of 
the structurally related triazoles were determined in vitro with the microculture tetrazolium assay 
on four malignant human cell lines of gynecological origin (Hela, SiHa, MCF-7 and MDA-MB-
231). 
 
 
Keywords: 3-methoxy- and 3-benzyloxy-16-azidomethylestra-1,3,5(10)-triene-17-ols; 1,3-dipolar 
cycloaddition, 4
’
substituted-steroid triazoles; cytotoxic activity 
 
1.  Introduction 
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Among the hybrid natural products, hybrids of steroid frameworks have attracted great attention 
due to significant biological properties and numerous therapeutic effects of the basic compound. 
Steroids have become ideal synthons for the development of diverse conjugates due to their rigid 
framework and potential for varying levels of functionalization, broad biological activity profile 
and their ability to penetrate the cell membranes and bind to specific hormonal receptors [1-3]. 
The place, length and orientation of the linkers between the two parts of the hybrids  
stems unequivocally from the method of their synthesis. The literature provides a large number of 
methods to introduce the linker onto the sterane skeleton. The effect of the length and character 
of the linker are very often discussed [4]. However, only limited information is available with 
respect to the steric effect of the linkers on biological properties. As concerns the 16-substituted 
estrogenes, usually the 16α-substituted-17β-hydroxy compounds have been studied. The 
biological activity has generally not been studied for the whole isomer series [5]. 
 In the 16-substituted 17-hydroxysteroids, the two chiral centres permit four 
stereochemical modifications. Since availability of the complete series of isomers would permit a 
number of interesting comparative examinations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
We have previously reported the preparation and configurational assignment of the four 
possible isomers of the 3-methoxy- and 3-benzyloxy-16-hydroxymethyl-estra-1,3,5(10)-trien-17-
ol derivatives (5a–8a and 9a–12a) [6‒8]. Treatment of 3-methoxy- and 3-benzyloxyestra-16-
hydroxymethylidene-estra-1,3,5(10)-trien-17-ones (2 and 4). The C-16 formyl compounds were 
reduced with KBH4 in methanol yielding a mixture of three (5a–7a and 9a–11a) of the four 
possible isomers of each of the 3-methoxy- and 3-benzyloxy-16-hydroxymethylestra-1,3,5(10)-
trien-17-ol isomers in a ratio of 50:45:5 in 94% yield [6,8  ]. The fourth isomers (8a and 12a) 
were prepared from 16α-acetoxymethyl-17β-toluenesulfonate mixed esters 6d and 10d, 
respectively, by neighbouring group participation during solvolysis in aqueous AcOH. The 
structures of the isomers were confirmed unambiguously by their IR, 
1
H and 
13
C NMR spectra 
(Scheme 1) [7,8]. 
 
(Scheme 1) 
 
The four 3-methoxy- and 3-benzyloxy-estra-1,3,5(10)-trien-17-ol isomers (5a–8a and 9a–
12a) are suitable starting materials to prepare 16-triazolyl-methyl derivatives. Triazoles are 
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attractive units because of their stability against metabolic degradation and their ability to form 
hydrogen bonds. The Cu(I)-catalysed azide–alkyne cycloaddition (CuAAC) is a facile method of 
wide applicability for the introduction of a triazole moiety into natural products [9]. In these 
compounds the triazole heterocycles and their substituted derivatives are connected through a 
methylene linker to the sterane skeleton. The 16-p-tolylsulfonyloxymethyl ester [5,6] and 16-
bromomethyl derivatives [10] of the 16-hydroxymethyl starting materials were used for 
substitution reaction with NaN3 in N,N-dimethylformamide to have the desired 3-methoxy- and 
3-benzyloxy-16-azidomethylestra-1,3,5(10)-trien-17-ols (13–16 and 17–20). From these azido 
compounds several D-ring-substituted estrane derivatives containing a 1,2,3-triazole ring were 
synthesized by the reaction of 13–16 and 17–20 with various terminal alkynes through the use of 
the “click” chemistry approach to deliver compounds 21a–e, 22a–e, 23a–e, 24a–e, 25a–e, 26a–e, 
27a–e and 28a–e. 
 
2. Experimental 
2.1. General 
 
Melting points (Mp) were determined on a Kofler block and are uncorrected. Specific rotations 
were measured in CHCl3 (c 1) at 20 
○
C with a POLAMAT-A (Zeiss-Jena) polarimeter and are 
given in units of 10
–1 
deg cm
2
 g
–1
. Elementary analysis data were determined with a Perkin-Elmer 
CHN analyzer model 2400. The reactions were monitored by TLC on Kieselgel-G (Merck Si 254 
F) layers (0.25 mm thick); solvent systems (ss): (A) diisopropyl ether, (B) 
acetone/toluene/hexane (30:35:35 v/v). The spots were detected by spraying with 5% 
phosphomolybdic acid in 50% aqueous phosphoric acid. The Rf values were determined for the 
spots observed by illumination at 254 and 365 nm. Flash chromatography: silica gel 60, 40–63 
m. All solvents were distilled prior to use. NMR spectra were recorded on a Bruker DRX 500 
and Bruker Ascend 500 instrument at 500 (
1
H NMR) or 125 MHz (
13
C NMR). Chemical shifts 
are reported in ppm (δ scale) and coupling constants (J) in Hertz. For the determination of 
multiplicities, the J-MOD pulse sequence was used. 
 
2.2. 3-Methoxy- and 3-benzyloxy-16-azidomethylestra-1,3,5(10)-trienes (13–16 and 17–20) 
General procedure 
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Compounds 5b–8b [5,6] (4.70 g, 10 mmol) or 9c–12c [] (4.55 g, 10 mmol) were dissolved in 
N,N-dimethylformamide (100 ml) and then NaN3 (2.6 g) was added. The mixture was stirred for 
12 h at 80 
o
C, then poured into water (500 ml). The precipitate separating out was filtered off and 
subjected to chromatographic separation with CH2Cl2/hexane in different ratios. 
 
2.2.1. 3-Methoxy-16-azidomethyl-estra-1,3,5(10)-trien-17-ol (13) 
Compound 5b (470 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The 
crude product was chromatographed on silica gel with CH2Cl2/hexane (1:3 v/v) to yield pure 13 
(318 mg, 93%). Mp 134135 oC; Rf = 0.65 (ss A); [α]D
20
 = + 80 (c 1 in CHCl3). (Found C, 70.23; 
H, 8.05. C20H27N3O2 (341.45) requires C, 70.35; H, 7.97%). 
1H NMR (δ, ppm, CDCl3): 0.82 (s, 
3H, 18-H3), 2.87 (m, 2H, 6-H2), 3.32 (dd, 1H, J = 12.5 Hz, J = 7.5 Hz, 16a-H2), 3.61 (dd, 1H, J = 
12.5 Hz, J = 7.5 Hz, 16a-H2), 3.78 (s, 3H, 3-OCH3), 3.87 (d, 1H, J = 10.0 Hz, 17-H), 6.64 (d, 1H, 
J = 2.5 Hz, 4-H), 6.72 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.20 (d, 1H, J = 8.5 Hz, 1-H). 
13
C 
NMR (δ, ppm, CDCl3): 12.2 (C-18), 26.3, 27.5, 29.7, 30.4, 37.7, 38.2, 40.2, 44.0, 44.3 (C-13), 
49.0, 53.4 (C-16a), 55.2 (3-OCH3), 81.5 (C-17), 111.6 (C-2), 113.9 (C-4), 126.2 (C-1), 132.5 (C-
10), 137.9 (C-5), 157.7 (C-3). 
  
2.2.2. 3-Methoxy-16-azidomethylestra-1,3,5(10)-trien-17-ol (14) 
Compound 6b (470 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The 
crude product was chromatographed on silica gel with CH2Cl2/hexane (1:3 v/v) to yield pure 14 
(287 mg, 84%). Mp 8586 oC; Rf = 0.62 (ss A); [α]D
20
 = + 48 (c 1 in CHCl3). (Found C, 70.42; H, 
7.65. C20H27N3O2 (341.45) requires C, 70.35; H, 7.97%). 
1H NMR (δ, ppm, CDCl3): 0.84 (s, 3H, 
18-H3), 2.86 (m, 2H, 6-H2), 3.43 (d, 1H, J = 7.5 Hz, 17-H), 3.48 (dd, 2H, J = 6.5 Hz, J = 3.5 Hz, 
16a-H2), 3.78 (s, 3H, 3-OCH3), 6.63 (s, 1H, 4-H), 6.72 (dd, 1H, J = 6.5 Hz, J = 2.0 Hz, 2-H), 7.20 
(d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, CDCl3): 11.8 (C-18), 26.1, 27.2, 28.0, 29.7, 36.6, 
38.5, 43.6, 43.9, 44.2 (C-13), 48.5, 55.2 (3-OCH3), 55.6 (C-16a), 85.1 (C-17), 111.5 (C-2), 113.8 
(C-4), 126.3 (C-1), 132.4 (C-10), 137.8 (C-5), 157.5 (C-3). 
 
2.2.3. 3-Methoxy-16-azidomethylestra-1,3,5(10)-trien-17-ol (15) 
Compound 7b (470 mg, 1 mmol) were used for the synthesis as described in Section 2.2. The 
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crude porduct was chromatographed on silica gel with CH2Cl2/hexane (1:3 v/v) to yield pure 15 
(275 mg, 80%). Mp 9698; oC; Rf = 0.60 (ss A); [α]D
20
 = + 68 (c 1 in CHCl3). (Found C, 70.26; 
H, 8.15. C20H27N3O2 (341.45) requires C, 70.35; H, 7.97%). 
1H NMR (δ, ppm, CDCl3): 0.76 (s, 
3H, 18-H3), 2.86 (m, 2H, 6-H2), 3.43 (dd, 2H, J = 7.5 Hz, J = 3.0 Hz, 16a-H2), 3.61 (s, 1H, 17-H), 
3.78 (s, 3H, 3-OCH3), 6.64 (d, 1H, J = 2.5 Hz, 4-H), 6.72 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 
7.22 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, CDCl3): 17.7 (C-18), 25.9, 27.9, 29.8, 30.3, 
31.9, 38.6, 43.3, 45.0 (C-13), 48.9, 55.2 (3-OCH3), 55.6 (C-16a), 83.0 (C-17), 111.5 (C-2), 113.8 
(C-4), 126.3 (C-1), 132.4 (C-10), 137.9 (C-5), 157.5 (C-3). 
 
2.2.4. 3-Methoxy-16-azidomethylestra-1,3,5(10)-trien-17-ol (16) 
Compound 8b (470 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The 
crude product was chromatographed on silica gel with CH2Cl2/hexane (1:3 v/v) to yield pure 16 
(283 mg, 86%). Mp 118120 oC; Rf = 0.65 (ss A); [α]D
20
 = + 34 (c 1 in CHCl3). (Found C, 70.55; 
H, 7.78. C20H27N3O2 (341.45) requires C, 70.35; H, 7.97%). 
1H NMR (δ, ppm, CDCl3): 0.80 (s, 
3H, 18-H3), 2.87 (m, 2H, 6-H2), 3.35 (dd, 1H, J = 12.0 Hz, J = 6.0 Hz, 16a-H2), 3.53 (dd, 1H, J = 
12.0 Hz, J = 9.5 Hz, 16a-H2), 3.78 (s, 3H, 3-OCH3), 3.84 (d, 1H, J = 6.0 Hz, 17-H), 6.63 (d, 1H, J 
= 2.5 Hz, 4-H), 6.72 (dd, 1H, J = 8.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, 
CDCl3): 17.3 (C-18), 26.1, 28.0, 29.2, 31.3, 39.1, 40.5, 43.6, 46.4 (C-13), 47.0, 52.4 (C-16a), 
55.2 (3-OCH3), 79.9 (C-17), 111.6 (C-2), 114.0 (C-4), 126.3 (C-1), 132.7 (C-10), 137.9 (C-5), 
157.6 (C-3). 
 
2.2.5. 3-Benzyloxy-16-azidomethylestra-1,3,5(10)-trien-17-ol (17) 
Compound 9c (455 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The 
crude product was chromatographed on silica gel with CH2Cl2/hexane (1:1 v/v) to yield pure 17 
(250 mg, 59%). Mp 115117 oC; Rf = 0.45 (ss A). (Found C, 74.55; H, 7.64. C26H31N3O2 
(417.54) requires C, 74.79; H, 7.48%). 
1H NMR (δ, ppm, CDCl3): 0.82 (s, 3H, 18-H3), 2.86 (m, 
2H, 6-H2), 3.33 (dd, 1H, J = 12.0 Hz, J = 7.5 Hz, 16a-H2), 3.60 (dd, 1H, J = 12.5 Hz, J = 7.5 Hz, 
16a-H2), 3.87 (d, 1H, J = 9.5 Hz, 17-H), 5.04 (s, 2H, Bn-H2), 6.73 (s, 1H, 4-H), 6.79 (d, 1H, J = 
8.0 Hz, J = 2.0 Hz, 2-H), 7.21 (d, 1H, J = 8.0 Hz, 1-H), 7.32 (t, 1H, J = 7.5 Hz, 4’-H), 7.39 (t, 2H, 
J = 7.5 Hz, 3’-H and 5’-H), 7.44 (d, 2H, J = 7.5 Hz, 2’-H and 6’-H). 13C NMR (δ, ppm, CDCl3): 
12.2 (C-18), 26.2, 27.5, 29.7, 30.3, 37.6, 38.1, 40.1, 43.9, 44.2 (C-13), 48.8 (C-16), 53.3 (C-16a), 
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69.9 (Bn-CH2), 81.5 (C-17), 112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.3 (C-2’ and C-6’), 127.8 
(C-4’), 128.5 (C-3’ and C-5’), 132.7 (C-10), 137.3 (C-1’), 137.9 (C-5), 156.8 (C-3). 
 
2.2.6. 3-Benzyloxy-16-azidomethylestra-1,3,5(10)-trien-17-ol (18) 
Compound 10c (455 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The 
 crude product was chromatographed on silica gel with CH2Cl2/hexane (3:1 v/v) to yield pure 18 
(254 mg, 61%). Mp 7577 oC; Rf = 0.40 (ss A). (Found C, 74.87; H, 7.32. C26H31N3O2 (417.54) 
requires C, 74.79; H, 7.48%). 
1H NMR (δ, ppm, CDCl3): 0.84 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 
3.44 (t, 1H, J = 8.0 Hz, 17-H), 3.48 (m, 2H, 16a-H2), 5.04 (s, 2H, Bn-H2), 6.73 (s, 1H, 4-H), 6.79 
(d, 1H, J = 8.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (t, 1H, J = 7.0 Hz, 4’-H), 7.39 (t, 2H, 
J = 7.0 Hz, 3’- and 5’-H), 7.44 (d, 2H, J = 7.0 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 11.8 
(C-18), 26.1, 27.2, 27.9, 29.7, 36.6, 38.5, 43.6, 43.9, 44.2 (C-13), 48.6 (C-16), 55.6 (C-16a), 69.9 
(Bn-CH2), 85.1 (C-17), 112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 
128.5 (C-3’ and -5’), 132.7 (C-10), 137.3 (C-1’), 137.9 (C-5), 156.8 (C-3). 
 
2.2.7. 3-Benzyloxy-16-azidomethyl-estra-1,3,5(10)-trien-17-ol (19) 
Copound 11c (455 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The crude 
product was chromatographed on silica gel with CH2Cl2/hexane (3:1 v/v) to yield pure 19 (23. 
mg, 40%). Mp. 134-136 
o
C. Rf = 0.38 (ss A). (Found C, 74.92; H, 7.37. C26H31N3O2 (417.54) 
requires C, 74.79; H, 7.48%). 
1H NMR (δ, ppm, CDCl3): 0.84 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 
3.43 (d, 2H, J = 8.0 Hz, 17-H), 3.48 (t, 2H, J = 6.5 Hz, 16a-H2), 5.04 (s, 2H, Bn-H2), 6.73 (s, 1H, 
4-H), 6.79 (d, 1H, J = 8.0 Hz, 2-H), 7.22 (d, 1H, J = 8.0 Hz 1-H), 7.33 (d, 1H, J = 7.0 Hz, 4’-H), 
7.39 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.44 (d, 2H, J = 7.0 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, 
CDCl3): 11.8 (C-18), 26.1, 27.2, 28.0, 29.7, 36.6, 38.4, 43.5, 43.9, 44.1 (C-13), 48.5 (C-16), 55.6 
(C-16a), 69.9 (Bn-CH2), 85.1 (C-17), 112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 
127.8 (C-4’), 128.5 (C-3’ and -5’), 132.7 (C-10), 137.3 (C-1’), 137.9 (C-5), 156.7 (C-3).  
 
2.2.8. 3-Benzyloxy-16-azidomethyl-estra-1,3,5(10)-trien-17-ol (20) 
Compound 12c (455 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The 
crude was chromatographed on silica gel with CH2Cl2/hexane (1:1 v/v) to yield pure 20 (330 mg, 
79%). Mp 9092 оC. Rf = 0.45 (ss A). (Found C, 74.68; H, 7.55. C26H31N3O2 (417.54) requires C, 
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74.79; H, 7.48%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.71 (m, 2H, 6-H2), 3.35 (dd, 
1H, J = 12.0 Hz, J = 6.5 Hz, 16a-H2), 3.52 (dd, 1H, J = 12.0 Hz, J = 6.5 Hz, 16a-H2), 3.84 (d, 1H, 
J = 5.0 Hz, 17-H), 5.04 (s, 2H, Bn-H2), 6.73 (s, 1H, 4-H), 6.79 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-
H), 7.22 (d, 1H, J = 8.5 Hz, 1-H), 7.33 (t, 1H, J = 7.5 Hz, 4’-H), 7.39 (t, 2H, J = 7.5 Hz, 3’- and 
5’-H), 7.44 (d, 2H, J = 7.5 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 17.2 (C-18), 26.0, 27.9, 
29.0, 29.7, 31.2, 38.9, 40.4, 43.5, 46.3 (C-13), 46.8 (C-16), 52.2 (C-16a), 69.9 (Bn-CH2), 79.7 (C-
17), 112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -
5’), 132.8 (C-10), 137.3 (C-1’), 138.0 (C-5), 156.7 (C-3).  
 
2.3. General procedure for the synthesis of triazoles (21a–e, 22a–e, 23a–e, 24a–e, 25a–e, 26a–e, 
27a–e, and 28a–e) 
3-Methoxy-16-azidomethylestra-1,3,5(10)-trien-17-ol isomers (13–16) (342 mg, 1 mmol) or 3-
benzyloxy-16-azidomethylestra-1,3,5(10)-trien-17-ol isomers (17–20) 418 mg, 1 mmol) were 
dissolved in CH2Cl2 (20 ml), then CuI (19 mg, 0.10 mmol), Et3N (0.2 ml, 2 mmol) and the 
appropriate terminal alkynes (2 mmol) were added. The mixtures were stirred under reflux for 24 
h, then diluted with water (30 ml) and extracted with CH2Cl2 (2 × 30 ml). The combined organic 
phases were dried over Na2SO4 and evaporated in vacuo. The crude products were purified by 
flash chromatography using CH2Cl2/ethyl acetate in different ratios. 
 
2.3.1. 3-Methoxy-16β-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-
ol (21a) 
Compound 13 (342 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
CH2Cl2/hexane (3:1 v/v) to yield pure 21a (210 mg, 51%) as a white solid. Mp: 189191 
о
C; Rf = 
0.44 (ss B). (Found C, 73.84; H, 7.98. C25H33N3O2 (407.55) requires C, 73.68; H, 8.16%). 
1
H 
NMR (δ, ppm, CDCl3): 0.80 (s, 3H, 18-H3), 0.83 (s, 2H, cyclopropyl-H2), 0.94 (s, 2H, 
cyclopropyl-H2), 2.72 (d, 1H, J = 7.0 Hz, 1”-H), 2.84 (m, 2H, 6-H2), 3.77 (s, 3H, 3-OCH3), 3.93 
(d, 1H, J = 9.5 Hz, 17-H), 4.21 (dd, 1H, J = 13.0 Hz, J = 6.0 Hz, 16a-H2), 4.62 (t, 1H, J = 8.0 Hz, 
16a-H2), 6.62 (s, 1H, 4-H), 6.71 (d, 1H, J = 8.5 Hz, 2-H), 7.20 (d, 1H, J = 8.5 Hz, 1-H), 7.29 (s, 
1H, 5’-H). 13C NMR (δ, ppm, CDCl3): 6.7 (C-1”), 7.68 (C-2” and -3”),12.3 (C-18), 26.2, 27.4, 
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29.7, 30.8, 37.5, 38.0, 41.4, 43.8, 44.3 (C-16a), 48.7, 51.7 (C-13), 55.2 (3-OCH3), 80.7 (C-17), 
111.5 (C-2), 113.8 (C-4), 126.3 (C-1), 132.4 (C-10), 137.8 (C-5), 157.5 (C-3).  
 
2.3.2. 3-Methoxy-16β-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-
ol (21b) 
Compound 13 (342 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
CH2Cl2 to yield pure 21b (370 mg, 85%) as a white solid. Mp: 191192 
о
C; Rf= 0.46 (ss B). 
(Found C, 74.62; H, 8.42. C27H37N3O2 (435.60) requires C, 74.45; H, 8.56%). 
1H NMR (δ, ppm, 
CDCl3): 0.79 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.19 (s, 1H, 1”-H), 3.77 (s, 3H, 3-OCH3), 3.94 
(d, 1H, J = 9.5 Hz, 17-H), 4.24 (d, 1H, J = 8.0 Hz, 16a-H2), 4.65 (s, 1H, 16a-H2), 6.62 (s, 1H, 4-
H), 6.71 (d, 1H, J = 8.5 Hz, 2-H), 7.20 (d, 1H, J = 8.5 Hz, 1-H), 7.34 (s, 1H, 5’-H). 13C NMR (δ, 
ppm, CDCl3): 12.3 (C-18), 25.1 (C-3” and -4”), 26.2, 27.4, 29.7 (C-2” and 5”), 30.8, 33.2, 36.7, 
37.5, 38.0, 42.4 (C-16a), 43.8, 44.3 (C-13), 48.7, 51.8, 55.2 (3-OCH3), 62.1 (C-16), 80.7 (C-17), 
111.5 (C-2), 113.7 (C-4), 126.3 (C-1), 132.4 (C-10), 137.8 (C-5), 157.4 (C-3). 
 
2.3.3. 3-Methoxy-16β-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-
ol (21c) 
Compound 13 (342 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 21c (370 mg, 82%) as a white solid. Mp: 189190 
о
C; Rf= 0,40 (ss B). (Found C, 74.92; H, 8.55. C28H41N3O2 (449.63) requires C, 74.80; H, 8.74%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.84 (m, 2H, 6-H2), 3.77 (s, 3H, 3-OCH3), 3.94 
(d, 1H, J = 9.5 Hz, 17-H), 4.24 (m, 1H, 16a-H2), 4.65 (m, 1H, 16a-H2), 6.62 (s, 1H, 4-H), 6.71 (d, 
1H, J = 8.5 Hz, 2-H), 7.20 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (s, 1H, 5’-H). 13C NMR (δ, ppm, 
CDCl3): 12.3 (C-18), 26.0, 26.1 (C-2” and -6”), 26.2, 27.4, 29.7, 30.8, 33.0, 37.5, 38.0, 41.4 (C-
1”), 43.8, 44.3 (C-13), 48.3, 55.2 (3-OCH3), 62.1, 80.7 (C-17), 111.5 (C-2), 113.7 (C-4), 126.3 
(C-1), 132.4 (C-10), 137.8 (C-5), 157.4 (C-3). 
 
2.3.4. 3-Methoxy-16β-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-ol 
(21d) 
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Compound 13 (342 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 21d (368 mg, 83%) as a white solid. Mp: 232234 
о
C; Rf= 0.35 (ss B). (Found C, 75.98; H, 7.36. C28H33N3O2 (443.58) requires C, 75.81; H, 7.50%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.73 (m, 2H, 6-H2), 3.68 (s, 3H, 3-OCH3), 3.79 
(d, 1H, J = 10.0 Hz, 17-H), 4.20 (t, 1H, J = 13.5 Hz, 16a-H2), 4.63 (dd, 1H, J = 13.5 Hz, J = 4.5 
Hz, 16a-H2), 6.59 (s, 1H, 4-H), 6.67 (d, 1H, J = 8.5 Hz, 2-H), 7.16 (d, 1H, J = 8.5 Hz, 1-H), 7.32 
(t, 1H, J = 7.5 Hz, 4”-H), 7.44 (t, 2H, J = 7.5 Hz, 3”- and 5”-H), 7.85 (d, 2H, J = 7.5 Hz, 2”- and 
6”-H), 8.60 (s, 1H, 5’-H). 13C NMR (δ, ppm, CDCl3): 12.4 (C-18), 25.8, 26.9, 29.1, 30.0, 36.9, 
37.8, 40.4, 43.3, 43.7 (C-13), 47.8, 52.3 (C-16a), 54.8 (3-OCH3), 79.5 (C-17), 111.4 (C-2), 113.3 
(C-4), 121.5 (C-5’), 124.5 (C-2” and -6”), 126.0 (C-1), 127.6 (C-4”), 127.8 (C-3” and -5”), 130.9 
(C-1”), 132.0 (C-10), 137.3 (C-5), 146.0 (C-4’), 156.9 (C-3). 
 
2.3.5. 3-Methoxy-16β-(4’-nitro-benzoyloxymethyl-1’H-1’,2,’3’-triazol-1’-yl)methylestra-
1,3,5(10)-trien-17β-ol (21e) 
Compound 13 (342 mg, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 410 mg) were used for 
the synthesis as described in Section 2.3. The crude product was chromatographed on silica gel 
with ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 21e (475 mg, 86%) as a yellow solid. Mp: 
134135.5 оC; Rf= 30 (ss B). (Found C, 66.12; H, 6.08. C30H34N4O6 (546.61) requires C, 65.92; 
H, 6.27%). 
1H NMR (δ, ppm, CDCl3): 0.73 (s, 3H, 18-H3), 2.70 (m, 2H, 6-H2), 3.66 (s, 3H, 3-
OCH3), 4.18 (dd, 1H, J = 13.5 Hz, J = 11.5 Hz, 16a-H2), 4.58 (dd, 1H, J = 13.5 Hz, J = 4.5 Hz, 
16a-H2), 5.02 (d, 1H, J = 4.5 Hz, 17-H), 5.44 (s, 2H, 4’-H2), 6.55 (d, 1H, J = 1.5 Hz, 4-H), 6.63 
(dd, 1H, J = 8.5 Hz, J = 2.0 Hz, 2-H), 7.12 (d, 1H, J = 8.5 Hz, 1-H), 8.16 (d, 2H, J = 8.5 Hz, 3”- 
and 5”-H), 8.31 (t, 3H, J = 8.5 Hz, 2”- and 6”-H, 5’-H). 13C NMR (δ, ppm, CDCl3): 12.3 (C-18), 
25.8, 26.9, 29.1, 30.0, 36.9, 37.8, 40.4, 43.3, 43.7 (C-13), 47.8, 52.2 (C-16a), 54.7 (3-OCH3), 
58.7 (4’-CH2), 79.5 (C-17), 111.3 (C-2), 113.3 (C-4), 123.8 (C-2” and -6”), 125.1 (C-5’), 126.0 
(C-1), 130.6 (C-3” and -5”), 131.9 (C-10), 134.7 (C-1”), 137.2 (C-5), 141.0 (C-4”), 150.2 (C-4’), 
156.9 (C-3), 163.9 (C=O). 
 
2.3.6. 3-Methoxy-16β-(4’-hydroxymethyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (21f) 
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Compound 13 (274 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from a mixture of ethyl 
acetate/hexane to afford 21f (171 mg, 86%) as a white crystalline material. Mp: 194195 оC; Rf= 
0.25 (ss B). (Found C, 69.23; H, 8.04. C23H31N3O3 (397.51) requires C, 69.49; H, 7.86%). 
1
H 
NMR (δ, ppm, DMSO-d6): 0.76 (s, 3H, 18-H3), 2.71 (m, 2H, 6-H2), 3.68 (s, 3H, 3-OCH3), 3.76 
(d, 1H, J = 5.5 Hz, 17-H), 4.14 (t, 1H, J = 12.5 Hz, 16a-H2), 4.49 (m, 3H, 4’-H2 and 16a-H2), 
5.03 (d, 1H, J = 3.5 Hz, 17-OH), 5.15 (brs, 1H, CH2-OH), 6.59 (s, 1H, 4-H), 6.66 (d, 1H, J = 8.5 
Hz, 2-H), 7.16 (d, 1H, J = 8.5 Hz, 1-H), 7.99 (s, 1H, 5’-H). 13C NMR (δ, ppm, DMSO-d6): 12.4 
(C-18), 25.9, 26.9, 29.2, 30.0, 36.9, 37.9, 40.5, 43.4, 43.8 (C-13), 47.8, 52.0 (C-16a), 54.8 (3-
OCH3), 55.0 (4’-CH2), 79.5 (C-17), 111.4 (C-2), 113.4 (C-4), 122.8 (C-5’), 126.1 (C-1), 132.0 
(C-10), 137.3 (C-5), 147.6 (C-4’), 157.0 (C-3). 
 
2.3.7. 3-Methoxy-16a-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-
ol (22a) 
Compound 14 (342 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 22a (261 mg, 64%) as a white solid. Mp: 6769 
о
C; 
Rf= 0.35 (ss B). (Found C, 73.55; H, 7.98. C25H33N3O2 (407.55) requires C, 73.68; H, 8.16%). 
1
H 
NMR (δ, ppm, CDCl3): 0.82 (m, 5H, 18-H3 and cyclopropyl-H2), 0.95 (m, 2H, cyclopropyl-H2), 
2.83 (m, 2H, 6-H2), 3.53 (d, 1H, J = 7.5 Hz, 17-H), 3.77 (s, 3H, 3-OCH3), 4.35 (t, 1H, J = 7.5 Hz, 
16a-H2), 4.44 (dd, 1H, J = 13.5 Hz, J = 7.5 Hz, 16a-H2), 6.62 (d, 1H, J = 2.0 Hz, 4-H), 6.70 (dd, 
1H, J = 8.5 Hz, J = 2.0 Hz, 2-H), 7.18 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, CDCl3): 6.7 
(C-1”), 7.7 (C-2” and -3”), 11.8 (C-18), 26.1, 27.2, 28.2, 29.7, 36.6, 38.4, 43.9, 44.3, 44,3 (C-
16a), 48.3, 54.5 (C-13), 62.1 (3-OCH3), 85.1 (C-17), 111.5 (C-2), 113.8 (C-4), 126.2 (C-1), 132.3 
(C-10), 137.8 (C-5), 157.4 (C-3). 
 
2.3.8. 3-Methoxy-16a-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1-yl)methylestra-1,3,5(10)-trien-17β-
ol (22b) 
Compound 14 (342 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
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ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 22b (290 mg, 66%) as a white solid. Mp: 163165 
о
C; Rf= 0.32 (ss B). (Found C, 74.63; H, 8.41. C27H37N3O2 (435.60) requires C, 74.45; H, 8.56%). 
1H NMR (δ, ppm, CDCl3): 0.83 (s, 3H, 18-H3), 1.68 (s, 4H, 3”- and 4”-H2), 2.83 (m, 2H, 6-H2), 
3.19 (m, 1H, 1”-H), 3.56 (d, 1H, J = 7.0 Hz, 17-H), 3.77 (s, 3H, 3-OCH3), 4.43 (m, 2H, 16a-H2), 
6.62 (s, 1H, 4-H), 6.70 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H), 7.35 (s, 1H, 5’-H). 
13C NMR (δ, ppm, CDCl3): 11.9 (C-18), 25.1 (C-3” and -4”), 26.1, 27.2, 28.3, 29.7 (C-2” and -
5”), 33.2, 36.6, 38.4, 43.9, 44.2, 44.3 (C-13), 48.4, 55.2 (3-OCH3), 62.1 (C-16a), 85.3 (C-17), 
111.5 (C-2), 113.8 (C-4), 126.3 (C-1), 132.3 (C-10), 137.8 (C-5), 157.5 (C-3). 
 
2.3.9. 3-Methoxy-16a-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-
ol (22c) 
Compound 14 (342 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 22c (345 mg, 76%) as a white solid. Mp: 8082 
о
C; 
Rf= 0.34 (ss B). (Found 74.96; H, 8.54. C28H41N3O2 (449.63) requires C, 74.80; H, 8.74%). 
1
H 
NMR (δ, ppm, CDCl3): 0.83 (s, 3H, 18-H3), 2.83 (m, 2H, 6-H2), 3.55 (s, 1H, 17-H), 3.77 (s, 3H, 
3-OCH3), 4.46 (s, 2H, 16a-H2), 6.62 (d, 1H, J = 2.0 Hz, 4-H), 6.70 (dd, 1H, J = 8.5 Hz, J = 2.0 
Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, CDCl3): 11.9 (C-18), 26.0 and 26.1 
(C-2” and -6”, C-3” and -5”), 27.2, 28.3, 29.7, 36.6, 38.4, 43.9, 44.3 (C-13), 48.4, 55.2 (3-OCH3), 
62.1 (C-1”), 62.1 (C-16a), 85.2 (C-17), 111.5 (C-2), 113.8 (C-4), 126.2 (C-1), 132.3 (C-10), 
137.8 (C-5), 157.4 (C-3).  
 
2.3.10. 3-Methoxy-16a-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-ol 
(22d) 
Compound 14 (342 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel ethyl 
acetate/CH2Cl2 (5:95 v/v) to yield pure 22d (368 mg, 82%) as a white solid. Mp: 204205 
о
C; 
Rf= 0.38 (ss B). (Found C, 75.63; H, 7.72. C28H33N3O2 (443.58) requires C, 75.81; H, 7.50%). 
1
H 
NMR (δ, ppm, DMSO-d6): 0.73 (s, 3H, 18-H3), 2.73 (m, 2H, 6-H2), 3.67 (s, 3H, 3-OCH3), 4.36 (t, 
1H, J = 13.5 Hz, 16a-H2), 4.54 (dd, 1H, J = 13.5 Hz, J = 4.0 Hz, 16a-H2), 4.91 (d, 1H, J = 4.0 Hz, 
17-H), 6.58 (s, 1H, 4-H), 6.67 (d, 1H, J = 8.5 Hz, 2-H), 7.15 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (t, 1H, 
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J = 7.0 Hz, 4”-H), 7.44 (t, 2H, J = 7.0 Hz, 3”- and 5”-H), 7.86 (d, 2H, J = 7.0 Hz, 2”- and 6”-H), 
8.61 (s, 1H, 5’-H). 13C NMR (δ, ppm, DMSO-d6): 11.8 (C-18), 25.8, 26.7, 27.3, 29.1, 36.3, 38.1, 
43.4, 43.5, 43.8, 47.5, 53.5 (C-13), 54.8 (3-OCH3), 83.1 (C-17), 111.4 (C-2), 113.3 (C-4), 121.4 
(C-5’), 125.0 (C-2” and -6”), 126.0 (C-1), 127.6 (C-4”), 128.8 (C-3” and -5”), 130.8 (C-1”), 
132.0 (C-10), 137.3 (C-5), 146.1 (C-4’), 156.9 (C-3). 
 
2.3.11.3-Methoxy-16a-[4’(4’’-nitro-benzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl]methylestra-
1,3,5(10)-trien-17β-ol (22e) 
Compound 14 (342 mg, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 410 mg) were used for 
the synthesis as described in Section 2.3. The crude product was chromatographed on silica gel 
with ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 22e (445 mg, 81%) as a yellow solid. Mp: 
8688 оC; Rf= 0.28 (ss B). (Found C, 66.08; H, 6.43. C30H34N4O6 (546.61) requires C, 65.92; H, 
6.27%). 
1H NMR (δ, ppm, DMSO-d6): 0.69 (s, 3H, 18-H3), 2.68 (m, 2H, 6-H2), 3.57 (s, 3H, 3-
OCH3), 4.38 (dd, 1H, J = 13.5 Hz, J = 9.0 Hz, 16a-H2), 4.52 (dd, 1H, J = 13.5 Hz, J = 4.5 Hz, 
16a-H2), 4.86 (d, 1H, J = 4.5 Hz, 17-H), 5.46 (s, 2H, 4’-H2), 6.55 (d, 1H, J = 1.5 Hz, 4-H), 6.63 
(dd, 1H, J = 8.5 Hz, 2-H), 7.10 (d, 1H, J = 8.5 Hz, 1-H), 8.16 (d, 2H, J = 8.5 Hz, 3”- and 5”-H), 
8.28 (d, 2H, J = 8.5 Hz, 2”- and 6”-H), 8.31 (s, 1H, 5’-H). 13C NMR (δ, ppm, DMSO-d6): 11.7 
(C-18), 25.7, 26.6, 27.1, 29.0, 36.4, 38.0, 43.3, 43.4 (C-13), 43.7, 47.7, 53.1 (C-16a), 54.7 (3-
OCH3), 58.6 (4”-CH2), 82.8 (C-17), 111.3 (C-2), 113.3 (C-4), 123.8 (C-2” and -6”), 125.2 (C-5’), 
125.9 (C-1), 130.6 (C-3” and -5”), 131.8 (C-10), 134.7 (C-1’), 137.2 (C-5), 141.1 (C-4”), 150.2 
(C-4’), 156.9 (C-3), 163.9 (C=O). 
 
2.3.12. 3-Methoxy-16a-(4’-hydroxymethyl-1’H-1’,2’3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (22f)  
 
Compound 22e (274 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from a mixture of ethyl 
acetate/hexane to afford 22f (175 mg, 88%) as a white crystalline product. Mp: 98100 оC; Rf= 
0.28 (ss B). (Found C, 69.74; H, 7.72. C23H31N3O3 (397.51) requires C, 69.49; H, 7.86%). 
1
H 
NMR (δ, ppm, CDCl3): 0.81 (s, 3H, 18-H3), 2.82 (m, 2H, 6-H2), 3.50 (d, 1H, J = 7.0 Hz, 17-H), 
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3.76 (s, 3H, 3-OCH3), 4.42 (d, 2H, J = 7.0 Hz, 16a-H2), 4.71 (s, 2H, 4’-H2), 6.61 (s, 1H, 4-H), 
6.69 (d, 1H, J = 8.5 Hz, 2-H), 7.17 (d, 1H, J = 8.5 Hz, 1-H), 7.68 (s, 1H, 5’-H). 13C NMR (δ, 
ppm, CDCl3): 11.9 (C-18), 26.1, 27.2, 28.2, 29.6, 36.5, 38.4, 43.8, 44.0, 44.4 (C-13), 48.2, 54.6 
(C-16a), 55.2 (3-OCH3), 56.0 (4’-CH2), 85.1 (C-17), 111.5 (C-2), 113.8 (C-4), 126.3 (C-1), 132.3 
(C-10), 137.8 (C-5), 157.4 (C-3).  
 
2.3.13. 3-Methoxy-16a-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (23a) 
Compound 15 (342 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 23a (261 mg, 64%) as a white solid. Mp: 6769 
о
C; 
Rf= 0.32 (ss B). (Found C, 73.85; H, 8.32. C25H33N3O2 (407.55) requires C, 73.68; H, 8.16%). 
1
H 
NMR (δ, ppm, CDCl3): 0.82 (m, 5H, 18-H3 and cyclopropyl-H2), 0.95 (m, 2H, cyclopropyl-H2), 
2.83 (m, 2H, 6-H2), 3.53 (d, 1H, J = 7.5 Hz, 17-H), 3.77 (s, 3H, 3-OCH3), 4.35 (t, 1H, J = 7.5 Hz, 
16a-H2), 4.44 (dd, 1H, J = 13.5 Hz, J = 7.5 Hz, 16a-H2), 6.62 (d, 1H, J = 2.0 Hz, 4-H), 6.70 (dd, 
1H, J = 8.5 Hz, J = 2.0 Hz, 2-H), 7.18 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, CDCl3): 6.7 
(C-1”), 7.7 (C-2” and -3”), 11.8 (C-18), 26.1, 27.2, 28.2, 29.7, 36.6, 38.4, 43.9, 44.3, 44,3 (C-
16a), 48.3, 54.5 (C-13), 62.1 (3-OCH3), 85.1 (C-17), 111.5 (C-2), 113.8 (C-4), 126.2 (C-1), 132.3 
(C-10), 137.8 (C-5), 157.4 (C-3). 
 
2.3.14. 3-Methoxy-16β-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1-yl)methylestra-1,3,5(10)-trien-17a-
ol (23b) 
Compound 15 (342 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 23b (380 mg, 87%) as yellow crystalline material. 
Mp: 6768 оC; Rf= 0.36 (ss B). (Found C, 74.28; H, 8.47. C27H37N3O2 (435.60) requires C, 
74.45; H, 8.56%). 
1H NMR (δ, ppm, CDCl3): 0.75 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.68 (s, 
1H, 17-H), 3.77 (s, 3H, 3-OCH3), 4.44 (d, 2H, J = 15.0 Hz, 16a-H2), 6.62 (s, 1H, 4-H), 6.70 (d, 
1H, J = 8.5 Hz, 2-H), 7.20 (t, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, CDCl3): 17.9 (C-18), 25.1 
(C-3” and -4”), 25.9, 26.1, 27.2, 28.0, 29.7, 30.4, 31.8, 36.6 (C-16a), 38.5, 43.3, 43.8, 45.1 (C-
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13), 48.9, 55.2 (3-OCH3), 62.1 (C-1”), 82.6 (C-17), 111.5 (C-2), 113.7 (C-4), 113.8 (C-5’), 126.2 
(C-1), 132.1 (C-10), 137.8 (C-5), 137.8 (C-4’), 157.4 (C-3).  
 
2.3.15. 3-Methoxy-16β-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methyestra-1,3,5(10)-trien-17a-
ol (23c) 
Compound 15 (342, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 23c (306 mg, 68%) as a white solid. Mp: 90-92 
о
C; 
Rf = 0.37 (ss B). (Found C, 74.95; H, 8.83. C28H41N3O2 (449.63) requires C, 74.80; H, 8.74%). 
1
H 
NMR (δ, ppm, CDCl3): 0.75 (s, 3H, 18-H3), 2.84 (m, 2H, 6-H2), 3.67 (d, 1H, J = 1.0 Hz, 17-H), 
3.77 (S, 3H, 3-OCH3), 4.43 (m, 1H, 16a-H2), 6.62 (d, 1H, J = 2.5 Hz, 4-H), 6.71 (dd, 1H, J = 8.5 
Hz, J = 2.5 Hz, 2-H), 7.20 (t, 1H, J = 8.5 Hz, 1-H), 7.35 (s, 1H, 5’-H). 13C NMR (δ, ppm, 
CDCl3): 17.9 (C-18), 25.9, 26.0, 26.1 (C-2” and -6”), 28.0, 29.7, 30.4, 31.8, 33.0, 35.2 (C-1”), 
36.6, 38.5, 43.3, 45.1 (C-13), 48.9, 49.1, 54.3 (C-16a), 55.2 (3-OCH3), 82.6 (C-1), 132.4 (C-10), 
137.8 (C-5), 153.7 (C-4’), 157.7 (C-3). 
 
2.3.16. 3-Methoxy-16β-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methy-estra-1,3,5(10)-trien-17a-ol 
(23d) 
Compound 15 (342 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (2.5:97.5 v/v) to yield pure 23d (299 mg, 67%) as white crystals. Mp: 
173174 оC; Rf= 0.34 (ss B). (Found C 75.98; H, 7.33. C28H33N3O2 (443.58) requires C, 75.81; 
H, 7.50%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.71 (d, 1H, J = 
1.5 Hz, 17-H), 3.78 (s, 3H, 3-OCH3), 4.46 (dd, 1H, J = 13.5 Hz, J = 8.0 Hz, 16a-H2), 4.55 (dd, 
1H, J = 13.5 Hz, J = 8.0 Hz, 16a-H2), 6.63 (d, 1H, J = 2.0 Hz, 4-H), 6.72 (dd, 1H, J = 8.5 Hz, J = 
2.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.27 (t, 1H J = 7.5 Hz, 4”-H), 7.42 (t, 2H, J = 7.5 Hz, 
3”- and 5”-H), 7.83 (d, 2H, J = 7.5 Hz, 2”- and 6”-H), 7.87 (s, 1H, 5’-H). 13C NMR (δ, ppm, 
CDCl3): 17.9 (C-18), 25.9, 27.9, 29.7, 30.4, 31.8, 38.5, 43.3, 45.1, (C-13), 48.8, 49.1, 54.5 (C-
16a), 55.2 (3-OCH3), 82.5 (C-17), 111.5 (C-2), 113.7 (C-4), 119.6 (C-5’), 125.7 (C-2” and -6”), 
126.3 (C-1), 128.1 (C-4”), 128.8 (C-3” and -5”), 130.5 (C-1”), 132.4 (C-10), 137.8 (C-5), 147.8 
(C-4’), 157.4 (C-3). 
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2.3.17.3-Methoxy-16β-[4’(4”-nitro-benzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl)methylestra-
1,3,5(10)-trien-17a-ol (23e) 
Compound 15 (342, 1 mmol) and propargyl 4-nitro benzoate (2 mmol, 410 mg) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 23e (370 mg, 67%) as a yellow crystalline material. 
Mp: 6263 оC; Rf = 0.38 (ss B). (Found C, 66.14; H, 6.42. C30H34N4O6 (546.61) requires C, 
65.92; H, 6.27%). 
1H NMR (δ, ppm, DMSO-d6): 0.65 (s,3 H, 18-H3), 2.74 (m,2H, 6-H2), 3.68 (s, 
3H, 3-OCH3), 4.41 (dd, 1H, J = 13.0 Hz, J = 8.5 Hz, 16a-H2), 4.56 (dd, 1H, J = 13.0 Hz, J = 8.5 
Hz, 16a-H2), 4.63 (d, 1H, J = 4.5 Hz, 17-H), 6.58 (s, 1H, 4-H), 6.66 (d, 1H, J = 8.5 Hz, 2-H), 7.16 
(d, 1H, J = 8.5 Hz, 1-H), 8.19 (d, 2H, J = 8.5 Hz, 3”- and 5”-H), 8.34 (d, 2H, J = 8.5 Hz, 2”- and 
6”-H). 13C NMR (δ, ppm, DMSO-d6): 17.5 (C-18), 25.6, 27.5, 29.6, 31.8, 38.2, 43.0, 44.5, 47.9 
(C-13), 48.2, 49.1, 53.6 (C-16a), 54.8 (3-OCH3), 58.7 (4’-CH2), 80.8 (C-17), 111.3 (C-2), 113.3 
(C-4), 123.8 (C-1), 126.1 (C-5’), 130.6 (C-2” and -6”), 131.9 (C-3” and -5”), 133.0 (C-10), 134.7 
(C-1”), 137.3 (C-5), 141.4 (C-4”), 150.2 (C-4’), 156.9 (C-3), 163.9 (C=O). 
 
2.3.18. 3-Methoxy-16β-(4’-hydroxymethyl-1’H-1’,2’3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (23f) 
Compound 23e (274 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off, dissolved in dichloromethane and washed with 
water. The organic phase was dried over Na2SO4, and evaporated in vacuo to afford 23f (183 mg, 
92%) as oil. Rf= 0.26 (ss B). (Found C, 69.28; H, 7.95. C23H31N3O3 (397.51) requires C, 69.49; 
H, 7.86%). 
1H NMR (δ, ppm, CDCl3): 0.78 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.65 (s, 1H, 17-
H), 3.77 (s, 3H, 3-OCH3), 4.46 (m, 2H, 16a-H2), 4.78 (s, 2H, 4’-H2), 6.62 (d, 1H, J = 2.0 Hz, 4-
H), 6.72 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, 
CDCl3): 17.9 (C-18), 25.9, 27.9, 29.7, 30.3, 31.8, 38.5, 43.3, 45.2 (C-13), 48.8, 49.2, 54.6 (C-
16a), 55.2 (3-OCH3), 56.1 (4’-CH2), 82.1 (C-17), 111.5 (C-2), 113.7 (C-4), 123.5 (C-5’), 126.3 
(C-1), 132.4 (C-10), 137.8 (C-5), 157.4 (C-3). 
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2.3.19. 3-Methoxy-16a-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (24a) 
Compound 16 (342 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (2.5:97.5 v/v) to yield pure 24a (310 mg, 76%) as a white solid. Mp: 
165166 оC; Rf= 0.40 (ss B). (Found C, 73.85; H, 8.34. C25H33N3O2 (407.55) requires C, 73.68; 
H, 8.16%). 
1H NMR (δ, ppm, CDCl3): 0.74 (s, 3H, 18-H3), 0.85 and 0.96 (2 x m, 4H, 2”- and 3”-
H2), 2.85 (m, 2H, 6-H2), 3.63 (d, 1H, J = 5.0 Hz, 17-H), 3.77 (s, 3H, 3-OCH3), 4.28 (dd, 1H, J = 
13.0 Hz, J = 5.0 Hz, 16a-H2), 4.59 (t, 1H, J = 12.0 Hz, 16a-H2), 6.63 (d, 1H, J = 2.0 Hz, 4-H), 
6.71 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.22 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, 
CDCl3): 6.6 (C-1”), 7.7 and 7.8 (C-2” and -3”), 17.1 (C-18), 26.0, 28.0, 28.9, 29.8, 31.2, 38.9, 
42.3, 46.3 (C-16a), 47.0, 50.5 (C-13), 55.2 (3-OCH3), 78.8 (C-17), 111.4 (C-2), 113.7 (C-4), 
120.6 (C-5’), 126.3 (C-1), 132.5 (C-10), 137.9 (C-5), 149.8 (C-4’), 157.4 (C-3). 
 
2.3.20. 3-Methoxy-16a-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1’-yl)methyl-estra-1,3,5(10)-trien-
17a-ol (24b) 
Compound 16 (342 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 24b (383 mg, 88%) as yellow crystalline product. 
Mp: 171173 оC; Rf= 0.42 (ss B). (Found C, 74.67; H, 8.72. C27H37N3O2 (435.60) requires C, 
74.45; H, 8.56%). 
1H NMR (δ, ppm, CDCl3): 075 (s, 3H, 18-H3), 1.25 (s, 8H, 2”-, 3”-, 4”- and 
5”-H2), 2.86 (m, 2H, 6-H2), 3.18 (m, 1H, 1”-H), 3.64 (d, 1H, J = 5.0 Hz, 17-H), 3.77 (s, 3H, 3-
OCH3), 4.29 (dd, 1H, J = 13.5 Hz, J = 5.5 Hz, 16a-H2), 4.62 (dd, 1H, J = 13.5 Hz, J = 11.5 Hz, 
16a-H2), 6.63 (d, 1H, J = 2.0 Hz, 4-H), 6.71 (dd, 1H, J = 8.5 Hz, J = 2.0 Hz, 2-H), 7.22 (d, 1H, J 
= 8.5 Hz, 1-H), 7.36 (s, 1H, 5’-H). 13C NMR (δ, ppm, CDCl3): 17.2 (C-18), 25.1 (C-3” and -4”), 
26.0, 28.0, 29.0, 29.7, 29.9, 31.2, 33.2, 36.7, 38.9, 42.4, 43.5, 46.3 (C-13), 47.0 (C-1”), 50.5 (C-
16a), 55.2 (3-OCH3), 78.8 (C-17), 111.4 (C-2), 113.8 (C-4), 120.6 (C-5’), 126.3 (C-1), 132.6 (C-
10), 137.9 (C-5), 152.3 (C-4’), 157.4 (C-3). 
 
2.3.21. 3-Methoxy-16a-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17a-
ol (24c) 
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Compound 16 (342 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 24c (162 mg, 36%) as yellow crystals. Mp: 208210 
о
C; Rf= 0.42 (ss B). (Found C, 74.97; H, 8.56. C28H41N3O2 (449.63) requires C, 74.80; H, 8.74%). 
1H NMR (δ, ppm, CDCl3): 0.75 (s, 3H, 18-H3), 1.26 (s, 8H, 2”-, 3”-, 5”- and 6”-H2), 2.88 (m, 2H, 
6-H2), 2.90 (m, 2H, 4”-H2), 3.64 (d, 1H, J = 5.0 Hz, 17-H), 3.77 (s, 3H, 3-OCH3), 4.29 (dd, 1H, J 
= 13.5 Hz, J = 5.0 Hz, 16a-H2), 4.62 (dd, 1H, J = 13.5 Hz, J = 11.0 Hz, 16a-H2), 6.63 (d, 1H, J = 
2.0 Hz, 4-H), 6.71 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.22 (d, 1H, J = 8.5 Hz, 1-H), 7.34 (s, 
1H, 5’-H). 13C NMR (δ, ppm, CDCl3): 17.2 (C-18), 26.0 and 26.1 (C-2”, -3”, -5” and -6”), 28.0, 
29.0, 29.7, 29.8, 31.2, 33.0, 25.2, 38.9, 42.4, 43.5, 46.3 (C-13), 47.0 (C-1”), 50.5 (C-16a), 55.0 
(3-OCH3), 78.8 (C-17), 111.4 (C-2), 113.8 (C-4), 120.2 (C-5’), 126.3 (C-1), 132.6 (C-10), 137.9 
(C-5), 153.3 (C-4’), 157.4 (C-3).  
 
2.3.22. 3-Methoxy-16a-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17a-ol 
(24d) 
Compound 16 342 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
CH2Cl2 yield pure 24d (394 mg, 89%) as white solid. Mp: 189.5191 
о
C; Rf= 0.46 (ss B). (Found 
C, 75.65; H, 7.67. C28H33N3O2 (443.58) requires C, 75.81; H, 7.50%). 
1H NMR (δ, ppm, CDCl3): 
0.75 (s, 3H, 18-H3), 2.86 (m, 2H, 6-H2), 3.68 (d, 1H, J = 5.0 Hz, 17-H), 3.78 (s, 3H, 3-OCH3), 
4.41 (dd, 1H, J = 13.5 Hz, J = 6.0 Hz, 16a-H2), 4.69 (dd, 1H, J = 14.5 Hz, J = 10.5 Hz, 16a-H2), 
6.64 (d, 1H, J = 2.0 Hz, 4-H), 6.72 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.22 (d, 1H, J = 8.5 Hz, 
1-H), 7.34 (t, 1H, J = 7.5 Hz, 4”-H), 7.43 (t, 2H, J = 7.5 Hz, 3”- and 5”-H), 7.83 (d, 2H, J = 7.5 
Hz, 2”- and 6”-H), 7.88 (s, 1H, 5’-H). 13C NMR (δ, ppm, CDCl3): 17.1 (C-18), 26.0, 28.0, 29.8, 
31.2, 38.9, 42.3, 43.5, 46.4 (C-13), 47.0, 50.7, 55.2 (3-OCH3), 78.8 (C-17), 111.5 (C-2), 113.8 
(C-4), 120.6 (C-5’), 125.6 (C-2” and -6”), 126.3 (C-1), 128.1 (C-4”), 128.8 (C-3” and -5”), 130.5 
(C-1”), 132.5 (C-10), 137.9 (C-5), 147.3 (C-4’), 157.4 (C-3). 
 
2.3.23. 3-Methoxy-16a-[4’-(4’’nitrobenzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl]methylestra-
1,3,5(10)-trien-17a-ol (24e) 
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Compound 16 (342, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 210 mg) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
CH2Cl2/hexane (1:3, v/v) to yield pure (344 mg, 63%) as yellow crystals. Mp: 64 
о
C; Rf= 0.45 (ss 
B). (Found, C, 66.14; H, 6.05. C30H34N4O6 (546.61) requires C, 65.92; H, 6.27%). 
1H NMR (δ, 
ppm, CDCl3): 0.75 (s, 3H, 18-H3), 2.84 (m, 2H, 6-H2), 3.66 (d, 1H, J = 4.5 Hz, 17-H), 3.77 (s, 
3H, 3-OCH3), 4.40 (dd, 1H, J = 13.5 Hz, J = 5.5 Hz, 16a-H2), 4.66 (t, 1H, J = 13.5 Hz, 16a-H2), 
5.53 (s, 2H, 4’-H2), 6.62 (t, 1H, J = 2.0 Hz, 4-H), 6.71 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.20 
(d, 1H, J = 8.5 Hz, 1-H), 7.85 (s, 1H, 5’-H), 8.22 (d, 2H, J = 9.0 Hz, 3”- and 5”-H), 8.72 (d, 2H, J 
= 9.0 Hz, 2”- and 6”-H). 13C NMR (δ, ppm, CDCl3): 17.1 (C-18), 22.7, 25.9, 28.0, 29.0, 29.8, 
31.2, 38.9, 42.0, 43.5, 46.4 (C-13), 47.0 (4’-CH2), 78.8 (C-17), 111.5 (C-2), 113.8 (C-4), 114.0 
(C-1’), 123.5 (C-2” and -6”) 126.3 (C-5’), 130.9 (C-3” and -5”), 135.0 (C-10), 137.8 (C-5), 141.5 
(C-4”), 150.6 (C-4’), 157.5 (C-3), 164.6 (C=O). 
 
2.3.24. 3-Methoxy-16a-(4’-hydroxymethyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (24f) 
Compound 24e (274 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from a mixture of 
acetone/hexane to afford 24f (187 mg, 94%) as a white crystalline product. Mp: 149150 оC; Rf 
= 0.25 (ss B). (Found C, 69.55; H, 7.95. C23H31N3O3 (397.51) requires C, 69.49; H, 7.86%). 
1
H 
NMR (δ, ppm, CDCl3): 0.74 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.62 (d, 1H, J = 4.0 Hz, 17-H), 
3.77 (s, 3H, 3-OCH3), 4.39 (m, 1H, 16a-H2), 4.64 (m, 1H, 16a-H2), 6.63 (s, 1H, 4-H), 6.71 (d, 1H, 
J = 8.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.77 (s, 1H, 5’-H). 13C NMR (δ, ppm, CDCl3): 
11.9 (C-18), 26.0, 28.0, 28.9, 31.3, 31.9, 33.8 (C-13), 38.9, 41.9, 43.5, 46.4 (4’-CH2), 46.9, 51.0 
(C-16a), 55.2 (3-OCH3), 78.6 (C-17), 111.5 (C-2), 113.8 (C-4), 123.4 (C-5’), 126.3 (C-1), 132.5 
(C-10), 137.8 (C-5), 157.4 (C-3).  
 
2.3.25. 3-Benzyloxy-16β-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (25a) 
Compound 17 (420 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
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ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 25a (394 mg, 84%) as a white solid. Mp: 278280 
о
C; Rf= 0.35 (ss B). (Found C, 77.16; H, 7.62. C31H37N3O2 (483.64) requires C, 76.98; H, 
7.71%). 
1H NMR (δ, ppm, CDCl3): 0.80 (s, 3H, 18-H3), 0.86 and 0.97 (2 x m, 2 x 2H, 2”- and 3”-
H), 2.83 (m, 2H, 6-H2), 3.93 (d, J = 9.5 Hz, 1H, 17-H), 4.21 (m, 1H, 16a-H2), 4.64 (m, 1H, 16a-
H2), 5.03 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.20 (d, 1H, J = 8.5 Hz, 
1-H), 7.31 (t, 1H, J = 7.0 Hz, 4’-H), 7.38 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.43 (d, 2H, J = 7.0 
Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 7.8 (C-2” and -3”), 12.3 (C-18), 26.2, 27.4, 29.7, 
30.8, 37.5, 38.0, 41.4, 43.9, 44.3 (C-13), 48.7 (C-16), 67.8 (C-16a), 69.9 (Bn-CH2), 80.7 (C-17), 
112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and C-5’), 
132.7 (C-10), 137.3 (C-1’), 137.8 (C-5), 156.8 (C-3).  
 
2.3.26. 3-Benzyloxy-16β-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (25b) 
Compound 17 (420 mg, 1 mmol) and cyclopentylacetylene (2 mol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 25b (350 mg, 68%) as a white solid. Mp: 288290 
о
C; Rf= 0.38 (ss B). Found C, 77.58; H, 7.92. C33H41N3O2 (511.70) requires C, 77.46; H, 8.08%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.75 (s, 1H, 1”-H), 2.83 (m, 2H, 6-H2), 3.94 (d, 
1H, J = 9.5 Hz, 17-H), 4.24 (m, 1H, 16-H2), 4.67 (m, 1H, 16-H2), 5.03 (s., 2H, Bn-H2), 6.71 (s, 
1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.5 Hz, 4’-
H), 7.38 (t, 2H, J = 7.5 Hz, 3’- and 5’-H), 7.42 (d, 2H, J = 7.5 Hz, 2’- and 6’-H). 13C NMR (δ, 
ppm, CDCl3): 12.3 (C-18), 25.1 (C-3” and -4”), 26.2, 27.5, 29.7, 30.8, 34.3 (C-2” and -5”), 37.5, 
38.0, 41.4, 43.9, 44.3 (C-13), 48.7 (C-16), 62.1 (16a-CH2), 69.9 (Bn-CH2), 80.7 (C-17), 112.3 (C-
2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 132.7 (C-
10), 137.3 (C-1’), 137.8 (C-5), 156.8 (C-3).  
 
2.3.27. 3-Benzyloxy-16β-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (25c) 
Compound 17 (420 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99, v/v) to yield pure 25c (146 mg, 28%) as a white solid. Mp: 214216 
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о
C; Rf= 0.38 (ss B). (Found C, 77.43; H, 8.36. C34H43N3O2 (525.72) requires C, 77.68; H, 8.24%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.79 (m, 4H, 3”- and 5”-H), 3.94 (d, J = 9.5 Hz, 
1H, 17-H), 4.25 (m, 1H, 16a-H2), 4.67 (m, 1H, 16a-H2), 5.03 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 
6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (d, 1H, J = 7.0 Hz, 4’-H), 7.38 
(t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.42 (d, 2H, J = 7 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 
12.3 (C-18), 26.0 (C-4”), 26.1 (C-3” and -5”), 26.2, 27.5, 29.7, 30.8 (C-2” and -6”), 33.0 (C-1”), 
37.5, 38.0, 41.4, 43.9, 44.3 (C-13), 48.7 (C-16), 62.1 (C-16a), 69.9 (Bn-CH2), 80.7 (C-17), 112.3 
(C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 132.7 
(C-10), 137.3 (C-1’), 137.8 (C-5), 157.8 (C-3).  
 
2.3.28. 3-Benzyloxy-16β-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-ol 
(25d) 
Compound 17 (420 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 25d (391 mg, 75%) as a white solid. Mp: 202204 
о
C; Rf= 0.45 (ss B). (Found C, 78.73; H, 6.98. C34H37N3O2 (519.68) requires C, 78.58; H, 7.18%). 
1H NMR (δ, ppm, C6D6): 0.68 (s, 3H, 18-H3), 2.69 (m, 2H, 6-H2), 3.43 (dd, J = 9.5 Hz, J = 4 Hz, 
1H, 17-H), 3.77 (dd, 1H, J = 13.5 Hz, J = 7.0 Hz, 16a-H2), 4.29 (dd, 1H, J = 13.5 Hz, J = 7.0 Hz, 
16a-H2), 4.83 (s, 2H, Bn-H2), 6.79 (s, 1H, 4-H), 6.87 (d, 1H, J = 8.0 Hz, 2-H), 7.02 (s, 1H, 1-H), 
7.08 (t, 1H, J = 7.5 Hz, 4’-H), 7,26 (t, 2H, J = 7.5 Hz, 3’- and 5’-H), 7.32 (d, 2H, J = 7.5 Hz, 2’- 
and 6’-H), 8.01 (d, 2H, J = 7.5 Hz, 2”- and 6”-H). 
 
2.3.29. 3-Benzyloxy-16β-[4’-(4’’-nitro-benzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl]methyestra-
1,3,5(10)-trien-17β-ol (25e) 
Compound 17 (420 mg, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 210 mg) were used for 
the synthesis as described in Section 2.3. The crude product was chromatographed on silica gel 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 25e (480 mg, 77%) as a yellow solid. Mp: 187189 
о
C; Rf= 0.45 (ss B). (Found C, 69.32; 5.98. C36H38N4O6 (622.71) requires C, 69.44; H, 6.15%). 
1H NMR (δ, ppm, CDCl3): 0.80 (s, 3H, 18-H3), 2.82 (m, 2H, 6-H2), 3.94 (d, J = 10.0 Hz, 1H, 17-
H), 4.32 (dd, 1H, J = 13.0 Hz, J = 6.0 Hz, 16a-H2), 4.72 (t, 1H, J = 6.0 Hz, 16a-H2), 5.03 (s, 2H, 
Bn-H2), 5.52 (s, 2H, triazol-H), 6.71 (s, 1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 
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8.5 Hz, 1-H), 7.32 (t, 1H, J = 7.0 Hz, 4’-H), 7.38 (t, J = 7.5 Hz, 2H, 3’- and 5’-H), 7.42 (d, J = 
7.5 Hz, 2H, 2’- and 6’-H), 8.22 (d, J = 8 Hz, 2H, 3”- and 5”-H), 8.27 (d, J = 8 Hz, 2H, 2”- and 
6”-H). 13C NMR (δ, ppm, CDCl3): 12.3 (C-18), 26.2, 27.4, 29.7, 30.8, 37.4, 38.0, 41.2, 43.8, 44.4 
(C-13), 48.7 (C-16), 55.5 (C-16a), 58.7 (linker-CH2), 69.9 (Bn-CH2), 80.7 (C-17), 112.4 (C-2), 
114.8 (C-4), 123.5 (C-2’ and -6’), 126.3 (C-1), 127.4 (C-2” and -6”), 127.8 (C-4’), 128.5 (C-3” 
and -5”), 130.9 (C-3’ and -5’), 132.5 (C-10), 135.1 (C-1”), 137.3 (C-1’), 137.8 (C-5), 150.7 (C-
4”), 156.8 (C-3), 164.6 (C=O).  
 
2.3.30. 3-Benzyloxy-16β-(4’-hydroxymethyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-
trien-17β-ol (25f) 
Compound 25e (210 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from methanol to afford 25f 
(232 mg, 98%) as a white crystalline product. Mp: 283285 оC; Rf= 0.25 (ss B). (Found C, 
73.42; H, 7.35. C29H35N3O3 (473.61) requires C, 73.54; H, 7.45%). 
1H NMR (δ, ppm, DMSO-d6): 
0.77 (s, 3H, 18-H3), 3.77 (dd, 1H, J = 9.5 Hz, J = 3.5 Hz, 16a-H2), 4.15 (t, 1H, J = 12.5 Hz, 16a-
H2), 5.12 (d, 1H, J = 5.5 Hz, 17-H), 6.68 (s, 1H, 4-H), 6.74 (d, 1H, J = 8.5 Hz, 2-H), 7.16 (d, J = 
8.5 Hz, 1H, 1-H), 7.31 (d, 1H, J = 7.0 Hz, 4’-H), 7.37 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.41 (d, 
2H, J = 7.0 Hz., 2’- and 6’-H), 7.98 (s, 1H, triazol-H). 13C NMR (δ, ppm, DMSO-d6): 12.3 (C-
18), 25.8, 26.9, 29.1, 30.0, 36.9, 37.8, 40.4, 43.4, 43.7 (C-13), 47.8 (C-16a), 55.0 (linker-CH2), 
68.9 (Bn-CH2), 79.5 (C-17), 112.1 (C-2), 114.4 (C-4), 122.7 (triazol-CH), 126.0 (C-1), 127.4 (C-
2’ and -6’), 127.6 (C-4’), 128.3 (C-3’ and -5’), 132.3 (C-10), 137.3 (C-5), 147.6 (triazol-C), 156.0 
(C-3).  
 
2.3.31. 3-Benzyloxy-16a-(4’-cyclopropyl-1’H-1’,2,’3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (26a) 
Compound 18 (420.0 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 26a (310 mg, 64%) as a white solid. Mp: 191193 
о
C; Rf= 0.35 (ss B). (Found C, 76.82; H, 7.94. C31H37N3O2 (483.64) requires C, 76.98; H, 
7.71%). 
1H NMR (δ, ppm, CDCl3): 0.83 (s, 3H, 18-H3), 2.83 (m, 2H, 6-H2), 3.54 (d, J = 7.5 Hz, 
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1H, 17-H), 4.35 (dd, 1H, J = 13.0 Hz, J = 7.5 Hz, 16a-H2), 4.44 (dd, 1H, J = 13.0 Hz, J = 7.5 Hz, 
16a-H2), 5.03 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.77 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 
8.5 Hz, 1-H), 7.31 (t, 2H, J = 7.5 Hz, 4’-H and triazol-H), 7.38 (t, 2H, J = 7.5 Hz, 3’- and 5’-H), 
7.42 (d, 2H, J = 7.5 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 6.6 (C-1”), 7.8 (C-2” and -3”), 
11.8 (C-18), 26.1, 27.2, 28.2, 29.7, 36.6, 38.4, 43.9, 44.3, 44.3 (C-13), 48.3 (C-16), 54.5 (C-16a), 
69.9 (Bn-CH2), 85.2 (C-17), 112.3 (C-2), 114.8 (C-4), 120.0 (triazol-CH), 126.3 (C-1), 127.4 (C-
2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 132.6 (C-10), 137.3 (C-1’), 137.8 (C-5), 150.2 
(triazol-C), 156.8 (C-3). 
 
2.3.32. 3-Benzyloxy-16a-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (26b) 
Compound 18 (420 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 26b (442 mg, 86%) as a white solid. Mp: 268270 
о
C; Rf= 0.36 (ss B). (Found C, 77.52; H, 7.93. C33H41N3O2 (511.70) requires C, 77.46; H, 8.08%). 
1H NMR (δ, ppm, CDCl3): 0.83 (s, 3H, 18-H3), 2.83 (m, 2H, 6-H2), 3.19 (s, 1H, 1”-H), 3.46 (d, 
1H, J = 7.0 Hz, 17-H), 4.42 (dd, 2H, J = 22.5 Hz, J, = 6.5 Hz, 16-H2), 5.03 (s, 2H, Bn-H2), 6.71 
(s, 1H, 4-H), 6.76 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.5 Hz, 
4’-H), 7 .37 (t, 3H, J = 7.5 Hz, 3’-, 5’-H and triazol-H), 7.42 (d, 2H, J = 7.5 Hz, 2’- and 6’-H). 
13C NMR (δ, ppm, CDCl3): 11.9 (C-18), 25.1 (C-3” and -4”), 26.1, 27.2, 28.3, 29.7, 33.2 (C-2” 
and -5”), 36.6 (2C, C-1”), 36.7, 38.4, 43.9, 44.3 (C-13), 48.4 (C-16), 54.5 (C-16a), 69.9 (Bn-
CH2), 85.2 (C-17), 112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-3’ and -5’), 127.8 (C-4’), 
128.5 (C-2’ and -6’), 132.6 (C-10), 137.3 (C-1’), 137.8 (C-5), 156.7 (C-3).  
 
2.3.33. 3-Benzyloxy-16a-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (26c) 
Compound 18 (420 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (2.5:77.5 v/v) to yield pure 26c (386 mg, 76%) as a white solid. Mp: 
261263 оC; Rf= 0.34 (ss B). (Found C, 77.93; H, 8.36. C34H43N3O2 (525.72) requires C, 77.68; 
H, 8.24%). 
1H NMR (δ, ppm, CDCl3): 0.83 (s, 3H, 18-H3), 2.83 (m, 2H, 6-H2), 3.55 (d, J = 7.0 
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Hz, 1H, 17-H), 4.43 (m, 2H, 16-H2), 5.03 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.77 (d, 1H, J = 8.5 
Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 2H, J = 7.0 Hz, 4’-H and triazol-H), 7.37 (t, 2H, 
J = 7.0 Hz. 3’- and 5’-H), 7.42 (d, 2H, J = 7 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 11.9 
(C-18), 25.9 (C-4”), 26.1 (C-3” and -5”), 27.2, 28.3, 29.7 (C-2” and -6”), 32.9, 33.0, 36.6, 38.4, 
43.9, 44.2, 44.3 (C-13), 48.4 (C-16), 54.5 (C-16a), 69.9 (Bn-CH2), 85.2 (C-17), 112.3 (C-2), 
114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 132.6 (C-10), 
137.3 (C-1’), 137.8 (C-5), 156.7 (C-3).  
 
2.3.34. 3-Benzyloxy-16a-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-ol 
(26d) 
Compound 18 (420 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 5:95 v/v) to yield pure 26d (372 mg, 71%) as a white solid. Mp: 132134 
о
C; Rf= 0.38 (ss B). (Found C, 78.63; H, 6.97. C34H37N3O2 (519.68) requires C, 78.58; H, 7.18%). 
1H NMR (δ, ppm, CDCl3): 0.84 (s, 3H, 18-H3), 2.83 (m, 2H, 6-H2), 3.58 (d, 1H, J = 7.5 Hz, 17-
H), 4.46 (dd, 2H, J = 13.5 Hz, J = 8.0 Hz, 16a-H2), 4.55 (dd, 1H, J = 13.5 Hz, J = 8.0 Hz, 16a-
H2) 5.03 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 
1-H), 7.30-7.86 (m, 11H, 2’-, 6’-, 3’-, 5’-, 4’-, 2”-, 6”-, 3”-, 5”-, 4”- and triazol-H). 13C NMR (δ, 
ppm, CDCl3): 11.8 (C-18), 26.1, 27.2, 28.2, 29.6, 36.5, 38.4, 43.9, 44.3, 48.3 (C-16), 54.6 (C-
16a), 62.1, 69.9 (Bn-CH2), 85.2 (C-17), 112.3 (C-2), 114.8 (C-4), 123.8 (triazol-CH), 125.7 (C-2’ 
and -6’), 126.3 (C-1’), 127.4 (C-2” and -6”), 127.8 (C-4’), 128.2 (C-4), 128.5 (C-3” and -5”), 
128.8 (C-3’ and -5’), 130.4 (C-10), 132.6 (C-1”), 137.3 (C-1’), 137.8 (C-5), 156.8 (C-3).  
 
2.3.35. 3-Benzyloxy-16a-[4’-(4’’-nitro-benzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl]methylestra-
1,3,5(10)-trien-17β-ol (26e) 
Compound 18 (420 mg, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 210 mg) were used for 
the synthesis as described in Section 2.3. The crude product was chromatographed on silica gel 
with ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 26e (484 mg, 77%) as a yellow solid. Mp: 
9496 оC; Rf= 0.40 (ss B). (Found C, 69.73; H, 5.94. C36H38N4O6 (622.71) requires C, 69.44; H, 
6.15%). 
1H NMR (δ, ppm, DMSO-d6): 0.70 (s, 3H, 18-H3), 3.33 (m, 2H, 6-H2), 4.38 (dd, 1H, J = 
13.5 Hz, J = 9.0 Hz, 16a-H2), 4.52 (dd, 1H, J = 13.5 Hz, J = 5.0 Hz, 16a-H2), 4.86 (d, 1H, J = 5 
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Hz, 17-H), 5.02 (s, 2H, Bn-H2), 5.47 (s, 2H, linker-H2), 6.64 (d, 1H, J = 2.0 Hz, 4-H), 6.72 (dd, 
1H, J = 8.5 Hz, J = 2.0 Hz, 2-H), 7.10 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.0 Hz, 4’-H), 
7.37 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.42 (d, 2H, J = 7.0 Hz, 2’- and 6’-H), 8.16 (d, 2H, J = 9.0 
Hz, 3”- and 5”-H), 8.28 (d, 2H, J = 9.0 Hz, 2”- and 6”-H), 8.32 (s, 1H, triazol-H). 13C NMR (δ, 
ppm, DMSO-d6): 11.7 (C-18), 25.7, 26.6, 27.1, 29.0, 30.6, 36.4, 37.9, 43.4, 43.4 (C-13), 43.7 (C-
16), 53.1 (C-16a), 58.6 (linker-CH2), 68.9 (Bn-CH2), 82.8 (C-17), 112.1 (C-2), 114.3 (C-4), 123.7 
(C-2’ and -6’), 125.1 (triazol-CH), 125.9 (C-1), 127.4 (C-2” and -6”), 127.5 (C-4’), 128.3 (C-3” 
and -5”), 130.6 (C-3’ and -5’), 132.1 (C-10), 134.7 (C-1”), 137.2 (C-1’), 137.3 (C-5), 141.1 
(triazol-C), 150.1 (C-4”), 155.9 (C-3), 163.9 (C=O). 
2.3.36. 3-Benzyloxy-16a-(4’-hydroxymethyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-
trien-17-ol (26f) 
Compound 26e (210 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from a mixture of 
acetone/hexane to afford 26f (190 mg, 89%) as a white crystalline product. Mp: 152154 оC; Rf= 
0.20 (ss B). (Found C, 73.72; H, 7.63. C29H35N3O3 (473.61) requires C, 73.54; H, 7.45%). 
1
H 
NMR (δ, ppm, DMSO-d6): 0.71 (s, 3H, 18-H3), 2.73 (m, 2H, 6H2), 3.29 (d, J = 8.0 Hz, 1H, 17-
H), 4.28 (dd, 2H, J = 13.0 Hz, J = 10.0 Hz, 16a-H2), 4.47 (dd, 1H, J = 13.0 Hz, J = 4.5 Hz, 16a-
H2), 4.51 (s, 2H, Bn-H2), 4.87 (s, 1H, linker-H2), 5.03 (s, 2H, triazol-H2), 5.15 (s, 1H, linker-H2), 
6.68 (s, 1H, 4-H), 6.74 (d, 1H, J = 8.5 Hz, 2-H), 7.15 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.0 
Hz, 4’-H), 7.37 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.41 (d, 2H, J = 7.0 Hz, 2’- and 6’-H), 7.97 (s, 
1H, triazol-H). 
13C NMR (δ, ppm, DMSO-d6): 11.8 (C-18), 25.8, 26.7, 27.3, 29.1, 36.4, 38.1, 
43.4, 43.5 (C-13), 43.9, 47.5 (C-16), 53.1 (C-16a), 54.9 (linker-CH2), 68.9 (Bn-CH2), 83.0 (C-
17), 112.1 (C-2), 114.4 (C-4), 122.7 (triazol-CH), 126.0 (C-1), 127.4 (C-2’ and -6’), 127.6 (C-4’), 
128.3 (C-3’ and -5’), 132.3 (C-10), 137.3 (C-1’), 137.4 (C-5), 147.6 (triazol-C), 156.0 (C-3). 
2.3.37. 3-Benzyloxy-16β-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (27a) 
Compound 19 (420.0 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
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ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 27a (454 mg, 93%) as white crystals. Mp: 199201 
о
C; Rf= 0.38 (ss B). (Found C, 77.15; H, 7.62. C31H37N3O2 (483.64) requires C, 76.98; H, 
7.71%). 
1H NMR (δ, ppm, CDCl3): 0.77 (s, 3H, 18-H3), 0.87 and 0.98 (2 x s, 2 x 2H, 2”- and 3”-
H2), 2.05 (s, 1H, 1”-H), 2.84 (m, 2H, 6-H2), 3.66 (s, 1H, 17-H), 4.42 (m, 2H, 16a-H2), 5.03 (s, 
2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.31 
(t, 1H, J = 7.0 Hz, 4’-H), 7.38 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.43 (d, 2H, J = 7.0 Hz, 2’- and 
6’-H). 13C NMR (δ, ppm, CDCl3): 6.7 (C-1”), 7.7 (C-2” and -3”), 17.9 (C-18), 25.9, 27.9, 29.7, 
30.4, 31.8, 38.5, 43.3, 45.1 (C-13), 48.9, 49.1 (C-16), 62.1 (C-16a), 69.9 (Bn-CH2), 82.6 (C-17), 
112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 
132.7 (C-10), 137.3 (C-1’), 137.9 (C-5), 156.7 (C-3).  
 
2.3.38. 3-Benzyloxy-16β-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (27b) 
Compound 19 (420 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 27b (408 mg, 79%) as white crystalline. Mp: 
220222 оC; Rf= 0.40 (ss B). (Found C, 77.32; H, 7.93. C33H41N3O2 (511.70) requires C, 77.46; 
H, 8.08%). 
1H NMR (δ, ppm, CDCl3): 0.76 (s, 3H, 18-H3), 2.84 (m, 2H, 6-H2), 3.20 (s, 1H, 1”-
H), 3.67 (s, 1H, 17-H), 4.43 (m, 2H, 16a-H2), 5.03 (s, 2H, Bn-H2), 6.72 (s, 1H, 4-H), 6.78 (dd, 
1H, J = 8.5 Hz, J = 2.0 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.0 Hz, 4’-H), 
7.38 (t, 3H, J = 7.0 Hz, 3’- and 5’-H, triazol-H), 7.43 (d, 2H, J = 7.0 Hz, 2’- and 6’-H). 13C NMR 
(δ, ppm, CDCl3): 18.0 (C-18), 25.1 (C-3” and -5”), 25.9, 28.0, 29.7, 30.4, 31.8 (C-2” and -6”), 
33.2, 36.7, 38.5, 43.3, 45.1 (C-13), 48.9 (C-16), 49.1 (C-1”), 54.3 (C-16a), 69.9 (Bn-CH2), 82.6 
(C-17), 112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and 
-5’), 132.7 (C-10), 137.3 (C-1’), 137.9 (C-5), 156.7 (C-3).  
 
2.3.39. 3-Benzyloxy-16β-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (27c) 
Compound 19 (420 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 27c (360 mg, 68%) as white crystalline product. 
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Mp: 243245 оC; Rf= 0.38 (ss B). (Found C, 77.54; H, 8.38. C34H43N3O2 (525.72) requires C, 
77.68; H, 8.24%). 
1H NMR (δ, ppm, CDCl3): 0.75 (s, 3H, 18-H3), 2.84 (m, 2H, 6-H2), 3.68 (s, 
1H, 17-H), 4.44 (m, 2H, 16a-H2), 5.03 (s, 2H, Bn-H2), 6.72 (s, 1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 
2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (t, 1H, J = 7.0 Hz, 4’-H), 7.38 (t, 3H, J = 7.0 Hz, 3’- and 
5’-H, triazol-H), 7.43 (d, 2H, J = 7.0 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 17.9 (C-18), 
25.9 (C-4”), 26.0, 26.1 (C-3” and -5”), 27.9, 29.7, 30.4, 31.8 (C-2” and -6”), 32.1, 32.9 (C-1”), 
38.5, 43.3, 45.1 (C-13), 48.9, 49.1 (C-16), 62.1 (C-16a), 69.9 (Bn-CH2), 82.5 (C-17), 112.3 (C-2), 
114.7 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 132.7 (C-10), 
137.2 (C-1’), 137.9 (C-5), 156.7 (C-3).  
 
 
2.3.40. 3-Benzyloxy-16β-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17a-ol 
(27d) 
Compound 19 (420 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (10:90 v/v) to yield pure 27d (487 mg, 93%) as white crystals. Mp: 
202204 оC; Rf= 0.45 (ss B). (Found C, 78.68; H, 7.38. C34H37N3O2 (519.68) requires C, 78.58; 
H, 7.18%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.84 (m, 2H, 6-H2), 3.72 (s, 1H, 17-
H), 4.48 (dd, 1H, J = 13.5 Hz, J = 7.5 Hz, 16a-H2), 4.56 (t, 1H, J = 13.5 Hz, 16a-H2), 5.03 (s, 2H, 
Bn-H2), 6.72 (s, 1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.33 (t, 
1H, J = 7.5 Hz, 4’-H), 7.38 (t, 2H, J = 7.5 Hz, 3’- and 5’-H), 7.42 (d, J = 3.5 Hz, 4H, 2’- and 6’-
H, 3”- and 5”-H), 7.84 (d, 2H, J = 7.5 Hz, 2”- and 6”-H), 7.88 (s, 1H, triazol-H). 13C NMR (δ, 
ppm, CDCl3): 17.9 (C-18), 25.9, 27.9, 29.7, 30.4, 31.8, 38.5, 43.3, 45.2 (C-13), 48.9, 49.1 (C-16), 
54.6 (C-16a), 69.9 (Bn-CH2), 82.6 (C-17), 112.3 (C-2), 114.8 (C-4), 119.6 (triazol-CH), 125.7 
(C-2’ and -6’), 126.3 (C-1’), 127.4 (C-2” and -6”), 127.8 (C-4’), 128.2 (C-4”), 128.5 (C-3” and -
5”), 128.8 (C-3’ and -5’), 130.5 (C-10), 132.64 (C-1”), 137.3 (C-1’), 137.9 (C-5), 147.7 (triazol-
C); 156.8 (C-3). 
 
2.3.41. 3-Benzyloxy-16β-[4’-(4’’-nitro-benzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl]methylestra-
1,3,5(10)-trien-17a-ol (27e) 
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Compound 19 (420.0 mg, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 210 mg) were used 
for the synthesis as described in Section 2.3. The crude product was chromatographed on silica 
gel with ethyl acetate/CH2Cl2 (10:90 v/v) to yield pure 27e (550 mg, 88%) as yellow crystals. 
Mp: 177179 оC; Rf= 0.48 (ss B). (Found C, 69.55; H, 5.93. C36H38N4O6 (622.71) requires: C, 
69.44; H, 6.15%). 
1H NMR (δ, ppm, DMSO-d6): 0.65 (s, 3H, 18-H3), 2.73 (m, 2H, 6-H2), 4.40 
(dd, 1H, J = 13.0 Hz, J = 8.5 Hz, 16a-H2), 4.56 (dd, 1H, J = 13.5 Hz, J = 7.5 Hz, 16a-H2), 4.63 
(d, 1H, J = 5.0 Hz, 17-H), 5.04 (s, 2H, Bn-H2), 5.47 (s, 2H, triazol-H2), 6.68 (s, 1H, 4-H), 6.74 (d, 
1H, J = 8.5 Hz, 2-H), 7.16 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.0 Hz, 4’-H), 7.37 (t, 2H, J 
= 7.0 Hz, 3’- and 5’-H), 7.41 (d, 2H, J = 7.0 Hz, 2’- and 6’-H), 8.18 (d, 2H, J = 8.5 Hz, 3”- and 
5”-H), 8.33 (d, 3H, J = 6 Hz, 2”- and 6”-H, triazol-H). 13C NMR (δ, ppm, DMSO-d6): 17.5 (C-
18), 25.6, 27.5, 29.2, 29.6, 31.8, 38.2, 42.9, 44.5 (C-13), 48.2, 49.1 (C-16), 53.6 (C-16a), 58.7 
(linker-CH2), 68.9 (Bn-CH2), 80.8 (C-17), 112.1 (C-2), 114.4 (C-4), 123.8 (C-2’ and C-6’), 125.0 
(triazol-CH), 126.1 (C-1), 127.4 (C-2” and -6”), 127.6 (C-4’), 128.3 (C-3” and -5”), 130.6 (C-3’ 
and -5’), 132.3 (C-10), 134.7 (C-1”), 137.3 (C-5 and C-1’), 141.1 (triazol-C), 150.2 (C-4”), 160.0 
(C-3), 163.9 (C=O). 
 
2.3.42. 3-Benzyloxy-16β-(4’-hydroxymethyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-
trien-17a-ol (27f) 
Compound 27e (210 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from methanol to afford 27e 
(273 mg, 99%) as a white crystalline product. Mp: 172174 оC; Rf= 0.25 (ss B). (Found C, 
73.68; H, 7.66. C29H35N3O3 (473.61) requires C, 73.54; H, 7.45%). 
1H NMR (δ, ppm, DMSO-d6): 
0.67 (s, 3H, 18-H3), 2.74 (m, 2H, 6-H2), 3.43 (s, 1H, 17-H), 4.34 (m, 1H, 16a-H2), 4.50 (m, 3H, 
16a-H2 and Bn-H2), 4.61 (brs, 1H, OH), 5.04 (s, 2H, triazol-H2), 5.16 (brs, 1H, OH), 6.69 (s, 1H, 
4-H), 6.74 (d, 1H, J = 8.5 Hz, 2-H), 7.17 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (d, 1H, J = 7.0 Hz, 4’-H), 
7.37 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.41 (d, 2H, J = 7.0 Hz, 2’- and 6’-H), 8.00 (s, 1H, triazol-
H). 
13C NMR (δ, ppm, DMSO-d6): 17.5 (C-18), 25.6, 27.5, 29.2, 29.6, 31.9, 38.2, 43.0, 44.5 (C-
13), 48.2, 49.1 (C-16), 53.5 (C-16a), 55.0 (linker-CH2), 61.6, 68.9 (Bn-CH2), 80.8 (C-17), 112.2 
(C-2), 114.4 (C-4), 122.6 (triazol-CH), 126.6 (C-1), 127.4 (C-2’ and -6’), 127.6 (C-4’), 128.3 (C-
3’ and -5’), 132.4 (C-10), 137.3 (C-5 and C-1’), 147.6 (triazol-C), 156.0 (C-3). 
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2.3.43. 3-Benzyloxy-16a-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (28a) 
Compound 20 (420.0 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 28a (305 mg, 63%) as white crystals. Mp: 143144 
о
C; Rf= 0.40 (ss B). (Found C, 77.15; H, 7.53. C31H37N3O2 (483.64) requires C, 76.98; H, 
7.71%). 
1H NMR (δ, ppm, CDCl3): 0.74 (s, 3H, 18-H3), 0.87 and 0.97 (2 x s, 2 x 2H, 2”- and 3”-
H2), 2.85 (m, 2H, 6-H2), 3.63 (d, 1H, J = 5.0 Hz, 17-H), 4.26 (dd, 1H, J = 13.5 Hz, J = 5.5 Hz, 
16a-H2), 4.60 (t, 1H, J = 13.5 Hz, 16a-H2), 5.03 (s, 2H, Bn-H2), 6.72 (d, 1H, J = 2.0 Hz, 4-H), 
6.78 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.22 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (t, 1H, J = 7.5 Hz, 
4’-H), 7.38 (t, 3H, J = 7.5 Hz, 3’- and 5’-H, triazol-H), 7.43 (d, 2H, J = 7.5 Hz, 2’- and 6’-H). 13C 
NMR (δ, ppm, CDCl3): 6.5 (C-1”), 7.9 (2C, C-2” and -3”), 17.1 (C-18), 26.0, 27.9, 28.9, 29.8, 
31.2, 38.9, 42.3, 43.5, 46.3 (C-16a), 47.0 (C-16), 50.7 (C-13), 69.9 (Bn-CH2), 78.7 (C-17), 112.2 
(C-2), 114.8 (C-4), 120.8 (triazol-CH)), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.4 (C-4’), 128.5 
(C-3’ and -5’), 132.5 (C-10), 137.2 (C-1’), 137.9 (C-5), 149.6 (triazol-C), 156.7 (C-3). 
 
2.3.44. 3-Benzyloxy-16a-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (28b) 
Compound 20 (420.0 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (2.5:97.5 v/v) to yield pure 28b (417 mg, 82%) as white crystals. Mp: 
197199 оC; Rf= 0.42 (ss B). (Found: C, 77.62; H, 7.85. C33H41N3O2 (511.70) requires C, 77.46; 
H, 8.08%). 
1H NMR (δ, ppm, CDCl3): 0.76 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.20 (s, 1H, 1”-
H), 3.66 (d, 1H, J = 5.0 Hz, 17-H), 4.29 (dd, 1H, J = 13.5 Hz, J = 5.5 Hz, 16a-H2), 4.62 (dd, 1H, 
J = 13.5 Hz, J = 9.5 Hz, 16a-H2), 5.04 (s, 2H, Bn-H2), 6.72 (s, 1H, 4-H), 6.78 (dd, 1H, J = 8.5 Hz, 
J = 2.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.0 Hz, 4’-H), 7.37 (t, 2H, J = 7.0 
Hz, 3’- and 5’-H), 7.43 (d, 2H, J = 7.0 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 17.3 (C-
18), 25.2 (2C), 26.1, 28.0, 29.1, 29.8 (2C), 31.3, 33.2, 36.8 (C-1”), 39.0, 42.4, 43.6, 46.4 (C-16a), 
47.2 (C-16), 50.6 (C-13), 70.1 (Bn-CH2), 79.0 (C-17), 112.4 (C-2), 115.0 (C-4), 126.3 (C-1), 
127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 133.0 (C-10), 137.5 (C-1’), 137.9 (C-5), 
156.9 (C-3). 
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2.3.45. 3-Benzyloxy-16a-(4-cyclohexyl-1H-1,2,3-triazol-1-yl)methyl-estra-1,3,5(10)-trien-17a-ol 
(28c) 
Compound 20 (420.0 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (2.5:97.5 v/v) to yield pure 28c (200 mg, 76%) as a white solid. Mp: 
223225 оC; Rf= 0.44 (ss B). (Found C, 77.82; H, 8.35. C34H43N3O2 (525.72) requires C, 77.68; 
H, 8.24%). 
1H NMR (δ, ppm, CDCl3): 0.75 (s, 3H, 18-H3), 2.84 (m, 3H, 6-H2, 1”-H), 3.64 (s, 1H, 
17-H), 4.37 (m, 1H, 16a-H2), 4.69 (m, 1H, 16a-H2), 5.03 (s, 2H, Bn-H2), 6.72 (d, 1H, J = 1.5 Hz, 
4-H), 6.78 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.22 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (t, 1H, J = 
7.0 Hz, 4’-H), 7.38 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.43 (d, 2H, J = 7.0 Hz, 2’- and 6’-H 
 
2.3.46. 3-Benzyloxy-16a-(4-phenyl-1H-1,2,3-triazol-1-yl)methyl-estra-1,3,5(10)-trien-17a-ol 
(28d) 
Compound 20 (420.0 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 28d (337 mg, 64%) as a white solid. Mp: 205206 
о
C; Rf= 0.46 (ss B). (Found C, 78.42; H, 7.32. C34H37N3O2 (519.68) requires C, 78.58; H, 7.18%). 
1H NMR (δ, ppm, CDCl3): 0.76 (s, 3H, 18-H3), 2.87 (m, 2H, 6-H2), 3.68 (d, 1H, J = 5.0 Hz, 17-
H), 4.41 (dd, 1H, J = 13.5 Hz, J = 5.5 Hz, 16a-H2), 4.69 (t, 1H, J = 13.5 Hz, 16a-H2), 5.04 (s, 2H, 
Bn-H2), 6.73 (s, 1H, 4-H), 6.79 (dd, 1H, J = 8.0 Hz, J = 2.0 Hz, 2-H), 7.22 (d, 1H, J = 8.0 Hz, 1-
H), 7.38 (m, 8H, 2’-, 3’-, 4’-, 5’- and 6’-H, 3”-, 4”- and 5”-H), 7.84 (d, 2H, J = 7.5 Hz, 2”- and 
6”-H), 7.89 (s, 1H, triazol-H). 13C NMR (δ, ppm, CDCl3): 17.1 (C-18), 26.0, 27.9, 29.8, 31.2, 
38.9, 42.2, 43.5, 46.4 (C-13), 47.0 (C-16), 50.8 (C-16a), 69.9 (Bn-CH2), 78.8 (C-17), 112.3 (C-2), 
114.8 (C-4), 120.7 (triazol-CH), 125.7 (C-2’ and -6’), 126.3 (C-1), 127.4 (C-2” and -6”), 127.8 
(C-4’), 128.3 (C-4”), 128.5 (C-3” and -5”), 128.9 (C-3’ and -5’), 130.2 (C-10), 132.8 (C-1’), 
137.3 (C-1”), 137.9 (C-5), 147.1 (triazol-C), 156.7 (C-3). 
 
2.3.47. 3-Benzyloxy-16a-[4’-(4’’-nitro-benzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl]methylestra-
1,3,5(10)-trien-17a-ol (28e) 
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Compound 20 (420 mg, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 210 mg) were used for 
the synthesis as described in Section 2.3. The crude product was chromatographed on silica gel 
with ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 28e (610 mg, 98%) as a yellow solid. Mp: 
7577 оC; Rf= 0.45 (ss B). (Found C, 69.57; H, 61.32. C36H38N4O6 (622.71) requires C, 69.44; H, 
6.15%). 
1H NMR (δ, ppm, DMSO-d6): 0.66 (s, 3H, 18-H3), 2.71 (m, 2H, 6-H2), 3.57 (s, 1H, 16-
H), 4.29 (dd, 1H, J = 13.5 Hz, J = 8.5 Hz, 16a-H2), 4.47 (dd, 1H, J = 13.5 Hz, J = 8.5 Hz, 16a-
H2), 4.85 (d, 1H, J = 5.0 Hz, 17-H), 5.44 (s, 2H, Bn-H2), 6.65 (s, 1H, 4-H), 6.72 (d, 1H, J = 8.5 
Hz, 2-H), 7.14 (d, 1H, J = 8.5 Hz, 1-H), 7.29 (t, 1H, J = 7.5 Hz, 4’-H), 7.35 (t, 2H, J = 7.5 Hz, 3’- 
and 5’-H), 7.40 (d, 2H, J = 7.5 Hz, 2’- and 6’-H), 8.17 (d, 2H, J = 8.5 Hz, 3”- and 5”-H), 8.28 (s, 
1H, triazol H), 8.31 (d, 2H, J = 8.5 Hz, 2”- and 6”-H). 13C NMR (δ, ppm, DMSO-d6): 16.9 (C-
18), 25.6, 27.5, 28.4, 29.2, 31.1, 38.5, 39.8, 39.9, 43.2, 45.9 (C-16a), 46.2 (C-16), 53.4 (C-13), 
58.7 (linker CH2), 68.9 (Bn-CH2), 78.0 (C-17), 112.1 (C-2), 114.4 (C-4), 123.8 (C-2” and -6”), 
125.0 (triazol CH), 126.1 (C-1), 127.4 (C-2’ and -6’), 127.5 (C-4’), 128.3 (C-3’ and -5’), 130.6 
(C-3” and -5”), 132.3 (C-10), 134.7 (C-1’), 137.3 (C-5), 141.0 (C-1”), 150.2 (triazol C), 156.0 
(C-3), 163.9 (C=O). 
 
2.3.48. 3-Benzyloxy-16a-(4’-hydroxymethyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-
trien-17-ol (28f) 
Compound 28e (220 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from methanol to afford 28f 
(126 mg, 53%) as a white crystalline product. Mp: 8688 оC; Rf= 0.25 (ss B). (Found C, 73.68; 
H, 7.63. C29H35N3O3 (473.61) requires C, 73.54; H, 7.45%). 
1H NMR (δ, ppm, DMSO-d6): 0.68 
(s, 3H, 18-H3), 2.74 (m, 2H, 6-H2), 3.58 (brs, 1H, OH), 4.26 (t, 1H, J = 8.5 Hz, 16a-H2), 4.43 (dd, 
1H, J = 13.0 Hz, J = 7.0 Hz, 16a-H2), 4.51 (d, 2H, J = 5.0 Hz, linker H2), 4.85 (d, 1H, J = 4.0 Hz, 
17-H), 5.04 (s, 2H, Bn-H2), 5.13 (brs, 1H, OH), 6.68 (s, 1H, 4-H), 6.74 (d, 1H, J = 8.5 Hz, 2-H), 
7.17 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (d, 1H, J = 7.0 Hz, 4’-H), 7.37 (t, 2H, J = 7.0 Hz, 3’- and 5’-
H), 7.42 (d, 2H, J = 7.0 Hz, 2’- and 6’-H), 7.97 (s, 1H, triazol H). 13C NMR (δ, ppm, DMSO-d6): 
16.9 (C-18), 25.6, 27.5, 28.5, 29.2, 31.1, 38.5, 40.7, 43.2, 45.9, 46.2 (C-16), 47.9 (C-13), 50.6 (C-
16a), 55.0 (linker CH2), 68.9 (Bn-CH2), 78.0 (C-17), 112.1 (C-2), 114.4 (C-4), 122.7 (triazol 
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CH), 126.1 (C-1), 127.4 (C-2’ and -6’), 127.6 (C-4’), 128.3 (C-3’ and -5’), 132.4 (C-10), 137.3 
(C-1’), 137.4 (C-5), 147.6 (triazol C), 156.0 (C-3). 
 
2.4. Determination of the antiproliferative activities 
The growth-inhibitory effects of the compounds were tested in vitro by means of the MTT 
assay against a gynecological panel containing two breast cancer cell lines (MCF-7, MD-MB-
231) and two cell lines isolated from cervical malignancies (HeLa, SiHa) [11]. All cell lines were 
obtained from the European Collection of Cell Cultures (Salisbury, UK). The cells were 
maintained in minimal essential medium supplemented with 10% fetal bovine serum (FBS), 1% 
non-essential amino acids and an antibiotic–antimycotic mixture (AAM). All chemicals, if 
otherwise not specified, were purchased from Sigma-Aldrich Ltd. (Budapest, Hungary). All cell 
lines were grown in a humidified atmosphere of 5% CO2 at 37 
o
C. For pharmacological 
investigations, 10 mM stock solutions of the tested compounds were prepared with dimethyl 
sulfoxide (DMSO). The highest applied DMSO concentration of the medium (0.3%) did not have 
any substantial effect on the determined cellular functions. Cells were seeded into 96-well plates 
(5000 cells/well), allowed to stand overnight under cell culturing conditions, and the medium 
containing the tested compounds at two final concentrations (10 or 30 µM) was then added. After 
a 72-hour incubation viability was determined by the addition of 20 µl 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/ml). The formazan crystals 
precipitated in 4 h were solubilized in DMSO and the absorbance was determined at 545 nm with 
an ELISA plate reader utilizing untreated cells as controls. The most effective compounds 
eliciting at least 60% growth inhibition at 10 μM were tested again with a set of dilutions (0.3−30 
µM) in order to determine the IC50 values by means of Graphpad Prism 4.0 (Graphpad Software; 
San Diego, CA, US). These promising compounds were additionally tested using nonmalignant 
murine fibroblasts (NIH-3T3) to obtain preliminary data concerning cancer selectivity of the 
tested molecules. Two independent experiments were performed with 5 parallel wells and 
cisplatin (Ebewe GmbH, Unterach, Austria), an agent administered clinically in the treatment of 
certain gynecological malignancies, was used as reference compound. 
 
3. Results and discussion 
3.1. Synthetic studies 
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 To prepare novel steroid triazoles via 1,3-dipolar cycloaddition, we chose the 3-methoxy- and 3-
benzyloxy-16-hydroxymethylestra-1,3,5(10)-trien-17-ol diastereomers (5–8 and 9–12). The 
synthesis strategy for the preparation of the starting diols (21–28) is illustrated in Scheme 1. The 
synthesis of steroidal 1,2,3-triazoles by CuAAC is outlined in Scheme 2. 
     Stereoselective tosylation of 5–8 and bromination of 9–12 gave 5b–8b and 9c–12c, 
respectively, which then underwent facile SN2 substitution with NaN3 in N,N-dimethylformamide 
to furnish the corresponding 16-azidomethyl compounds (13–16 and 17–20). 
 The 16-azido compounds were subjected to the azide–alkyne CuAAC reaction with different 
alkyl- and aryl-acetylenes. The azide–alkyne reactions of these compounds were carried out with 
CuI as catalyst in the presence of Et3N in CH2Cl2 under reflux conditions to obtain the required 3-
methoxy- and 3-benzyloxyestra-1,3,5(10)-trien-16-(1’,4’-substituted 1’,2’,3’)-triazolyl 
derivatives (21–24 and 25–28). 
 
 
3.2. Determination of the antiproliferative properties of the 16-triazolylmethyl diastereomers 
 
We have published recently that introduction of a substituted triazole moiety onto 
different positions of the estrane skeleton might increase the antiproliferative properties of 
estrone derivatives [12]. It was also established that the presence of certain alkyl or aralkyl 
protecting groups at the phenolic OH function is advantageous. Concerning that 16-
hydroxymethylene-17-hydroxy derivatives of estrone-3-methyl ether or 3-benzyl ether (5a‒12a) 
displayed substantial cytostatic potential against different types of breast cancer cell lines, these 
compounds might be suitable for directed modifications with the aim of developing potentially 
more active antiproliferative steroidal derivatives [13]. In the light of the above-mentioned recent 
observations, here we aimed to combine the substituted triazole and the 16,17-disubstituted 
estrone 3-ether moieties. The present study included an evaluation of the direct antiproliferative 
capacities of the newly synthesized heterocyclic compounds (21af, 22af, 23af, 24af and 
25af, 26af, 27af, 28af). The antiproliferative activities were determined in vitro by means 
of MTT assays against human adherent cervical (SiHa, HeLa) and breast cancer (MCF-7 and 
MDA-MB-231) cell lines.  
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 The antiproliferative activities of the newly synthesized heterocyclic compounds 
depended on the nature of the protecting group at the 3-hydroxy function and on the orientation 
of the substituents at C-16 and C-17. In general, the 3-methyl ethers (2124) exhibited weak 
antiproliferative action; none of them exerted any substantial effect at 10 M (Table 1). All 
diastereomers of the 3-benzyl ether series (2528) proved to be more potent in comparison with 
their 3-methyl ether counterparts (Table 2). This is in agreement with our earlier results [14]. 
Based on the substantial difference of the two groups, i.e. that of 3-methyl ethers and 3-benzyl 
ethers, it can be concluded that only the latter derivatives are promising from pharmacological 
point of view. 
Concerning the orientation of the substituents at position C-16 and C-17, the 16,17-
derivatives (25af) displayed outstanding growth-inhibitory properties. Two derivatives bearing 
similar cycloalkyl groups at position C-4’ displayed substantial selective antiproliferative action 
against the triple-negative breast cancer cell line MDA-MB-231 with IC50 values in the low 
micromolar range. It should be underlined  that 25b and 25c did not significantly influence the 
proliferation of other cell lines tested, including the non-cancerous fibroblast. Although both the 
4’-cyclohexyl (25c) and the 4’-phenyl derivative (25d) have six-membered substituents, their 
cytostatic behavior is completely different. This might be attributed to the different steric 
structure of the two rings (chair or planar) at C-4’. Compound 25d exerted potent 
antiproliferative action against all tested cell lines without any selectivity. The cis-16α,17α-3-
benzyl ethers (28a–f) were less potent than their β,β-counterparts (25a–f), except for 28d, which 
behaved similarly  to its diastereomer 25d. The trans-16β,17α-isomers (27a–f) exhibited activity 
exclusively on the breast cancer cell lines. Surprisingly, the tendency observed earlier (in the case 
of compounds 25a–f) concerning the nature of C-4’ substituent was not valid  here. Only 26a and 
26e inhibited cell growth markedly, but with no tumor selectivity. It’s worth mentioning that 
trans-16α,17β isomer 26c was the sole compound, which inhibited the proliferation of HPV 16+ 
squamous cell carcinoma SiHa, showing an IC50 value comparable with that of cisplatin. 
In view of the cell lines, it should be noted that triple-negative breast cancer cell line MDA-MB-
231 proved to be the most sensitive and all calculated IC50 values were lower than that of the 
reference agent cisplatin (19.1 μM). 
Regarding the present and earlier results obtained for 16,17-disubstituted 3-benzyl ethers, it can 
be stated that introduction of a substituted triazolyl moiety onto the C-16 methylene group of the 
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cis isomers proved to be advantageous. In the case of compounds 25b and 25c,  both the 
antiproliferative potential and the tumor selectivity were markedly improved. 
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Legends for Schemes and Tables 
Scheme 1 Reagents and conditions: (i) NaOMe, HCOOEt, anhydrous toluene, 50 °C; (ii) KBH4, 
MeOH; (iii) KOAc, CH3COOH, NaOMe/MeOH. 
 
Scheme 2 Reagents and conditions: (i) appropriate alkyne, TEA, CuI, CH2Cl2, 40 °C, 24 h; (ii) 
NaOMe, MeOH, 24 h. 
 
Table 1 Antiproliferative activities of compounds 21af, 22af, 23af and 24af 
 
Table 2 Antiproliferative activities of compounds 25af, 26af, 27af and 28af 
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Table 1 
Growth Inhibition, % ± SEM 
[calculated IC50 (μM)] 
Conc. 
(M) 
HeLa SiHa MCF-7 
MDA-MB-
231 
21 
a 
10 
30 
<20 
<20 
21.28±1.88 
28.71±2.20 
<20 
46.42±1.47 
<20 
<20 
b 
10 
30 
<20 
39.86±.38 
<20 
<20 
<20 
57.42±1.77 
<20 
29.88±1.57 
c 
10 
30 
<20 
40.22±1.02 
<20 
<20 
<20 
70.84±1.55 
<20 
37.96±1.55 
d 
10 
30 
<20 
44.16±0.48 
<20 
<20 
<20 
54.93±1.78 
<20 
38.28±1.84 
e 
10 
30 
<20 
37.18±1.65 
23.91±1.61 
54.72±0.48 
34.23±3.10 
76.26±0.72 
<20 
35.93±2.13 
f 
10 
30 
<20 
41.03±0.77 
28.06±1.99 
57.69±1.12 
29.45±1.67 
70.23±1.35 
<20 
34.81±2.88 
22 
a 
10 
30 
<20 
<20 
25.55±1.01 
34.78±2.47 
<20 
57.43±1.91 
<20 
<20 
b 
10 
30 
<20 
<20 
<20 
26.57±2.26 
<20 
67.59±1.65 
<20 
<20 
c 
10 
30 
<20 
<20 
<20 
29.90±2.59 
<20 
69.68±0.77 
<20 
<20 
d 
10 
30 
<20 
<20 
<20 
29.96±1.79 
<20 
70.75±1.05 
<20 
14.54±1.32 
e 
10 
30 
<20 
<20 
<20 
38.69±2.09 
<20 
63.12±2.14 
<20 
<20 
f 
10 
30 
<20 
<20 
<20 
37.79±1.04 
22.02±1.61 
50.94±1.55 
<20 
<20 
23 
a 
10 
30 
<20 
31.14±1.28 
<20 
<20 
<20 
28.72±0.93 
<20 
25.08±3.15 
b 
10 
30 
<20 
58.25±2.03 
<20 
<20 
<20 
48.01±1.31 
<20 
<20 
c 
10 
30 
<20 
<20 
30.97±2.69 
33.89±2.35 
<20 
<20 
<20 
<20 
d 
10 
30 
<20 
26.90±2.15 
<20 
<20 
<20 
63.27±0.82 
<20 
<20 
e 
10 
30 
<20 
<20 
<20 
37.53±3.00 
<20 
33.94±0.75 
<20 
28.19±0.96 
f 
10 
30 
<20 
26.61±0.57 
29.13±1.59 
43.85±3.32 
<20 
38.45±1.93 
<20 
43.85±3.32 
24 
a 
10 
30 
<20 
89.01±0.47 
<20 
<20 
<20 
78.65±0.78 
<20 
46.21±1.54 
b 
10 
30 
<20 
34.18±0.81 
<20 
<20 
<20 
31.07±2.36 
<20 
<20 
c 
10 
30 
<20 
49.11±0.55 
<20 
<20 
<20 
43.22±1.52 
<20 
<20 
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d 
10 
30 
<20 
42.13±1.66 
<20 
<20 
<20 
55.41±0.76 
<20 
<20 
e 
10 
30 
<20 
83.66±0.34 
<20 
42.06±2.50 
<20 
70.11±1.06 
<20 
50.27±2.00 
f 
10 
30 
<20 
84.77±1.18 
<20 
29.80±1.66 
22.34±2.06 
68.27±1.19 
<20 
47.74±1.21 
cisplatin 
10 
30 
42.61±2.33 
99.93±0.26 
[12.43] 
86.84±0.50 
90.18±1.78 
[7.84] 
53.03±2.29 
86.90±1.24 
[5.78] 
20.84±0.81 
74.47±1.20 
[19.13] 
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Table 2 
Growth Inhibition, % ± SEM 
[calculated IC50 (μM)] 
 
Conc. 
(M) 
HeLa SiHa MCF-7 
MDA-MB-
231 
NIH-3T3 
25  
a 
10 
30 
44.94±1.04 
52.45±2.39 
21.17±2.05 
66.23±0.86 
41.71±0.64 
64.32±0.56 
47.32±1.15 
71.49±0.75 
44.91±1.36 
91.28±0.50 
b 
10 
30 
 
51.49±3.62 
62.58±2.21 
 
49.36±1.69 
73.94±2.04 
 
44.58±1.50 
50.52±3.26 
 
93.00±0.26 
93.71±0.09 
[3.33] 
44.81±1.50 
59.09±0.73 
 
c 
10 
30 
54.70±1.88 
53.66±2.56 
49.58±2.11 
61.83±2.77 
44.04±3.32 
59.33±2.99 
77.13±1.07 
88.81±0.55 
[5.91] 
 
d 
10 
30 
 
64.14±0.86 
90.12±0.99 
[2.28] 
70.88±1.03 
94.14±0.29 
[4.05] 
73.41±1.22 
80.16±3.40 
[3.91] 
95.04±0.16 
95.60±0.06 
[3.65] 
95.60±0.25 
98.22±0.04 
[3.34] 
e 
10 
30 
<20 
92.12±0.25 
<20 
89.25±0.68 
41.63±2.83 
97.00±0.11 
21.96±0.73 
95.22±0.91 
 
f 
10 
30 
45.08±0.72 
39.39±0.49 
41.26±1.25 
52.60±1.31 
55.41±1.26 
62.52±0.67 
55.57±1.50 
88.92±0.99 
 
26  
a 
10 
30 
 
37.98±2.68 
96.56±0.11 
 
<20 
96.71±0.17 
 
72.42±2.19 
98.72±0.09 
[6.11] 
46.43±2.05 
97.96±0.17 
 
85.50±1.22 
97.63±0.12 
[5.97] 
b 
10 
30 
38.55±1.32 
43.97±2.23 
<20 
<20 
31.80±1.35 
84.44±0.71 
17.13±2.36 
37.72±2.28 
 
c 
10 
30 
36.30±1.45 
35.53±1.24 
<20 
<20 
24.95±2.15 
74.73±1.00 
<20 
<20 
 
d 
10 
30 
<20 
22.15±1.29 
<20 
<20 
47.25±1.78 
57.30±0.77 
45.55±2.63 
59.79±1.22 
 
e 
10 
30 
 
<20 
96.98±0.33 
 
<20 
96.91±0.14 
 
68.51±0.71 
99.12±0.07 
[6.53] 
89.24±0.70 
97.73±0.23 
[5.69] 
31.41±2.21 
99.01±0.05 
[11.75] 
f 
10 
30 
21.62±3.46 
30.79±2.92 
<20 
27.28±1.90 
29.14±2.06 
43.28±1.53 
40.46±2.98 
76.93±1.60 
10.00±1.01 
23.40±0.60 
27  
a 
10 
30 
24.26±2.63 
85.22±1.32 
34.00±1.43 
82.68±1.25 
58.38±3.20 
97.21±0.10 
56.24±0.98 
84.18±0.44 
25.56±2.21 
99.24±0.07 
b 
10 
30 
37.10±1.77 
52.08±2.08 
39.59±1.17 
69.54±1.24 
51.92±1.00 
65.12±1.91 
56.44±0.98 
71.81±0.96 
 
c 
10 
30 
 
38.89±2.60 
55.93±2.39 
 
64.05±1.24 
83.34±1.31 
[9.29] 
49.68±1.66 
61.26±1.72 
 
72.37±1.27 
85.81±1.04 
[6.74] 
13.99±1.79 
29.56±1.17 
 
d 
10 
30 
34.23±1.39 
47.74±0.78 
30.04±2.07 
39.96±2.34 
47.03±1.25 
42.43±1.69 
55.77±1.03 
57.71±1.00 
 
e 
10 
30 
<20 
99.06±0.09 
21.53±1.81 
96.91±0.06 
35.74±1.33 
98.50±0.93 
<20 
99.01±0.52 
 
f 
10 
30 
<20 
98.72±0.13 
24.65±1.46 
96.04±0.25 
25.50±2.93 
98.41±0.15 
24.79±2.20 
98.79±0.16 
 
28  
 1 
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a 
10 
30 
35.48±1.91 
63.44±1.79 
46.07±1.13 
69.86±0.55 
52.88±0.82 
73.39±0.74 
25.61±2.84 
52.16±2.52 
 
b 
10 
30 
39.75±2.45 
47.34±1.62 
<20 
<20 
43.51±1.85 
42.28±1.44 
44.86±0.93 
43.73±2.25 
 
c 
10 
30 
56.71±0.57 
58.21±0.73 
39.93±3.14 
31.15±2.86 
48.56±0.48 
49.93±1.33 
30.30±1.64 
31.60±3.08 
 
d 
10 
30 
 
74.18±1.15 
91.17±0.33 
[2.30] 
76.88±0.49 
87.39±0.86 
[4.14] 
75.97±0.89 
88.99±0.25 
[3.87] 
86.12±0.33 
90.72±1.00 
[3.89] 
70.18±1.15 
91.12±1.64 
[3.71] 
e 
10 
30 
27.42±2.16 
92.94±0.17 
<20 
91.91±0.23 
52.86±1.30 
96.38±0.07 
29.58±1.69 
94.09±0.43 
 
f 
10 
30 
30.97±1.02 
91.88±0.26 
39.85±1.24 
90.94±0.18 
50.60±0.65 
95.12±0.10 
31.89±2.92 
92.56±0.34 
 
cisplatin 
10 
30 
42.61±2.33 
99.93±0.26 
[12.43] 
86.84±0.50 
90.18±1.78 
[7.84] 
53.03±2.29 
86.90±1.24 
[5.78] 
20.84±0.81 
74.47±1.20 
[19.13] 
94.20±0.39 
96.44±0.17 
[3.23] 
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Scheme 1. Reagents and conditions: (i) NaOMe, HCOOEt, anhydrous toluene, 50 °C; (ii) 
KBH4, MeOH; (iii) KOAc, CH3COOH, NaOMe/MeOH 
 
          Scheme 1.  
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Scheme 2.  
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ABSTRACT The four possible isomers of each of 3-methoxy- and 3-benzyloxyestra-1,3,5(10)-
trien-17-ols (5–8 and 9–12) were converted through 16-p-tosyloxymethyl- or 16-bromomethyl 
derivatives into their 3-methoxy- and 3-benzyloxy-16-azidomethylestra(1,3,5(10)-triene 
derivatives (13–16 and 17–20). The regioselective Cu(I)-catalyzed 1,3-dipolar cycloaddition of 
these compounds with different terminal alkynes afforded novel 1,4-disubstituted diastereomers 
(21a–f, 22a–f, 23a–f, 24a–f and 25a–f, 26a–f, 27a–f, 28a‒f). The antiproliferative activities of 
the structurally related triazoles were determined in vitro with the microculture tetrazolium assay 
on four malignant human cell lines of gynecological origin (Hela, SiHa, MCF-7 and MDA-MB-
231). 
 
 
Keywords: 3-methoxy- and 3-benzyloxy-16-azidomethylestra-1,3,5(10)-triene-17-ols; 1,3-dipolar 
cycloaddition, 4
’
substituted-steroid triazoles; cytotoxic activity 
 
1.  Introduction 
 
*Manuscript
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Among the hybrid natural products, hybrids of steroid frameworks have attracted great attention 
due to significant biological properties and numerous therapeutic effects of the basic compound. 
Steroids have become ideal synthons for the development of diverse conjugates due to their rigid 
framework and potential for varying levels of functionalization, broad biological activity profile 
and their ability to penetrate the cell membranes and bind to specific hormonal receptors [1-3]. 
The place, length and orientation of the linkers between the two parts of the hybrids  
stems unequivocally from the method of their synthesis. The literature provides a large number of 
methods to introduce the linker onto the sterane skeleton. The effect of the length and character 
of the linker are very often discussed [4]. However, only limited information is available with 
respect to the steric effect of the linkers on biological properties. As concerns the 16-substituted 
estrogenes, usually the 16α-substituted-17β-hydroxy compounds have been studied. The 
biological activity has generally not been studied for the whole isomer series [5]. 
 In the 16-substituted 17-hydroxysteroids, the two chiral centres permit four 
stereochemical modifications. Since availability of the complete series of isomers would permit a 
number of interesting comparative examinations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
We have previously reported the preparation and configurational assignment of the four 
possible isomers of the 3-methoxy- and 3-benzyloxy-16-hydroxymethyl-estra-1,3,5(10)-trien-17-
ol derivatives (5a–8a and 9a–12a) [6‒8]. Treatment of 3-methoxy- and 3-benzyloxyestra-16-
hydroxymethylidene-estra-1,3,5(10)-trien-17-ones (1 and 3) with NaOMe and ethyl formate gave 
3-methoxy- and 3-benzyloxy-16-hydroxymethylidene-estra-1,3,5(10)-trien-17 ones (2 and 4). 
The C-16 formyl compounds were reduced with KBH4 in methanol yielding a mixture of three 
(5a–7a and 9a–11a) of the four possible isomers of each of the 3-methoxy- and 3-benzyloxy-16-
hydroxymethylestra-1,3,5(10)-trien-17-ol isomers in a ratio of 50:45:5 in 94% yield [6,8  ]. The 
fourth isomers (8a and 12a) were prepared from 16α-acetoxymethyl-17β-toluenesulfonate mixed 
esters 6d and 10d, respectively, by neighbouring group participation during solvolysis in aqueous 
AcOH. The structures of the isomers were confirmed unambiguously by their IR, 
1
H and 
13
C 
NMR spectra (Scheme 1) [7,8]. 
 
(Scheme 1) 
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The four 3-methoxy- and 3-benzyloxy-estra-1,3,5(10)-trien-17-ol isomers (5a–8a and 9a–
12a) are suitable starting materials to prepare 16-triazolyl-methyl derivatives. Triazoles are 
attractive units because of their stability against metabolic degradation and their ability to form 
hydrogen bonds. The Cu(I)-catalysed azide–alkyne cycloaddition (CuAAC) is a facile method of 
wide applicability for the introduction of a triazole moiety into natural products [9]. In these 
compounds the triazole heterocycles and their substituted derivatives are connected through a 
methylene linker to the sterane skeleton. The 16-p-tolylsulfonyloxymethyl ester [5,6] and 16-
bromomethyl derivatives [10] of the 16-hydroxymethyl starting materials were used for 
substitution reaction with NaN3 in N,N-dimethylformamide to have the desired 3-methoxy- and 
3-benzyloxy-16-azidomethylestra-1,3,5(10)-trien-17-ols (13–16 and 17–20). From these azido 
compounds several D-ring-substituted estrane derivatives containing a 1,2,3-triazole ring were 
synthesized by the reaction of 13–16 and 17–20 with various terminal alkynes through the use of 
the “click” chemistry approach to deliver compounds 21a–e, 22a–e, 23a–e, 24a–e, 25a–e, 26a–e, 
27a–e and 28a–e. 
 
2. Experimental 
2.1. General 
 
Melting points (Mp) were determined on a Kofler block and are uncorrected. Specific rotations 
were measured in CHCl3 (c 1) at 20 
○
C with a POLAMAT-A (Zeiss-Jena) polarimeter and are 
given in units of 10
–1 
deg cm
2
 g
–1
. Elementary analysis data were determined with a Perkin-Elmer 
CHN analyzer model 2400. The reactions were monitored by TLC on Kieselgel-G (Merck Si 254 
F) layers (0.25 mm thick); solvent systems (ss): (A) diisopropyl ether, (B) 
acetone/toluene/hexane (30:35:35 v/v). The spots were detected by spraying with 5% 
phosphomolybdic acid in 50% aqueous phosphoric acid. The Rf values were determined for the 
spots observed by illumination at 254 and 365 nm. Flash chromatography: silica gel 60, 40–63 
m. All solvents were distilled prior to use. NMR spectra were recorded on a Bruker DRX 500 
and Bruker Ascend 500 instrument at 500 (
1
H NMR) or 125 MHz (
13
C NMR). Chemical shifts 
are reported in ppm (δ scale) and coupling constants (J) in Hertz. For the determination of 
multiplicities, the J-MOD pulse sequence was used. 
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2.2. 3-Methoxy- and 3-benzyloxy-16-azidomethylestra-1,3,5(10)-trienes (13–16 and 17–20) 
General procedure 
 
Compounds 5b–8b [5,6] (470 mg, 1 mmol) or 9c–12c [8] (455 mg, 1 mmol) were dissolved in 
N,N-dimethylformamide (25 ml) and then NaN3 (260 mg) was added. The mixture was stirred for 
6 h at 80 
o
C, then poured into water (50 ml). The precipitate separating out was filtered off and 
subjected to chromatographic separation with CH2Cl2/hexane in different ratios. 
 
2.2.1. 3-Methoxy-16-azidomethyl-estra-1,3,5(10)-trien-17-ol (13) 
Compound 5b (470 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The 
crude product was chromatographed on silica gel with CH2Cl2/hexane (1:3 v/v) to yield pure 13 
(318 mg, 93%). Mp 134135 oC; Rf = 0.65 (ss A); [α]D
20
 = + 80 (c 1 in CHCl3). (Found C, 70.23; 
H, 8.05. C20H27N3O2 (341.45) requires C, 70.35; H, 7.97%). 
1H NMR (δ, ppm, CDCl3): 0.82 (s, 
3H, 18-H3), 2.87 (m, 2H, 6-H2), 3.32 (dd, 1H, J = 12.5 Hz, J = 7.5 Hz, 16a-H2), 3.61 (dd, 1H, J = 
12.5 Hz, J = 7.5 Hz, 16a-H2), 3.78 (s, 3H, 3-OCH3), 3.87 (d, 1H, J = 10.0 Hz, 17-H), 6.64 (d, 1H, 
J = 2.5 Hz, 4-H), 6.72 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.20 (d, 1H, J = 8.5 Hz, 1-H). 
13
C 
NMR (δ, ppm, CDCl3): 12.2 (C-18), 26.3, 27.5, 29.7, 30.4, 37.7, 38.2, 40.2, 44.0, 44.3 (C-13), 
49.0, 53.4 (C-16a), 55.2 (3-OCH3), 81.5 (C-17), 111.6 (C-2), 113.9 (C-4), 126.2 (C-1), 132.5 (C-
10), 137.9 (C-5), 157.7 (C-3). 
  
2.2.2. 3-Methoxy-16-azidomethylestra-1,3,5(10)-trien-17-ol (14) 
Compound 6b (470 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The 
crude product was chromatographed on silica gel with CH2Cl2/hexane (1:3 v/v) to yield pure 14 
(287 mg, 84%). Mp 8586 oC; Rf = 0.62 (ss A); [α]D
20
 = + 48 (c 1 in CHCl3). (Found C, 70.42; H, 
7.65. C20H27N3O2 (341.45) requires C, 70.35; H, 7.97%). 
1H NMR (δ, ppm, CDCl3): 0.84 (s, 3H, 
18-H3), 2.86 (m, 2H, 6-H2), 3.43 (d, 1H, J = 7.5 Hz, 17-H), 3.48 (dd, 2H, J = 6.5 Hz, J = 3.5 Hz, 
16a-H2), 3.78 (s, 3H, 3-OCH3), 6.63 (s, 1H, 4-H), 6.72 (dd, 1H, J = 6.5 Hz, J = 2.0 Hz, 2-H), 7.20 
(d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, CDCl3): 11.8 (C-18), 26.1, 27.2, 28.0, 29.7, 36.6, 
38.5, 43.6, 43.9, 44.2 (C-13), 48.5, 55.2 (3-OCH3), 55.6 (C-16a), 85.1 (C-17), 111.5 (C-2), 113.8 
(C-4), 126.3 (C-1), 132.4 (C-10), 137.8 (C-5), 157.5 (C-3). 
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2.2.3. 3-Methoxy-16-azidomethylestra-1,3,5(10)-trien-17-ol (15) 
Compound 7b (470 mg, 1 mmol) were used for the synthesis as described in Section 2.2. The 
crude porduct was chromatographed on silica gel with CH2Cl2/hexane (1:3 v/v) to yield pure 15 
(275 mg, 80%). Mp 9698; oC; Rf = 0.60 (ss A); [α]D
20
 = + 68 (c 1 in CHCl3). (Found C, 70.26; 
H, 8.15. C20H27N3O2 (341.45) requires C, 70.35; H, 7.97%). 
1H NMR (δ, ppm, CDCl3): 0.76 (s, 
3H, 18-H3), 2.86 (m, 2H, 6-H2), 3.43 (dd, 2H, J = 7.5 Hz, J = 3.0 Hz, 16a-H2), 3.61 (s, 1H, 17-H), 
3.78 (s, 3H, 3-OCH3), 6.64 (d, 1H, J = 2.5 Hz, 4-H), 6.72 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 
7.22 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, CDCl3): 17.7 (C-18), 25.9, 27.9, 29.8, 30.3, 
31.9, 38.6, 43.3, 45.0 (C-13), 48.9, 55.2 (3-OCH3), 55.6 (C-16a), 83.0 (C-17), 111.5 (C-2), 113.8 
(C-4), 126.3 (C-1), 132.4 (C-10), 137.9 (C-5), 157.5 (C-3). 
 
2.2.4. 3-Methoxy-16-azidomethylestra-1,3,5(10)-trien-17-ol (16) 
Compound 8b (470 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The 
crude product was chromatographed on silica gel with CH2Cl2/hexane (1:3 v/v) to yield pure 16 
(283 mg, 86%). Mp 118120 oC; Rf = 0.65 (ss A); [α]D
20
 = + 34 (c 1 in CHCl3). (Found C, 70.55; 
H, 7.78. C20H27N3O2 (341.45) requires C, 70.35; H, 7.97%). 
1H NMR (δ, ppm, CDCl3): 0.80 (s, 
3H, 18-H3), 2.87 (m, 2H, 6-H2), 3.35 (dd, 1H, J = 12.0 Hz, J = 6.0 Hz, 16a-H2), 3.53 (dd, 1H, J = 
12.0 Hz, J = 9.5 Hz, 16a-H2), 3.78 (s, 3H, 3-OCH3), 3.84 (d, 1H, J = 6.0 Hz, 17-H), 6.63 (d, 1H, J 
= 2.5 Hz, 4-H), 6.72 (dd, 1H, J = 8.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, 
CDCl3): 17.3 (C-18), 26.1, 28.0, 29.2, 31.3, 39.1, 40.5, 43.6, 46.4 (C-13), 47.0, 52.4 (C-16a), 
55.2 (3-OCH3), 79.9 (C-17), 111.6 (C-2), 114.0 (C-4), 126.3 (C-1), 132.7 (C-10), 137.9 (C-5), 
157.6 (C-3). 
 
2.2.5. 3-Benzyloxy-16-azidomethylestra-1,3,5(10)-trien-17-ol (17) 
Compound 9c (455 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The 
crude product was chromatographed on silica gel with CH2Cl2/hexane (1:1 v/v) to yield pure 17 
(250 mg, 59%). Mp 115117 oC; Rf = 0.45 (ss A). (Found C, 74.55; H, 7.64. C26H31N3O2 
(417.54) requires C, 74.79; H, 7.48%). 
1H NMR (δ, ppm, CDCl3): 0.82 (s, 3H, 18-H3), 2.86 (m, 
2H, 6-H2), 3.33 (dd, 1H, J = 12.0 Hz, J = 7.5 Hz, 16a-H2), 3.60 (dd, 1H, J = 12.5 Hz, J = 7.5 Hz, 
16a-H2), 3.87 (d, 1H, J = 9.5 Hz, 17-H), 5.04 (s, 2H, Bn-H2), 6.73 (s, 1H, 4-H), 6.79 (d, 1H, J = 
8.0 Hz, J = 2.0 Hz, 2-H), 7.21 (d, 1H, J = 8.0 Hz, 1-H), 7.32 (t, 1H, J = 7.5 Hz, 4’-H), 7.39 (t, 2H, 
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J = 7.5 Hz, 3’-H and 5’-H), 7.44 (d, 2H, J = 7.5 Hz, 2’-H and 6’-H). 13C NMR (δ, ppm, CDCl3): 
12.2 (C-18), 26.2, 27.5, 29.7, 30.3, 37.6, 38.1, 40.1, 43.9, 44.2 (C-13), 48.8 (C-16), 53.3 (C-16a), 
69.9 (Bn-CH2), 81.5 (C-17), 112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.3 (C-2’ and C-6’), 127.8 
(C-4’), 128.5 (C-3’ and C-5’), 132.7 (C-10), 137.3 (C-1’), 137.9 (C-5), 156.8 (C-3). 
 
2.2.6. 3-Benzyloxy-16-azidomethylestra-1,3,5(10)-trien-17-ol (18) 
Compound 10c (455 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The 
 crude product was chromatographed on silica gel with CH2Cl2/hexane (3:1 v/v) to yield pure 18 
(254 mg, 61%). Mp 7577 oC; Rf = 0.40 (ss A). (Found C, 74.87; H, 7.32. C26H31N3O2 (417.54) 
requires C, 74.79; H, 7.48%). 
1H NMR (δ, ppm, CDCl3): 0.84 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 
3.44 (t, 1H, J = 8.0 Hz, 17-H), 3.48 (m, 2H, 16a-H2), 5.04 (s, 2H, Bn-H2), 6.73 (s, 1H, 4-H), 6.79 
(d, 1H, J = 8.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (t, 1H, J = 7.0 Hz, 4’-H), 7.39 (t, 2H, 
J = 7.0 Hz, 3’- and 5’-H), 7.44 (d, 2H, J = 7.0 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 11.8 
(C-18), 26.1, 27.2, 27.9, 29.7, 36.6, 38.5, 43.6, 43.9, 44.2 (C-13), 48.6 (C-16), 55.6 (C-16a), 69.9 
(Bn-CH2), 85.1 (C-17), 112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 
128.5 (C-3’ and -5’), 132.7 (C-10), 137.3 (C-1’), 137.9 (C-5), 156.8 (C-3). 
 
2.2.7. 3-Benzyloxy-16-azidomethyl-estra-1,3,5(10)-trien-17-ol (19) 
Copound 11c (455 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The crude 
product was chromatographed on silica gel with CH2Cl2/hexane (3:1 v/v) to yield pure 19 (23. 
mg, 40%). Mp. 134-136 
o
C. Rf = 0.38 (ss A). (Found C, 74.92; H, 7.37. C26H31N3O2 (417.54) 
requires C, 74.79; H, 7.48%). 
1H NMR (δ, ppm, CDCl3): 0.84 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 
3.43 (d, 2H, J = 8.0 Hz, 17-H), 3.48 (t, 2H, J = 6.5 Hz, 16a-H2), 5.04 (s, 2H, Bn-H2), 6.73 (s, 1H, 
4-H), 6.79 (d, 1H, J = 8.0 Hz, 2-H), 7.22 (d, 1H, J = 8.0 Hz 1-H), 7.33 (d, 1H, J = 7.0 Hz, 4’-H), 
7.39 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.44 (d, 2H, J = 7.0 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, 
CDCl3): 11.8 (C-18), 26.1, 27.2, 28.0, 29.7, 36.6, 38.4, 43.5, 43.9, 44.1 (C-13), 48.5 (C-16), 55.6 
(C-16a), 69.9 (Bn-CH2), 85.1 (C-17), 112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 
127.8 (C-4’), 128.5 (C-3’ and -5’), 132.7 (C-10), 137.3 (C-1’), 137.9 (C-5), 156.7 (C-3).  
 
2.2.8. 3-Benzyloxy-16-azidomethyl-estra-1,3,5(10)-trien-17-ol (20) 
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Compound 12c (455 mg, 1 mmol) was used for the synthesis as described in Section 2.2. The 
crude was chromatographed on silica gel with CH2Cl2/hexane (1:1 v/v) to yield pure 20 (330 mg, 
79%). Mp 9092 оC. Rf = 0.45 (ss A). (Found C, 74.68; H, 7.55. C26H31N3O2 (417.54) requires C, 
74.79; H, 7.48%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.71 (m, 2H, 6-H2), 3.35 (dd, 
1H, J = 12.0 Hz, J = 6.5 Hz, 16a-H2), 3.52 (dd, 1H, J = 12.0 Hz, J = 6.5 Hz, 16a-H2), 3.84 (d, 1H, 
J = 5.0 Hz, 17-H), 5.04 (s, 2H, Bn-H2), 6.73 (s, 1H, 4-H), 6.79 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-
H), 7.22 (d, 1H, J = 8.5 Hz, 1-H), 7.33 (t, 1H, J = 7.5 Hz, 4’-H), 7.39 (t, 2H, J = 7.5 Hz, 3’- and 
5’-H), 7.44 (d, 2H, J = 7.5 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 17.2 (C-18), 26.0, 27.9, 
29.0, 29.7, 31.2, 38.9, 40.4, 43.5, 46.3 (C-13), 46.8 (C-16), 52.2 (C-16a), 69.9 (Bn-CH2), 79.7 (C-
17), 112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -
5’), 132.8 (C-10), 137.3 (C-1’), 138.0 (C-5), 156.7 (C-3).  
 
2.3. General procedure for the synthesis of triazoles (21a–e, 22a–e, 23a–e, 24a–e, 25a–e, 26a–e, 
27a–e, and 28a–e) 
3-Methoxy-16-azidomethylestra-1,3,5(10)-trien-17-ol isomers (13–16) (342 mg, 1 mmol) or 3-
benzyloxy-16-azidomethylestra-1,3,5(10)-trien-17-ol isomers (17–20) 418 mg, 1 mmol) were 
dissolved in CH2Cl2 (20 ml), then CuI (19 mg, 0.10 mmol), Et3N (0.2 ml, 2 mmol) and the 
appropriate terminal alkynes (2 mmol) were added. The mixtures were stirred under reflux for 24 
h, then diluted with water (30 ml) and extracted with CH2Cl2 (2 × 30 ml). The combined organic 
phases were dried over Na2SO4 and evaporated in vacuo. The crude products were purified by 
flash chromatography using CH2Cl2/ethyl acetate in different ratios. 
 
2.3.1. 3-Methoxy-16β-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-
ol (21a) 
Compound 13 (342 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
CH2Cl2/hexane (3:1 v/v) to yield pure 21a (210 mg, 51%) as a white solid. Mp: 189191 
о
C; Rf = 
0.44 (ss B). (Found C, 73.84; H, 7.98. C25H33N3O2 (407.55) requires C, 73.68; H, 8.16%). 
1
H 
NMR (δ, ppm, CDCl3): 0.80 (s, 3H, 18-H3), 0.83 (s, 2H, cyclopropyl-H2), 0.94 (s, 2H, 
cyclopropyl-H2), 2.72 (d, 1H, J = 7.0 Hz, 1”-H), 2.84 (m, 2H, 6-H2), 3.77 (s, 3H, 3-OCH3), 3.93 
(d, 1H, J = 9.5 Hz, 17-H), 4.21 (dd, 1H, J = 13.0 Hz, J = 6.0 Hz, 16a-H2), 4.62 (t, 1H, J = 8.0 Hz, 
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16a-H2), 6.62 (s, 1H, 4-H), 6.71 (d, 1H, J = 8.5 Hz, 2-H), 7.20 (d, 1H, J = 8.5 Hz, 1-H), 7.29 (s, 
1H, 5’-H). 13C NMR (δ, ppm, CDCl3): 6.7 (C-1”), 7.68 (C-2” and -3”),12.3 (C-18), 26.2, 27.4, 
29.7, 30.8, 37.5, 38.0, 41.4, 43.8, 44.3 (C-16a), 48.7, 51.7 (C-13), 55.2 (3-OCH3), 80.7 (C-17), 
111.5 (C-2), 113.8 (C-4), 126.3 (C-1), 132.4 (C-10), 137.8 (C-5), 157.5 (C-3).  
 
2.3.2. 3-Methoxy-16β-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-
ol (21b) 
Compound 13 (342 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
CH2Cl2 to yield pure 21b (370 mg, 85%) as a white solid. Mp: 191192 
о
C; Rf= 0.46 (ss B). 
(Found C, 74.62; H, 8.42. C27H37N3O2 (435.60) requires C, 74.45; H, 8.56%). 
1H NMR (δ, ppm, 
CDCl3): 0.79 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.19 (s, 1H, 1”-H), 3.77 (s, 3H, 3-OCH3), 3.94 
(d, 1H, J = 9.5 Hz, 17-H), 4.24 (d, 1H, J = 8.0 Hz, 16a-H2), 4.65 (s, 1H, 16a-H2), 6.62 (s, 1H, 4-
H), 6.71 (d, 1H, J = 8.5 Hz, 2-H), 7.20 (d, 1H, J = 8.5 Hz, 1-H), 7.34 (s, 1H, 5’-H). 13C NMR (δ, 
ppm, CDCl3): 12.3 (C-18), 25.1 (C-3” and -4”), 26.2, 27.4, 29.7 (C-2” and 5”), 30.8, 33.2, 36.7, 
37.5, 38.0, 42.4 (C-16a), 43.8, 44.3 (C-13), 48.7, 51.8, 55.2 (3-OCH3), 62.1 (C-16), 80.7 (C-17), 
111.5 (C-2), 113.7 (C-4), 126.3 (C-1), 132.4 (C-10), 137.8 (C-5), 157.4 (C-3). 
 
2.3.3. 3-Methoxy-16β-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-
ol (21c) 
Compound 13 (342 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 21c (370 mg, 82%) as a white solid. Mp: 189190 
о
C; Rf= 0,40 (ss B). (Found C, 74.92; H, 8.55. C28H41N3O2 (449.63) requires C, 74.80; H, 8.74%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.84 (m, 2H, 6-H2), 3.77 (s, 3H, 3-OCH3), 3.94 
(d, 1H, J = 9.5 Hz, 17-H), 4.24 (m, 1H, 16a-H2), 4.65 (m, 1H, 16a-H2), 6.62 (s, 1H, 4-H), 6.71 (d, 
1H, J = 8.5 Hz, 2-H), 7.20 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (s, 1H, 5’-H). 13C NMR (δ, ppm, 
CDCl3): 12.3 (C-18), 26.0, 26.1 (C-2” and -6”), 26.2, 27.4, 29.7, 30.8, 33.0, 37.5, 38.0, 41.4 (C-
1”), 43.8, 44.3 (C-13), 48.3, 55.2 (3-OCH3), 62.1, 80.7 (C-17), 111.5 (C-2), 113.7 (C-4), 126.3 
(C-1), 132.4 (C-10), 137.8 (C-5), 157.4 (C-3). 
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2.3.4. 3-Methoxy-16β-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-ol 
(21d) 
Compound 13 (342 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 21d (368 mg, 83%) as a white solid. Mp: 232234 
о
C; Rf= 0.35 (ss B). (Found C, 75.98; H, 7.36. C28H33N3O2 (443.58) requires C, 75.81; H, 7.50%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.73 (m, 2H, 6-H2), 3.68 (s, 3H, 3-OCH3), 3.79 
(d, 1H, J = 10.0 Hz, 17-H), 4.20 (t, 1H, J = 13.5 Hz, 16a-H2), 4.63 (dd, 1H, J = 13.5 Hz, J = 4.5 
Hz, 16a-H2), 6.59 (s, 1H, 4-H), 6.67 (d, 1H, J = 8.5 Hz, 2-H), 7.16 (d, 1H, J = 8.5 Hz, 1-H), 7.32 
(t, 1H, J = 7.5 Hz, 4”-H), 7.44 (t, 2H, J = 7.5 Hz, 3”- and 5”-H), 7.85 (d, 2H, J = 7.5 Hz, 2”- and 
6”-H), 8.60 (s, 1H, 5’-H). 13C NMR (δ, ppm, CDCl3): 12.4 (C-18), 25.8, 26.9, 29.1, 30.0, 36.9, 
37.8, 40.4, 43.3, 43.7 (C-13), 47.8, 52.3 (C-16a), 54.8 (3-OCH3), 79.5 (C-17), 111.4 (C-2), 113.3 
(C-4), 121.5 (C-5’), 124.5 (C-2” and -6”), 126.0 (C-1), 127.6 (C-4”), 127.8 (C-3” and -5”), 130.9 
(C-1”), 132.0 (C-10), 137.3 (C-5), 146.0 (C-4’), 156.9 (C-3). 
 
2.3.5. 3-Methoxy-16β-(4’-nitro-benzoyloxymethyl-1’H-1’,2,’3’-triazol-1’-yl)methylestra-
1,3,5(10)-trien-17β-ol (21e) 
Compound 13 (342 mg, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 410 mg) were used for 
the synthesis as described in Section 2.3. The crude product was chromatographed on silica gel 
with ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 21e (475 mg, 86%) as a yellow solid. Mp: 
134135.5 оC; Rf= 30 (ss B). (Found C, 66.12; H, 6.08. C30H34N4O6 (546.61) requires C, 65.92; 
H, 6.27%). 
1H NMR (δ, ppm, CDCl3): 0.73 (s, 3H, 18-H3), 2.70 (m, 2H, 6-H2), 3.66 (s, 3H, 3-
OCH3), 4.18 (dd, 1H, J = 13.5 Hz, J = 11.5 Hz, 16a-H2), 4.58 (dd, 1H, J = 13.5 Hz, J = 4.5 Hz, 
16a-H2), 5.02 (d, 1H, J = 4.5 Hz, 17-H), 5.44 (s, 2H, 4’-H2), 6.55 (d, 1H, J = 1.5 Hz, 4-H), 6.63 
(dd, 1H, J = 8.5 Hz, J = 2.0 Hz, 2-H), 7.12 (d, 1H, J = 8.5 Hz, 1-H), 8.16 (d, 2H, J = 8.5 Hz, 3”- 
and 5”-H), 8.31 (t, 3H, J = 8.5 Hz, 2”- and 6”-H, 5’-H). 13C NMR (δ, ppm, CDCl3): 12.3 (C-18), 
25.8, 26.9, 29.1, 30.0, 36.9, 37.8, 40.4, 43.3, 43.7 (C-13), 47.8, 52.2 (C-16a), 54.7 (3-OCH3), 
58.7 (4’-CH2), 79.5 (C-17), 111.3 (C-2), 113.3 (C-4), 123.8 (C-2” and -6”), 125.1 (C-5’), 126.0 
(C-1), 130.6 (C-3” and -5”), 131.9 (C-10), 134.7 (C-1”), 137.2 (C-5), 141.0 (C-4”), 150.2 (C-4’), 
156.9 (C-3), 163.9 (C=O). 
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2.3.6. 3-Methoxy-16β-(4’-hydroxymethyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (21f) 
Compound 13 (274 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from a mixture of ethyl 
acetate/hexane to afford 21f (171 mg, 86%) as a white crystalline material. Mp: 194195 оC; Rf= 
0.25 (ss B). (Found C, 69.23; H, 8.04. C23H31N3O3 (397.51) requires C, 69.49; H, 7.86%). 
1
H 
NMR (δ, ppm, DMSO-d6): 0.76 (s, 3H, 18-H3), 2.71 (m, 2H, 6-H2), 3.68 (s, 3H, 3-OCH3), 3.76 
(d, 1H, J = 5.5 Hz, 17-H), 4.14 (t, 1H, J = 12.5 Hz, 16a-H2), 4.49 (m, 3H, 4’-H2 and 16a-H2), 
5.03 (d, 1H, J = 3.5 Hz, 17-OH), 5.15 (brs, 1H, CH2-OH), 6.59 (s, 1H, 4-H), 6.66 (d, 1H, J = 8.5 
Hz, 2-H), 7.16 (d, 1H, J = 8.5 Hz, 1-H), 7.99 (s, 1H, 5’-H). 13C NMR (δ, ppm, DMSO-d6): 12.4 
(C-18), 25.9, 26.9, 29.2, 30.0, 36.9, 37.9, 40.5, 43.4, 43.8 (C-13), 47.8, 52.0 (C-16a), 54.8 (3-
OCH3), 55.0 (4’-CH2), 79.5 (C-17), 111.4 (C-2), 113.4 (C-4), 122.8 (C-5’), 126.1 (C-1), 132.0 
(C-10), 137.3 (C-5), 147.6 (C-4’), 157.0 (C-3). 
 
2.3.7. 3-Methoxy-16a-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-
ol (22a) 
Compound 14 (342 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 22a (261 mg, 64%) as a white solid. Mp: 6769 
о
C; 
Rf= 0.35 (ss B). (Found C, 73.55; H, 7.98. C25H33N3O2 (407.55) requires C, 73.68; H, 8.16%). 
1
H 
NMR (δ, ppm, CDCl3): 0.82 (m, 5H, 18-H3 and cyclopropyl-H2), 0.95 (m, 2H, cyclopropyl-H2), 
2.83 (m, 2H, 6-H2), 3.53 (d, 1H, J = 7.5 Hz, 17-H), 3.77 (s, 3H, 3-OCH3), 4.35 (t, 1H, J = 7.5 Hz, 
16a-H2), 4.44 (dd, 1H, J = 13.5 Hz, J = 7.5 Hz, 16a-H2), 6.62 (d, 1H, J = 2.0 Hz, 4-H), 6.70 (dd, 
1H, J = 8.5 Hz, J = 2.0 Hz, 2-H), 7.18 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, CDCl3): 6.7 
(C-1”), 7.7 (C-2” and -3”), 11.8 (C-18), 26.1, 27.2, 28.2, 29.7, 36.6, 38.4, 43.9, 44.3, 44,3 (C-
16a), 48.3, 54.5 (C-13), 62.1 (3-OCH3), 85.1 (C-17), 111.5 (C-2), 113.8 (C-4), 126.2 (C-1), 132.3 
(C-10), 137.8 (C-5), 157.4 (C-3). 
 
2.3.8. 3-Methoxy-16a-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1-yl)methylestra-1,3,5(10)-trien-17β-
ol (22b) 
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Compound 14 (342 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 22b (290 mg, 66%) as a white solid. Mp: 163165 
о
C; Rf= 0.32 (ss B). (Found C, 74.63; H, 8.41. C27H37N3O2 (435.60) requires C, 74.45; H, 8.56%). 
1H NMR (δ, ppm, CDCl3): 0.83 (s, 3H, 18-H3), 1.68 (s, 4H, 3”- and 4”-H2), 2.83 (m, 2H, 6-H2), 
3.19 (m, 1H, 1”-H), 3.56 (d, 1H, J = 7.0 Hz, 17-H), 3.77 (s, 3H, 3-OCH3), 4.43 (m, 2H, 16a-H2), 
6.62 (s, 1H, 4-H), 6.70 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H), 7.35 (s, 1H, 5’-H). 
13C NMR (δ, ppm, CDCl3): 11.9 (C-18), 25.1 (C-3” and -4”), 26.1, 27.2, 28.3, 29.7 (C-2” and -
5”), 33.2, 36.6, 38.4, 43.9, 44.2, 44.3 (C-13), 48.4, 55.2 (3-OCH3), 62.1 (C-16a), 85.3 (C-17), 
111.5 (C-2), 113.8 (C-4), 126.3 (C-1), 132.3 (C-10), 137.8 (C-5), 157.5 (C-3). 
 
2.3.9. 3-Methoxy-16a-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-
ol (22c) 
Compound 14 (342 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 22c (345 mg, 76%) as a white solid. Mp: 8082 
о
C; 
Rf= 0.34 (ss B). (Found 74.96; H, 8.54. C28H41N3O2 (449.63) requires C, 74.80; H, 8.74%). 
1
H 
NMR (δ, ppm, CDCl3): 0.83 (s, 3H, 18-H3), 2.83 (m, 2H, 6-H2), 3.55 (s, 1H, 17-H), 3.77 (s, 3H, 
3-OCH3), 4.46 (s, 2H, 16a-H2), 6.62 (d, 1H, J = 2.0 Hz, 4-H), 6.70 (dd, 1H, J = 8.5 Hz, J = 2.0 
Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, CDCl3): 11.9 (C-18), 26.0 and 26.1 
(C-2” and -6”, C-3” and -5”), 27.2, 28.3, 29.7, 36.6, 38.4, 43.9, 44.3 (C-13), 48.4, 55.2 (3-OCH3), 
62.1 (C-1”), 62.1 (C-16a), 85.2 (C-17), 111.5 (C-2), 113.8 (C-4), 126.2 (C-1), 132.3 (C-10), 
137.8 (C-5), 157.4 (C-3).  
 
2.3.10. 3-Methoxy-16a-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-ol 
(22d) 
Compound 14 (342 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel ethyl 
acetate/CH2Cl2 (5:95 v/v) to yield pure 22d (368 mg, 82%) as a white solid. Mp: 204205 
о
C; 
Rf= 0.38 (ss B). (Found C, 75.63; H, 7.72. C28H33N3O2 (443.58) requires C, 75.81; H, 7.50%). 
1
H 
NMR (δ, ppm, DMSO-d6): 0.73 (s, 3H, 18-H3), 2.73 (m, 2H, 6-H2), 3.67 (s, 3H, 3-OCH3), 4.36 (t, 
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1H, J = 13.5 Hz, 16a-H2), 4.54 (dd, 1H, J = 13.5 Hz, J = 4.0 Hz, 16a-H2), 4.91 (d, 1H, J = 4.0 Hz, 
17-H), 6.58 (s, 1H, 4-H), 6.67 (d, 1H, J = 8.5 Hz, 2-H), 7.15 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (t, 1H, 
J = 7.0 Hz, 4”-H), 7.44 (t, 2H, J = 7.0 Hz, 3”- and 5”-H), 7.86 (d, 2H, J = 7.0 Hz, 2”- and 6”-H), 
8.61 (s, 1H, 5’-H). 13C NMR (δ, ppm, DMSO-d6): 11.8 (C-18), 25.8, 26.7, 27.3, 29.1, 36.3, 38.1, 
43.4, 43.5, 43.8, 47.5, 53.5 (C-13), 54.8 (3-OCH3), 83.1 (C-17), 111.4 (C-2), 113.3 (C-4), 121.4 
(C-5’), 125.0 (C-2” and -6”), 126.0 (C-1), 127.6 (C-4”), 128.8 (C-3” and -5”), 130.8 (C-1”), 
132.0 (C-10), 137.3 (C-5), 146.1 (C-4’), 156.9 (C-3). 
 
2.3.11.3-Methoxy-16a-[4’(4’’-nitro-benzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl]methylestra-
1,3,5(10)-trien-17β-ol (22e) 
Compound 14 (342 mg, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 410 mg) were used for 
the synthesis as described in Section 2.3. The crude product was chromatographed on silica gel 
with ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 22e (445 mg, 81%) as a yellow solid. Mp: 
8688 оC; Rf= 0.28 (ss B). (Found C, 66.08; H, 6.43. C30H34N4O6 (546.61) requires C, 65.92; H, 
6.27%). 
1H NMR (δ, ppm, DMSO-d6): 0.69 (s, 3H, 18-H3), 2.68 (m, 2H, 6-H2), 3.57 (s, 3H, 3-
OCH3), 4.38 (dd, 1H, J = 13.5 Hz, J = 9.0 Hz, 16a-H2), 4.52 (dd, 1H, J = 13.5 Hz, J = 4.5 Hz, 
16a-H2), 4.86 (d, 1H, J = 4.5 Hz, 17-H), 5.46 (s, 2H, 4’-H2), 6.55 (d, 1H, J = 1.5 Hz, 4-H), 6.63 
(dd, 1H, J = 8.5 Hz, 2-H), 7.10 (d, 1H, J = 8.5 Hz, 1-H), 8.16 (d, 2H, J = 8.5 Hz, 3”- and 5”-H), 
8.28 (d, 2H, J = 8.5 Hz, 2”- and 6”-H), 8.31 (s, 1H, 5’-H). 13C NMR (δ, ppm, DMSO-d6): 11.7 
(C-18), 25.7, 26.6, 27.1, 29.0, 36.4, 38.0, 43.3, 43.4 (C-13), 43.7, 47.7, 53.1 (C-16a), 54.7 (3-
OCH3), 58.6 (4”-CH2), 82.8 (C-17), 111.3 (C-2), 113.3 (C-4), 123.8 (C-2” and -6”), 125.2 (C-5’), 
125.9 (C-1), 130.6 (C-3” and -5”), 131.8 (C-10), 134.7 (C-1’), 137.2 (C-5), 141.1 (C-4”), 150.2 
(C-4’), 156.9 (C-3), 163.9 (C=O). 
 
2.3.12. 3-Methoxy-16a-(4’-hydroxymethyl-1’H-1’,2’3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (22f)  
 
Compound 22e (274 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from a mixture of ethyl 
acetate/hexane to afford 22f (175 mg, 88%) as a white crystalline product. Mp: 98100 оC; Rf= 
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0.28 (ss B). (Found C, 69.74; H, 7.72. C23H31N3O3 (397.51) requires C, 69.49; H, 7.86%). 
1
H 
NMR (δ, ppm, CDCl3): 0.81 (s, 3H, 18-H3), 2.82 (m, 2H, 6-H2), 3.50 (d, 1H, J = 7.0 Hz, 17-H), 
3.76 (s, 3H, 3-OCH3), 4.42 (d, 2H, J = 7.0 Hz, 16a-H2), 4.71 (s, 2H, 4’-H2), 6.61 (s, 1H, 4-H), 
6.69 (d, 1H, J = 8.5 Hz, 2-H), 7.17 (d, 1H, J = 8.5 Hz, 1-H), 7.68 (s, 1H, 5’-H). 13C NMR (δ, 
ppm, CDCl3): 11.9 (C-18), 26.1, 27.2, 28.2, 29.6, 36.5, 38.4, 43.8, 44.0, 44.4 (C-13), 48.2, 54.6 
(C-16a), 55.2 (3-OCH3), 56.0 (4’-CH2), 85.1 (C-17), 111.5 (C-2), 113.8 (C-4), 126.3 (C-1), 132.3 
(C-10), 137.8 (C-5), 157.4 (C-3).  
 
2.3.13. 3-Methoxy-16a-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (23a) 
Compound 15 (342 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 23a (261 mg, 64%) as a white solid. Mp: 6769 
о
C; 
Rf= 0.32 (ss B). (Found C, 73.85; H, 8.32. C25H33N3O2 (407.55) requires C, 73.68; H, 8.16%). 
1
H 
NMR (δ, ppm, CDCl3): 0.82 (m, 5H, 18-H3 and cyclopropyl-H2), 0.95 (m, 2H, cyclopropyl-H2), 
2.83 (m, 2H, 6-H2), 3.53 (d, 1H, J = 7.5 Hz, 17-H), 3.77 (s, 3H, 3-OCH3), 4.35 (t, 1H, J = 7.5 Hz, 
16a-H2), 4.44 (dd, 1H, J = 13.5 Hz, J = 7.5 Hz, 16a-H2), 6.62 (d, 1H, J = 2.0 Hz, 4-H), 6.70 (dd, 
1H, J = 8.5 Hz, J = 2.0 Hz, 2-H), 7.18 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, CDCl3): 6.7 
(C-1”), 7.7 (C-2” and -3”), 11.8 (C-18), 26.1, 27.2, 28.2, 29.7, 36.6, 38.4, 43.9, 44.3, 44,3 (C-
16a), 48.3, 54.5 (C-13), 62.1 (3-OCH3), 85.1 (C-17), 111.5 (C-2), 113.8 (C-4), 126.2 (C-1), 132.3 
(C-10), 137.8 (C-5), 157.4 (C-3). 
 
2.3.14. 3-Methoxy-16β-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1-yl)methylestra-1,3,5(10)-trien-17a-
ol (23b) 
Compound 15 (342 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 23b (380 mg, 87%) as yellow crystalline material. 
Mp: 6768 оC; Rf= 0.36 (ss B). (Found C, 74.28; H, 8.47. C27H37N3O2 (435.60) requires C, 
74.45; H, 8.56%). 
1H NMR (δ, ppm, CDCl3): 0.75 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.68 (s, 
1H, 17-H), 3.77 (s, 3H, 3-OCH3), 4.44 (d, 2H, J = 15.0 Hz, 16a-H2), 6.62 (s, 1H, 4-H), 6.70 (d, 
1H, J = 8.5 Hz, 2-H), 7.20 (t, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, CDCl3): 17.9 (C-18), 25.1 
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(C-3” and -4”), 25.9, 26.1, 27.2, 28.0, 29.7, 30.4, 31.8, 36.6 (C-16a), 38.5, 43.3, 43.8, 45.1 (C-
13), 48.9, 55.2 (3-OCH3), 62.1 (C-1”), 82.6 (C-17), 111.5 (C-2), 113.7 (C-4), 113.8 (C-5’), 126.2 
(C-1), 132.1 (C-10), 137.8 (C-5), 137.8 (C-4’), 157.4 (C-3).  
 
2.3.15. 3-Methoxy-16β-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methyestra-1,3,5(10)-trien-17a-
ol (23c) 
Compound 15 (342, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 23c (306 mg, 68%) as a white solid. Mp: 90-92 
о
C; 
Rf = 0.37 (ss B). (Found C, 74.95; H, 8.83. C28H41N3O2 (449.63) requires C, 74.80; H, 8.74%). 
1
H 
NMR (δ, ppm, CDCl3): 0.75 (s, 3H, 18-H3), 2.84 (m, 2H, 6-H2), 3.67 (d, 1H, J = 1.0 Hz, 17-H), 
3.77 (S, 3H, 3-OCH3), 4.43 (m, 1H, 16a-H2), 6.62 (d, 1H, J = 2.5 Hz, 4-H), 6.71 (dd, 1H, J = 8.5 
Hz, J = 2.5 Hz, 2-H), 7.20 (t, 1H, J = 8.5 Hz, 1-H), 7.35 (s, 1H, 5’-H). 13C NMR (δ, ppm, 
CDCl3): 17.9 (C-18), 25.9, 26.0, 26.1 (C-2” and -6”), 28.0, 29.7, 30.4, 31.8, 33.0, 35.2 (C-1”), 
36.6, 38.5, 43.3, 45.1 (C-13), 48.9, 49.1, 54.3 (C-16a), 55.2 (3-OCH3), 82.6 (C-1), 132.4 (C-10), 
137.8 (C-5), 153.7 (C-4’), 157.7 (C-3). 
 
2.3.16. 3-Methoxy-16β-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methy-estra-1,3,5(10)-trien-17a-ol 
(23d) 
Compound 15 (342 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (2.5:97.5 v/v) to yield pure 23d (299 mg, 67%) as white crystals. Mp: 
173174 оC; Rf= 0.34 (ss B). (Found C 75.98; H, 7.33. C28H33N3O2 (443.58) requires C, 75.81; 
H, 7.50%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.71 (d, 1H, J = 
1.5 Hz, 17-H), 3.78 (s, 3H, 3-OCH3), 4.46 (dd, 1H, J = 13.5 Hz, J = 8.0 Hz, 16a-H2), 4.55 (dd, 
1H, J = 13.5 Hz, J = 8.0 Hz, 16a-H2), 6.63 (d, 1H, J = 2.0 Hz, 4-H), 6.72 (dd, 1H, J = 8.5 Hz, J = 
2.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.27 (t, 1H J = 7.5 Hz, 4”-H), 7.42 (t, 2H, J = 7.5 Hz, 
3”- and 5”-H), 7.83 (d, 2H, J = 7.5 Hz, 2”- and 6”-H), 7.87 (s, 1H, 5’-H). 13C NMR (δ, ppm, 
CDCl3): 17.9 (C-18), 25.9, 27.9, 29.7, 30.4, 31.8, 38.5, 43.3, 45.1, (C-13), 48.8, 49.1, 54.5 (C-
16a), 55.2 (3-OCH3), 82.5 (C-17), 111.5 (C-2), 113.7 (C-4), 119.6 (C-5’), 125.7 (C-2” and -6”), 
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126.3 (C-1), 128.1 (C-4”), 128.8 (C-3” and -5”), 130.5 (C-1”), 132.4 (C-10), 137.8 (C-5), 147.8 
(C-4’), 157.4 (C-3). 
 
2.3.17.3-Methoxy-16β-[4’(4”-nitro-benzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl)methylestra-
1,3,5(10)-trien-17a-ol (23e) 
Compound 15 (342, 1 mmol) and propargyl 4-nitro benzoate (2 mmol, 410 mg) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 23e (370 mg, 67%) as a yellow crystalline material. 
Mp: 6263 оC; Rf = 0.38 (ss B). (Found C, 66.14; H, 6.42. C30H34N4O6 (546.61) requires C, 
65.92; H, 6.27%). 
1H NMR (δ, ppm, DMSO-d6): 0.65 (s,3 H, 18-H3), 2.74 (m,2H, 6-H2), 3.68 (s, 
3H, 3-OCH3), 4.41 (dd, 1H, J = 13.0 Hz, J = 8.5 Hz, 16a-H2), 4.56 (dd, 1H, J = 13.0 Hz, J = 8.5 
Hz, 16a-H2), 4.63 (d, 1H, J = 4.5 Hz, 17-H), 6.58 (s, 1H, 4-H), 6.66 (d, 1H, J = 8.5 Hz, 2-H), 7.16 
(d, 1H, J = 8.5 Hz, 1-H), 8.19 (d, 2H, J = 8.5 Hz, 3”- and 5”-H), 8.34 (d, 2H, J = 8.5 Hz, 2”- and 
6”-H). 13C NMR (δ, ppm, DMSO-d6): 17.5 (C-18), 25.6, 27.5, 29.6, 31.8, 38.2, 43.0, 44.5, 47.9 
(C-13), 48.2, 49.1, 53.6 (C-16a), 54.8 (3-OCH3), 58.7 (4’-CH2), 80.8 (C-17), 111.3 (C-2), 113.3 
(C-4), 123.8 (C-1), 126.1 (C-5’), 130.6 (C-2” and -6”), 131.9 (C-3” and -5”), 133.0 (C-10), 134.7 
(C-1”), 137.3 (C-5), 141.4 (C-4”), 150.2 (C-4’), 156.9 (C-3), 163.9 (C=O). 
 
2.3.18. 3-Methoxy-16β-(4’-hydroxymethyl-1’H-1’,2’3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (23f) 
Compound 23e (274 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off, dissolved in dichloromethane and washed with 
water. The organic phase was dried over Na2SO4, and evaporated in vacuo to afford 23f (183 mg, 
92%) as oil. Rf= 0.26 (ss B). (Found C, 69.28; H, 7.95. C23H31N3O3 (397.51) requires C, 69.49; 
H, 7.86%). 
1H NMR (δ, ppm, CDCl3): 0.78 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.65 (s, 1H, 17-
H), 3.77 (s, 3H, 3-OCH3), 4.46 (m, 2H, 16a-H2), 4.78 (s, 2H, 4’-H2), 6.62 (d, 1H, J = 2.0 Hz, 4-
H), 6.72 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, 
CDCl3): 17.9 (C-18), 25.9, 27.9, 29.7, 30.3, 31.8, 38.5, 43.3, 45.2 (C-13), 48.8, 49.2, 54.6 (C-
16a), 55.2 (3-OCH3), 56.1 (4’-CH2), 82.1 (C-17), 111.5 (C-2), 113.7 (C-4), 123.5 (C-5’), 126.3 
(C-1), 132.4 (C-10), 137.8 (C-5), 157.4 (C-3). 
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2.3.19. 3-Methoxy-16a-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (24a) 
Compound 16 (342 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (2.5:97.5 v/v) to yield pure 24a (310 mg, 76%) as a white solid. Mp: 
165166 оC; Rf= 0.40 (ss B). (Found C, 73.85; H, 8.34. C25H33N3O2 (407.55) requires C, 73.68; 
H, 8.16%). 
1H NMR (δ, ppm, CDCl3): 0.74 (s, 3H, 18-H3), 0.85 and 0.96 (2 x m, 4H, 2”- and 3”-
H2), 2.85 (m, 2H, 6-H2), 3.63 (d, 1H, J = 5.0 Hz, 17-H), 3.77 (s, 3H, 3-OCH3), 4.28 (dd, 1H, J = 
13.0 Hz, J = 5.0 Hz, 16a-H2), 4.59 (t, 1H, J = 12.0 Hz, 16a-H2), 6.63 (d, 1H, J = 2.0 Hz, 4-H), 
6.71 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.22 (d, 1H, J = 8.5 Hz, 1-H). 
13C NMR (δ, ppm, 
CDCl3): 6.6 (C-1”), 7.7 and 7.8 (C-2” and -3”), 17.1 (C-18), 26.0, 28.0, 28.9, 29.8, 31.2, 38.9, 
42.3, 46.3 (C-16a), 47.0, 50.5 (C-13), 55.2 (3-OCH3), 78.8 (C-17), 111.4 (C-2), 113.7 (C-4), 
120.6 (C-5’), 126.3 (C-1), 132.5 (C-10), 137.9 (C-5), 149.8 (C-4’), 157.4 (C-3). 
 
2.3.20. 3-Methoxy-16a-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1’-yl)methyl-estra-1,3,5(10)-trien-
17a-ol (24b) 
Compound 16 (342 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 24b (383 mg, 88%) as yellow crystalline product. 
Mp: 171173 оC; Rf= 0.42 (ss B). (Found C, 74.67; H, 8.72. C27H37N3O2 (435.60) requires C, 
74.45; H, 8.56%). 
1H NMR (δ, ppm, CDCl3): 075 (s, 3H, 18-H3), 1.25 (s, 8H, 2”-, 3”-, 4”- and 
5”-H2), 2.86 (m, 2H, 6-H2), 3.18 (m, 1H, 1”-H), 3.64 (d, 1H, J = 5.0 Hz, 17-H), 3.77 (s, 3H, 3-
OCH3), 4.29 (dd, 1H, J = 13.5 Hz, J = 5.5 Hz, 16a-H2), 4.62 (dd, 1H, J = 13.5 Hz, J = 11.5 Hz, 
16a-H2), 6.63 (d, 1H, J = 2.0 Hz, 4-H), 6.71 (dd, 1H, J = 8.5 Hz, J = 2.0 Hz, 2-H), 7.22 (d, 1H, J 
= 8.5 Hz, 1-H), 7.36 (s, 1H, 5’-H). 13C NMR (δ, ppm, CDCl3): 17.2 (C-18), 25.1 (C-3” and -4”), 
26.0, 28.0, 29.0, 29.7, 29.9, 31.2, 33.2, 36.7, 38.9, 42.4, 43.5, 46.3 (C-13), 47.0 (C-1”), 50.5 (C-
16a), 55.2 (3-OCH3), 78.8 (C-17), 111.4 (C-2), 113.8 (C-4), 120.6 (C-5’), 126.3 (C-1), 132.6 (C-
10), 137.9 (C-5), 152.3 (C-4’), 157.4 (C-3). 
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2.3.21. 3-Methoxy-16a-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17a-
ol (24c) 
Compound 16 (342 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 24c (162 mg, 36%) as yellow crystals. Mp: 208210 
о
C; Rf= 0.42 (ss B). (Found C, 74.97; H, 8.56. C28H41N3O2 (449.63) requires C, 74.80; H, 8.74%). 
1
H NMR (δ, ppm, CDCl3): 0.75 (s, 3H, 18-H3), 1.26 (s, 8H, 2”-, 3”-, 5”- and 6”-H2), 2.88 (m, 2H, 
6-H2), 2.90 (m, 2H, 4”-H2), 3.64 (d, 1H, J = 5.0 Hz, 17-H), 3.77 (s, 3H, 3-OCH3), 4.29 (dd, 1H, J 
= 13.5 Hz, J = 5.0 Hz, 16a-H2), 4.62 (dd, 1H, J = 13.5 Hz, J = 11.0 Hz, 16a-H2), 6.63 (d, 1H, J = 
2.0 Hz, 4-H), 6.71 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.22 (d, 1H, J = 8.5 Hz, 1-H), 7.34 (s, 
1H, 5’-H). 13C NMR (δ, ppm, CDCl3): 17.2 (C-18), 26.0 and 26.1 (C-2”, -3”, -5” and -6”), 28.0, 
29.0, 29.7, 29.8, 31.2, 33.0, 25.2, 38.9, 42.4, 43.5, 46.3 (C-13), 47.0 (C-1”), 50.5 (C-16a), 55.0 
(3-OCH3), 78.8 (C-17), 111.4 (C-2), 113.8 (C-4), 120.2 (C-5’), 126.3 (C-1), 132.6 (C-10), 137.9 
(C-5), 153.3 (C-4’), 157.4 (C-3).  
 
2.3.22. 3-Methoxy-16a-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17a-ol 
(24d) 
Compound 16 342 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
CH2Cl2 yield pure 24d (394 mg, 89%) as white solid. Mp: 189.5191 
о
C; Rf= 0.46 (ss B). (Found 
C, 75.65; H, 7.67. C28H33N3O2 (443.58) requires C, 75.81; H, 7.50%). 
1H NMR (δ, ppm, CDCl3): 
0.75 (s, 3H, 18-H3), 2.86 (m, 2H, 6-H2), 3.68 (d, 1H, J = 5.0 Hz, 17-H), 3.78 (s, 3H, 3-OCH3), 
4.41 (dd, 1H, J = 13.5 Hz, J = 6.0 Hz, 16a-H2), 4.69 (dd, 1H, J = 14.5 Hz, J = 10.5 Hz, 16a-H2), 
6.64 (d, 1H, J = 2.0 Hz, 4-H), 6.72 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.22 (d, 1H, J = 8.5 Hz, 
1-H), 7.34 (t, 1H, J = 7.5 Hz, 4”-H), 7.43 (t, 2H, J = 7.5 Hz, 3”- and 5”-H), 7.83 (d, 2H, J = 7.5 
Hz, 2”- and 6”-H), 7.88 (s, 1H, 5’-H). 13C NMR (δ, ppm, CDCl3): 17.1 (C-18), 26.0, 28.0, 29.8, 
31.2, 38.9, 42.3, 43.5, 46.4 (C-13), 47.0, 50.7, 55.2 (3-OCH3), 78.8 (C-17), 111.5 (C-2), 113.8 
(C-4), 120.6 (C-5’), 125.6 (C-2” and -6”), 126.3 (C-1), 128.1 (C-4”), 128.8 (C-3” and -5”), 130.5 
(C-1”), 132.5 (C-10), 137.9 (C-5), 147.3 (C-4’), 157.4 (C-3). 
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2.3.23. 3-Methoxy-16a-[4’-(4’’nitrobenzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl]methylestra-
1,3,5(10)-trien-17a-ol (24e) 
Compound 16 (342, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 210 mg) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
CH2Cl2/hexane (1:3, v/v) to yield pure (344 mg, 63%) as yellow crystals. Mp: 64 
о
C; Rf= 0.45 (ss 
B). (Found, C, 66.14; H, 6.05. C30H34N4O6 (546.61) requires C, 65.92; H, 6.27%). 
1H NMR (δ, 
ppm, CDCl3): 0.75 (s, 3H, 18-H3), 2.84 (m, 2H, 6-H2), 3.66 (d, 1H, J = 4.5 Hz, 17-H), 3.77 (s, 
3H, 3-OCH3), 4.40 (dd, 1H, J = 13.5 Hz, J = 5.5 Hz, 16a-H2), 4.66 (t, 1H, J = 13.5 Hz, 16a-H2), 
5.53 (s, 2H, 4’-H2), 6.62 (t, 1H, J = 2.0 Hz, 4-H), 6.71 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.20 
(d, 1H, J = 8.5 Hz, 1-H), 7.85 (s, 1H, 5’-H), 8.22 (d, 2H, J = 9.0 Hz, 3”- and 5”-H), 8.72 (d, 2H, J 
= 9.0 Hz, 2”- and 6”-H). 13C NMR (δ, ppm, CDCl3): 17.1 (C-18), 22.7, 25.9, 28.0, 29.0, 29.8, 
31.2, 38.9, 42.0, 43.5, 46.4 (C-13), 47.0 (4’-CH2), 78.8 (C-17), 111.5 (C-2), 113.8 (C-4), 114.0 
(C-1’), 123.5 (C-2” and -6”) 126.3 (C-5’), 130.9 (C-3” and -5”), 135.0 (C-10), 137.8 (C-5), 141.5 
(C-4”), 150.6 (C-4’), 157.5 (C-3), 164.6 (C=O). 
 
2.3.24. 3-Methoxy-16a-(4’-hydroxymethyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (24f) 
Compound 24e (274 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from a mixture of 
acetone/hexane to afford 24f (187 mg, 94%) as a white crystalline product. Mp: 149150 оC; Rf 
= 0.25 (ss B). (Found C, 69.55; H, 7.95. C23H31N3O3 (397.51) requires C, 69.49; H, 7.86%). 
1
H 
NMR (δ, ppm, CDCl3): 0.74 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.62 (d, 1H, J = 4.0 Hz, 17-H), 
3.77 (s, 3H, 3-OCH3), 4.39 (m, 1H, 16a-H2), 4.64 (m, 1H, 16a-H2), 6.63 (s, 1H, 4-H), 6.71 (d, 1H, 
J = 8.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.77 (s, 1H, 5’-H). 13C NMR (δ, ppm, CDCl3): 
11.9 (C-18), 26.0, 28.0, 28.9, 31.3, 31.9, 33.8 (C-13), 38.9, 41.9, 43.5, 46.4 (4’-CH2), 46.9, 51.0 
(C-16a), 55.2 (3-OCH3), 78.6 (C-17), 111.5 (C-2), 113.8 (C-4), 123.4 (C-5’), 126.3 (C-1), 132.5 
(C-10), 137.8 (C-5), 157.4 (C-3).  
 
2.3.25. 3-Benzyloxy-16β-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (25a) 
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Compound 17 (420 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 25a (394 mg, 84%) as a white solid. Mp: 278280 
о
C; Rf= 0.35 (ss B). (Found C, 77.16; H, 7.62. C31H37N3O2 (483.64) requires C, 76.98; H, 
7.71%). 
1H NMR (δ, ppm, CDCl3): 0.80 (s, 3H, 18-H3), 0.86 and 0.97 (2 x m, 2 x 2H, 2”- and 3”-
H), 2.83 (m, 2H, 6-H2), 3.93 (d, J = 9.5 Hz, 1H, 17-H), 4.21 (m, 1H, 16a-H2), 4.64 (m, 1H, 16a-
H2), 5.03 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.20 (d, 1H, J = 8.5 Hz, 
1-H), 7.31 (t, 1H, J = 7.0 Hz, 4’-H), 7.38 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.43 (d, 2H, J = 7.0 
Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 7.8 (C-2” and -3”), 12.3 (C-18), 26.2, 27.4, 29.7, 
30.8, 37.5, 38.0, 41.4, 43.9, 44.3 (C-13), 48.7 (C-16), 67.8 (C-16a), 69.9 (Bn-CH2), 80.7 (C-17), 
112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and C-5’), 
132.7 (C-10), 137.3 (C-1’), 137.8 (C-5), 156.8 (C-3).  
 
2.3.26. 3-Benzyloxy-16β-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (25b) 
Compound 17 (420 mg, 1 mmol) and cyclopentylacetylene (2 mol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 25b (350 mg, 68%) as a white solid. Mp: 288290 
о
C; Rf= 0.38 (ss B). Found C, 77.58; H, 7.92. C33H41N3O2 (511.70) requires C, 77.46; H, 8.08%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.75 (s, 1H, 1”-H), 2.83 (m, 2H, 6-H2), 3.94 (d, 
1H, J = 9.5 Hz, 17-H), 4.24 (m, 1H, 16-H2), 4.67 (m, 1H, 16-H2), 5.03 (s., 2H, Bn-H2), 6.71 (s, 
1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.5 Hz, 4’-
H), 7.38 (t, 2H, J = 7.5 Hz, 3’- and 5’-H), 7.42 (d, 2H, J = 7.5 Hz, 2’- and 6’-H). 13C NMR (δ, 
ppm, CDCl3): 12.3 (C-18), 25.1 (C-3” and -4”), 26.2, 27.5, 29.7, 30.8, 34.3 (C-2” and -5”), 37.5, 
38.0, 41.4, 43.9, 44.3 (C-13), 48.7 (C-16), 62.1 (16a-CH2), 69.9 (Bn-CH2), 80.7 (C-17), 112.3 (C-
2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 132.7 (C-
10), 137.3 (C-1’), 137.8 (C-5), 156.8 (C-3).  
 
2.3.27. 3-Benzyloxy-16β-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (25c) 
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Compound 17 (420 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99, v/v) to yield pure 25c (146 mg, 28%) as a white solid. Mp: 214216 
о
C; Rf= 0.38 (ss B). (Found C, 77.43; H, 8.36. C34H43N3O2 (525.72) requires C, 77.68; H, 8.24%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.79 (m, 4H, 3”- and 5”-H), 3.94 (d, J = 9.5 Hz, 
1H, 17-H), 4.25 (m, 1H, 16a-H2), 4.67 (m, 1H, 16a-H2), 5.03 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 
6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (d, 1H, J = 7.0 Hz, 4’-H), 7.38 
(t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.42 (d, 2H, J = 7 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 
12.3 (C-18), 26.0 (C-4”), 26.1 (C-3” and -5”), 26.2, 27.5, 29.7, 30.8 (C-2” and -6”), 33.0 (C-1”), 
37.5, 38.0, 41.4, 43.9, 44.3 (C-13), 48.7 (C-16), 62.1 (C-16a), 69.9 (Bn-CH2), 80.7 (C-17), 112.3 
(C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 132.7 
(C-10), 137.3 (C-1’), 137.8 (C-5), 157.8 (C-3).  
 
2.3.28. 3-Benzyloxy-16β-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-ol 
(25d) 
Compound 17 (420 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 25d (391 mg, 75%) as a white solid. Mp: 202204 
о
C; Rf= 0.45 (ss B). (Found C, 78.73; H, 6.98. C34H37N3O2 (519.68) requires C, 78.58; H, 7.18%). 
1H NMR (δ, ppm, C6D6): 0.68 (s, 3H, 18-H3), 2.69 (m, 2H, 6-H2), 3.43 (dd, J = 9.5 Hz, J = 4 Hz, 
1H, 17-H), 3.77 (dd, 1H, J = 13.5 Hz, J = 7.0 Hz, 16a-H2), 4.29 (dd, 1H, J = 13.5 Hz, J = 7.0 Hz, 
16a-H2), 4.83 (s, 2H, Bn-H2), 6.79 (s, 1H, 4-H), 6.87 (d, 1H, J = 8.0 Hz, 2-H), 7.02 (s, 1H, 1-H), 
7.08 (t, 1H, J = 7.5 Hz, 4’-H), 7,26 (t, 2H, J = 7.5 Hz, 3’- and 5’-H), 7.32 (d, 2H, J = 7.5 Hz, 2’- 
and 6’-H), 8.01 (d, 2H, J = 7.5 Hz, 2”- and 6”-H). 
 
2.3.29. 3-Benzyloxy-16β-[4’-(4’’-nitro-benzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl]methyestra-
1,3,5(10)-trien-17β-ol (25e) 
Compound 17 (420 mg, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 210 mg) were used for 
the synthesis as described in Section 2.3. The crude product was chromatographed on silica gel 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 25e (480 mg, 77%) as a yellow solid. Mp: 187189 
о
C; Rf= 0.45 (ss B). (Found C, 69.32; 5.98. C36H38N4O6 (622.71) requires C, 69.44; H, 6.15%). 
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1H NMR (δ, ppm, CDCl3): 0.80 (s, 3H, 18-H3), 2.82 (m, 2H, 6-H2), 3.94 (d, J = 10.0 Hz, 1H, 17-
H), 4.32 (dd, 1H, J = 13.0 Hz, J = 6.0 Hz, 16a-H2), 4.72 (t, 1H, J = 6.0 Hz, 16a-H2), 5.03 (s, 2H, 
Bn-H2), 5.52 (s, 2H, triazol-H), 6.71 (s, 1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 
8.5 Hz, 1-H), 7.32 (t, 1H, J = 7.0 Hz, 4’-H), 7.38 (t, J = 7.5 Hz, 2H, 3’- and 5’-H), 7.42 (d, J = 
7.5 Hz, 2H, 2’- and 6’-H), 8.22 (d, J = 8 Hz, 2H, 3”- and 5”-H), 8.27 (d, J = 8 Hz, 2H, 2”- and 
6”-H). 13C NMR (δ, ppm, CDCl3): 12.3 (C-18), 26.2, 27.4, 29.7, 30.8, 37.4, 38.0, 41.2, 43.8, 44.4 
(C-13), 48.7 (C-16), 55.5 (C-16a), 58.7 (linker-CH2), 69.9 (Bn-CH2), 80.7 (C-17), 112.4 (C-2), 
114.8 (C-4), 123.5 (C-2’ and -6’), 126.3 (C-1), 127.4 (C-2” and -6”), 127.8 (C-4’), 128.5 (C-3” 
and -5”), 130.9 (C-3’ and -5’), 132.5 (C-10), 135.1 (C-1”), 137.3 (C-1’), 137.8 (C-5), 150.7 (C-
4”), 156.8 (C-3), 164.6 (C=O).  
 
2.3.30. 3-Benzyloxy-16β-(4’-hydroxymethyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-
trien-17β-ol (25f) 
Compound 25e (210 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from methanol to afford 25f 
(232 mg, 98%) as a white crystalline product. Mp: 283285 оC; Rf= 0.25 (ss B). (Found C, 
73.42; H, 7.35. C29H35N3O3 (473.61) requires C, 73.54; H, 7.45%). 
1H NMR (δ, ppm, DMSO-d6): 
0.77 (s, 3H, 18-H3), 3.77 (dd, 1H, J = 9.5 Hz, J = 3.5 Hz, 16a-H2), 4.15 (t, 1H, J = 12.5 Hz, 16a-
H2), 5.12 (d, 1H, J = 5.5 Hz, 17-H), 6.68 (s, 1H, 4-H), 6.74 (d, 1H, J = 8.5 Hz, 2-H), 7.16 (d, J = 
8.5 Hz, 1H, 1-H), 7.31 (d, 1H, J = 7.0 Hz, 4’-H), 7.37 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.41 (d, 
2H, J = 7.0 Hz., 2’- and 6’-H), 7.98 (s, 1H, triazol-H). 13C NMR (δ, ppm, DMSO-d6): 12.3 (C-
18), 25.8, 26.9, 29.1, 30.0, 36.9, 37.8, 40.4, 43.4, 43.7 (C-13), 47.8 (C-16a), 55.0 (linker-CH2), 
68.9 (Bn-CH2), 79.5 (C-17), 112.1 (C-2), 114.4 (C-4), 122.7 (triazol-CH), 126.0 (C-1), 127.4 (C-
2’ and -6’), 127.6 (C-4’), 128.3 (C-3’ and -5’), 132.3 (C-10), 137.3 (C-5), 147.6 (triazol-C), 156.0 
(C-3).  
 
2.3.31. 3-Benzyloxy-16a-(4’-cyclopropyl-1’H-1’,2,’3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (26a) 
Compound 18 (420.0 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
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ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 26a (310 mg, 64%) as a white solid. Mp: 191193 
о
C; Rf= 0.35 (ss B). (Found C, 76.82; H, 7.94. C31H37N3O2 (483.64) requires C, 76.98; H, 
7.71%). 
1H NMR (δ, ppm, CDCl3): 0.83 (s, 3H, 18-H3), 2.83 (m, 2H, 6-H2), 3.54 (d, J = 7.5 Hz, 
1H, 17-H), 4.35 (dd, 1H, J = 13.0 Hz, J = 7.5 Hz, 16a-H2), 4.44 (dd, 1H, J = 13.0 Hz, J = 7.5 Hz, 
16a-H2), 5.03 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.77 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 
8.5 Hz, 1-H), 7.31 (t, 2H, J = 7.5 Hz, 4’-H and triazol-H), 7.38 (t, 2H, J = 7.5 Hz, 3’- and 5’-H), 
7.42 (d, 2H, J = 7.5 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 6.6 (C-1”), 7.8 (C-2” and -3”), 
11.8 (C-18), 26.1, 27.2, 28.2, 29.7, 36.6, 38.4, 43.9, 44.3, 44.3 (C-13), 48.3 (C-16), 54.5 (C-16a), 
69.9 (Bn-CH2), 85.2 (C-17), 112.3 (C-2), 114.8 (C-4), 120.0 (triazol-CH), 126.3 (C-1), 127.4 (C-
2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 132.6 (C-10), 137.3 (C-1’), 137.8 (C-5), 150.2 
(triazol-C), 156.8 (C-3). 
 
2.3.32. 3-Benzyloxy-16a-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (26b) 
Compound 18 (420 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 26b (442 mg, 86%) as a white solid. Mp: 268270 
о
C; Rf= 0.36 (ss B). (Found C, 77.52; H, 7.93. C33H41N3O2 (511.70) requires C, 77.46; H, 8.08%). 
1H NMR (δ, ppm, CDCl3): 0.83 (s, 3H, 18-H3), 2.83 (m, 2H, 6-H2), 3.19 (s, 1H, 1”-H), 3.46 (d, 
1H, J = 7.0 Hz, 17-H), 4.42 (dd, 2H, J = 22.5 Hz, J, = 6.5 Hz, 16-H2), 5.03 (s, 2H, Bn-H2), 6.71 
(s, 1H, 4-H), 6.76 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.5 Hz, 
4’-H), 7 .37 (t, 3H, J = 7.5 Hz, 3’-, 5’-H and triazol-H), 7.42 (d, 2H, J = 7.5 Hz, 2’- and 6’-H). 
13C NMR (δ, ppm, CDCl3): 11.9 (C-18), 25.1 (C-3” and -4”), 26.1, 27.2, 28.3, 29.7, 33.2 (C-2” 
and -5”), 36.6 (2C, C-1”), 36.7, 38.4, 43.9, 44.3 (C-13), 48.4 (C-16), 54.5 (C-16a), 69.9 (Bn-
CH2), 85.2 (C-17), 112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-3’ and -5’), 127.8 (C-4’), 
128.5 (C-2’ and -6’), 132.6 (C-10), 137.3 (C-1’), 137.8 (C-5), 156.7 (C-3).  
 
2.3.33. 3-Benzyloxy-16a-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17β-ol (26c) 
Compound 18 (420 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
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ethyl acetate/CH2Cl2 (2.5:77.5 v/v) to yield pure 26c (386 mg, 76%) as a white solid. Mp: 
261263 оC; Rf= 0.34 (ss B). (Found C, 77.93; H, 8.36. C34H43N3O2 (525.72) requires C, 77.68; 
H, 8.24%). 
1H NMR (δ, ppm, CDCl3): 0.83 (s, 3H, 18-H3), 2.83 (m, 2H, 6-H2), 3.55 (d, J = 7.0 
Hz, 1H, 17-H), 4.43 (m, 2H, 16-H2), 5.03 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.77 (d, 1H, J = 8.5 
Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 2H, J = 7.0 Hz, 4’-H and triazol-H), 7.37 (t, 2H, 
J = 7.0 Hz. 3’- and 5’-H), 7.42 (d, 2H, J = 7 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 11.9 
(C-18), 25.9 (C-4”), 26.1 (C-3” and -5”), 27.2, 28.3, 29.7 (C-2” and -6”), 32.9, 33.0, 36.6, 38.4, 
43.9, 44.2, 44.3 (C-13), 48.4 (C-16), 54.5 (C-16a), 69.9 (Bn-CH2), 85.2 (C-17), 112.3 (C-2), 
114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 132.6 (C-10), 
137.3 (C-1’), 137.8 (C-5), 156.7 (C-3).  
 
2.3.34. 3-Benzyloxy-16a-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17β-ol 
(26d) 
Compound 18 (420 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 5:95 v/v) to yield pure 26d (372 mg, 71%) as a white solid. Mp: 132134 
о
C; Rf= 0.38 (ss B). (Found C, 78.63; H, 6.97. C34H37N3O2 (519.68) requires C, 78.58; H, 7.18%). 
1H NMR (δ, ppm, CDCl3): 0.84 (s, 3H, 18-H3), 2.83 (m, 2H, 6-H2), 3.58 (d, 1H, J = 7.5 Hz, 17-
H), 4.46 (dd, 2H, J = 13.5 Hz, J = 8.0 Hz, 16a-H2), 4.55 (dd, 1H, J = 13.5 Hz, J = 8.0 Hz, 16a-
H2) 5.03 (s, 2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.19 (d, 1H, J = 8.5 Hz, 
1-H), 7.30-7.86 (m, 11H, 2’-, 6’-, 3’-, 5’-, 4’-, 2”-, 6”-, 3”-, 5”-, 4”- and triazol-H). 13C NMR (δ, 
ppm, CDCl3): 11.8 (C-18), 26.1, 27.2, 28.2, 29.6, 36.5, 38.4, 43.9, 44.3, 48.3 (C-16), 54.6 (C-
16a), 62.1, 69.9 (Bn-CH2), 85.2 (C-17), 112.3 (C-2), 114.8 (C-4), 123.8 (triazol-CH), 125.7 (C-2’ 
and -6’), 126.3 (C-1’), 127.4 (C-2” and -6”), 127.8 (C-4’), 128.2 (C-4), 128.5 (C-3” and -5”), 
128.8 (C-3’ and -5’), 130.4 (C-10), 132.6 (C-1”), 137.3 (C-1’), 137.8 (C-5), 156.8 (C-3).  
 
2.3.35. 3-Benzyloxy-16a-[4’-(4’’-nitro-benzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl]methylestra-
1,3,5(10)-trien-17β-ol (26e) 
Compound 18 (420 mg, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 210 mg) were used for 
the synthesis as described in Section 2.3. The crude product was chromatographed on silica gel 
with ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 26e (484 mg, 77%) as a yellow solid. Mp: 
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9496 оC; Rf= 0.40 (ss B). (Found C, 69.73; H, 5.94. C36H38N4O6 (622.71) requires C, 69.44; H, 
6.15%). 
1H NMR (δ, ppm, DMSO-d6): 0.70 (s, 3H, 18-H3), 3.33 (m, 2H, 6-H2), 4.38 (dd, 1H, J = 
13.5 Hz, J = 9.0 Hz, 16a-H2), 4.52 (dd, 1H, J = 13.5 Hz, J = 5.0 Hz, 16a-H2), 4.86 (d, 1H, J = 5 
Hz, 17-H), 5.02 (s, 2H, Bn-H2), 5.47 (s, 2H, linker-H2), 6.64 (d, 1H, J = 2.0 Hz, 4-H), 6.72 (dd, 
1H, J = 8.5 Hz, J = 2.0 Hz, 2-H), 7.10 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.0 Hz, 4’-H), 
7.37 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.42 (d, 2H, J = 7.0 Hz, 2’- and 6’-H), 8.16 (d, 2H, J = 9.0 
Hz, 3”- and 5”-H), 8.28 (d, 2H, J = 9.0 Hz, 2”- and 6”-H), 8.32 (s, 1H, triazol-H). 13C NMR (δ, 
ppm, DMSO-d6): 11.7 (C-18), 25.7, 26.6, 27.1, 29.0, 30.6, 36.4, 37.9, 43.4, 43.4 (C-13), 43.7 (C-
16), 53.1 (C-16a), 58.6 (linker-CH2), 68.9 (Bn-CH2), 82.8 (C-17), 112.1 (C-2), 114.3 (C-4), 123.7 
(C-2’ and -6’), 125.1 (triazol-CH), 125.9 (C-1), 127.4 (C-2” and -6”), 127.5 (C-4’), 128.3 (C-3” 
and -5”), 130.6 (C-3’ and -5’), 132.1 (C-10), 134.7 (C-1”), 137.2 (C-1’), 137.3 (C-5), 141.1 
(triazol-C), 150.1 (C-4”), 155.9 (C-3), 163.9 (C=O). 
2.3.36. 3-Benzyloxy-16a-(4’-hydroxymethyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-
trien-17-ol (26f) 
Compound 26e (210 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from a mixture of 
acetone/hexane to afford 26f (190 mg, 89%) as a white crystalline product. Mp: 152154 оC; Rf= 
0.20 (ss B). (Found C, 73.72; H, 7.63. C29H35N3O3 (473.61) requires C, 73.54; H, 7.45%). 
1
H 
NMR (δ, ppm, DMSO-d6): 0.71 (s, 3H, 18-H3), 2.73 (m, 2H, 6H2), 3.29 (d, J = 8.0 Hz, 1H, 17-
H), 4.28 (dd, 2H, J = 13.0 Hz, J = 10.0 Hz, 16a-H2), 4.47 (dd, 1H, J = 13.0 Hz, J = 4.5 Hz, 16a-
H2), 4.51 (s, 2H, Bn-H2), 4.87 (s, 1H, linker-H2), 5.03 (s, 2H, triazol-H2), 5.15 (s, 1H, linker-H2), 
6.68 (s, 1H, 4-H), 6.74 (d, 1H, J = 8.5 Hz, 2-H), 7.15 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.0 
Hz, 4’-H), 7.37 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.41 (d, 2H, J = 7.0 Hz, 2’- and 6’-H), 7.97 (s, 
1H, triazol-H). 
13C NMR (δ, ppm, DMSO-d6): 11.8 (C-18), 25.8, 26.7, 27.3, 29.1, 36.4, 38.1, 
43.4, 43.5 (C-13), 43.9, 47.5 (C-16), 53.1 (C-16a), 54.9 (linker-CH2), 68.9 (Bn-CH2), 83.0 (C-
17), 112.1 (C-2), 114.4 (C-4), 122.7 (triazol-CH), 126.0 (C-1), 127.4 (C-2’ and -6’), 127.6 (C-4’), 
128.3 (C-3’ and -5’), 132.3 (C-10), 137.3 (C-1’), 137.4 (C-5), 147.6 (triazol-C), 156.0 (C-3). 
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2.3.37. 3-Benzyloxy-16β-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (27a) 
Compound 19 (420.0 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 27a (454 mg, 93%) as white crystals. Mp: 199201 
о
C; Rf= 0.38 (ss B). (Found C, 77.15; H, 7.62. C31H37N3O2 (483.64) requires C, 76.98; H, 
7.71%). 
1H NMR (δ, ppm, CDCl3): 0.77 (s, 3H, 18-H3), 0.87 and 0.98 (2 x s, 2 x 2H, 2”- and 3”-
H2), 2.05 (s, 1H, 1”-H), 2.84 (m, 2H, 6-H2), 3.66 (s, 1H, 17-H), 4.42 (m, 2H, 16a-H2), 5.03 (s, 
2H, Bn-H2), 6.71 (s, 1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.31 
(t, 1H, J = 7.0 Hz, 4’-H), 7.38 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.43 (d, 2H, J = 7.0 Hz, 2’- and 
6’-H). 13C NMR (δ, ppm, CDCl3): 6.7 (C-1”), 7.7 (C-2” and -3”), 17.9 (C-18), 25.9, 27.9, 29.7, 
30.4, 31.8, 38.5, 43.3, 45.1 (C-13), 48.9, 49.1 (C-16), 62.1 (C-16a), 69.9 (Bn-CH2), 82.6 (C-17), 
112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 
132.7 (C-10), 137.3 (C-1’), 137.9 (C-5), 156.7 (C-3).  
 
2.3.38. 3-Benzyloxy-16β-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (27b) 
Compound 19 (420 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 27b (408 mg, 79%) as white crystalline. Mp: 
220222 оC; Rf= 0.40 (ss B). (Found C, 77.32; H, 7.93. C33H41N3O2 (511.70) requires C, 77.46; 
H, 8.08%). 
1H NMR (δ, ppm, CDCl3): 0.76 (s, 3H, 18-H3), 2.84 (m, 2H, 6-H2), 3.20 (s, 1H, 1”-
H), 3.67 (s, 1H, 17-H), 4.43 (m, 2H, 16a-H2), 5.03 (s, 2H, Bn-H2), 6.72 (s, 1H, 4-H), 6.78 (dd, 
1H, J = 8.5 Hz, J = 2.0 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.0 Hz, 4’-H), 
7.38 (t, 3H, J = 7.0 Hz, 3’- and 5’-H, triazol-H), 7.43 (d, 2H, J = 7.0 Hz, 2’- and 6’-H). 13C NMR 
(δ, ppm, CDCl3): 18.0 (C-18), 25.1 (C-3” and -5”), 25.9, 28.0, 29.7, 30.4, 31.8 (C-2” and -6”), 
33.2, 36.7, 38.5, 43.3, 45.1 (C-13), 48.9 (C-16), 49.1 (C-1”), 54.3 (C-16a), 69.9 (Bn-CH2), 82.6 
(C-17), 112.3 (C-2), 114.8 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and 
-5’), 132.7 (C-10), 137.3 (C-1’), 137.9 (C-5), 156.7 (C-3).  
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2.3.39. 3-Benzyloxy-16β-(4’-cyclohexyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (27c) 
Compound 19 (420 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 27c (360 mg, 68%) as white crystalline product. 
Mp: 243245 оC; Rf= 0.38 (ss B). (Found C, 77.54; H, 8.38. C34H43N3O2 (525.72) requires C, 
77.68; H, 8.24%). 
1H NMR (δ, ppm, CDCl3): 0.75 (s, 3H, 18-H3), 2.84 (m, 2H, 6-H2), 3.68 (s, 
1H, 17-H), 4.44 (m, 2H, 16a-H2), 5.03 (s, 2H, Bn-H2), 6.72 (s, 1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 
2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (t, 1H, J = 7.0 Hz, 4’-H), 7.38 (t, 3H, J = 7.0 Hz, 3’- and 
5’-H, triazol-H), 7.43 (d, 2H, J = 7.0 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 17.9 (C-18), 
25.9 (C-4”), 26.0, 26.1 (C-3” and -5”), 27.9, 29.7, 30.4, 31.8 (C-2” and -6”), 32.1, 32.9 (C-1”), 
38.5, 43.3, 45.1 (C-13), 48.9, 49.1 (C-16), 62.1 (C-16a), 69.9 (Bn-CH2), 82.5 (C-17), 112.3 (C-2), 
114.7 (C-4), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 132.7 (C-10), 
137.2 (C-1’), 137.9 (C-5), 156.7 (C-3).  
 
 
2.3.40. 3-Benzyloxy-16β-(4’-phenyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-17a-ol 
(27d) 
Compound 19 (420 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (10:90 v/v) to yield pure 27d (487 mg, 93%) as white crystals. Mp: 
202204 оC; Rf= 0.45 (ss B). (Found C, 78.68; H, 7.38. C34H37N3O2 (519.68) requires C, 78.58; 
H, 7.18%). 
1H NMR (δ, ppm, CDCl3): 0.79 (s, 3H, 18-H3), 2.84 (m, 2H, 6-H2), 3.72 (s, 1H, 17-
H), 4.48 (dd, 1H, J = 13.5 Hz, J = 7.5 Hz, 16a-H2), 4.56 (t, 1H, J = 13.5 Hz, 16a-H2), 5.03 (s, 2H, 
Bn-H2), 6.72 (s, 1H, 4-H), 6.78 (d, 1H, J = 8.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.33 (t, 
1H, J = 7.5 Hz, 4’-H), 7.38 (t, 2H, J = 7.5 Hz, 3’- and 5’-H), 7.42 (d, J = 3.5 Hz, 4H, 2’- and 6’-
H, 3”- and 5”-H), 7.84 (d, 2H, J = 7.5 Hz, 2”- and 6”-H), 7.88 (s, 1H, triazol-H). 13C NMR (δ, 
ppm, CDCl3): 17.9 (C-18), 25.9, 27.9, 29.7, 30.4, 31.8, 38.5, 43.3, 45.2 (C-13), 48.9, 49.1 (C-16), 
54.6 (C-16a), 69.9 (Bn-CH2), 82.6 (C-17), 112.3 (C-2), 114.8 (C-4), 119.6 (triazol-CH), 125.7 
(C-2’ and -6’), 126.3 (C-1’), 127.4 (C-2” and -6”), 127.8 (C-4’), 128.2 (C-4”), 128.5 (C-3” and -
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5”), 128.8 (C-3’ and -5’), 130.5 (C-10), 132.64 (C-1”), 137.3 (C-1’), 137.9 (C-5), 147.7 (triazol-
C); 156.8 (C-3). 
 
2.3.41. 3-Benzyloxy-16β-[4’-(4’’-nitro-benzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl]methylestra-
1,3,5(10)-trien-17a-ol (27e) 
Compound 19 (420.0 mg, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 210 mg) were used 
for the synthesis as described in Section 2.3. The crude product was chromatographed on silica 
gel with ethyl acetate/CH2Cl2 (10:90 v/v) to yield pure 27e (550 mg, 88%) as yellow crystals. 
Mp: 177179 оC; Rf= 0.48 (ss B). (Found C, 69.55; H, 5.93. C36H38N4O6 (622.71) requires: C, 
69.44; H, 6.15%). 
1H NMR (δ, ppm, DMSO-d6): 0.65 (s, 3H, 18-H3), 2.73 (m, 2H, 6-H2), 4.40 
(dd, 1H, J = 13.0 Hz, J = 8.5 Hz, 16a-H2), 4.56 (dd, 1H, J = 13.5 Hz, J = 7.5 Hz, 16a-H2), 4.63 
(d, 1H, J = 5.0 Hz, 17-H), 5.04 (s, 2H, Bn-H2), 5.47 (s, 2H, triazol-H2), 6.68 (s, 1H, 4-H), 6.74 (d, 
1H, J = 8.5 Hz, 2-H), 7.16 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.0 Hz, 4’-H), 7.37 (t, 2H, J 
= 7.0 Hz, 3’- and 5’-H), 7.41 (d, 2H, J = 7.0 Hz, 2’- and 6’-H), 8.18 (d, 2H, J = 8.5 Hz, 3”- and 
5”-H), 8.33 (d, 3H, J = 6 Hz, 2”- and 6”-H, triazol-H). 13C NMR (δ, ppm, DMSO-d6): 17.5 (C-
18), 25.6, 27.5, 29.2, 29.6, 31.8, 38.2, 42.9, 44.5 (C-13), 48.2, 49.1 (C-16), 53.6 (C-16a), 58.7 
(linker-CH2), 68.9 (Bn-CH2), 80.8 (C-17), 112.1 (C-2), 114.4 (C-4), 123.8 (C-2’ and C-6’), 125.0 
(triazol-CH), 126.1 (C-1), 127.4 (C-2” and -6”), 127.6 (C-4’), 128.3 (C-3” and -5”), 130.6 (C-3’ 
and -5’), 132.3 (C-10), 134.7 (C-1”), 137.3 (C-5 and C-1’), 141.1 (triazol-C), 150.2 (C-4”), 160.0 
(C-3), 163.9 (C=O). 
 
2.3.42. 3-Benzyloxy-16β-(4’-hydroxymethyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-
trien-17a-ol (27f) 
Compound 27e (210 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from methanol to afford 27e 
(273 mg, 99%) as a white crystalline product. Mp: 172174 оC; Rf= 0.25 (ss B). (Found C, 
73.68; H, 7.66. C29H35N3O3 (473.61) requires C, 73.54; H, 7.45%). 
1H NMR (δ, ppm, DMSO-d6): 
0.67 (s, 3H, 18-H3), 2.74 (m, 2H, 6-H2), 3.43 (s, 1H, 17-H), 4.34 (m, 1H, 16a-H2), 4.50 (m, 3H, 
16a-H2 and Bn-H2), 4.61 (brs, 1H, OH), 5.04 (s, 2H, triazol-H2), 5.16 (brs, 1H, OH), 6.69 (s, 1H, 
4-H), 6.74 (d, 1H, J = 8.5 Hz, 2-H), 7.17 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (d, 1H, J = 7.0 Hz, 4’-H), 
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7.37 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.41 (d, 2H, J = 7.0 Hz, 2’- and 6’-H), 8.00 (s, 1H, triazol-
H). 
13C NMR (δ, ppm, DMSO-d6): 17.5 (C-18), 25.6, 27.5, 29.2, 29.6, 31.9, 38.2, 43.0, 44.5 (C-
13), 48.2, 49.1 (C-16), 53.5 (C-16a), 55.0 (linker-CH2), 61.6, 68.9 (Bn-CH2), 80.8 (C-17), 112.2 
(C-2), 114.4 (C-4), 122.6 (triazol-CH), 126.6 (C-1), 127.4 (C-2’ and -6’), 127.6 (C-4’), 128.3 (C-
3’ and -5’), 132.4 (C-10), 137.3 (C-5 and C-1’), 147.6 (triazol-C), 156.0 (C-3). 
2.3.43. 3-Benzyloxy-16a-(4’-cyclopropyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (28a) 
Compound 20 (420.0 mg, 1 mmol) and cyclopropylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (1:99 v/v) to yield pure 28a (305 mg, 63%) as white crystals. Mp: 143144 
о
C; Rf= 0.40 (ss B). (Found C, 77.15; H, 7.53. C31H37N3O2 (483.64) requires C, 76.98; H, 
7.71%). 
1H NMR (δ, ppm, CDCl3): 0.74 (s, 3H, 18-H3), 0.87 and 0.97 (2 x s, 2 x 2H, 2”- and 3”-
H2), 2.85 (m, 2H, 6-H2), 3.63 (d, 1H, J = 5.0 Hz, 17-H), 4.26 (dd, 1H, J = 13.5 Hz, J = 5.5 Hz, 
16a-H2), 4.60 (t, 1H, J = 13.5 Hz, 16a-H2), 5.03 (s, 2H, Bn-H2), 6.72 (d, 1H, J = 2.0 Hz, 4-H), 
6.78 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.22 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (t, 1H, J = 7.5 Hz, 
4’-H), 7.38 (t, 3H, J = 7.5 Hz, 3’- and 5’-H, triazol-H), 7.43 (d, 2H, J = 7.5 Hz, 2’- and 6’-H). 13C 
NMR (δ, ppm, CDCl3): 6.5 (C-1”), 7.9 (2C, C-2” and -3”), 17.1 (C-18), 26.0, 27.9, 28.9, 29.8, 
31.2, 38.9, 42.3, 43.5, 46.3 (C-16a), 47.0 (C-16), 50.7 (C-13), 69.9 (Bn-CH2), 78.7 (C-17), 112.2 
(C-2), 114.8 (C-4), 120.8 (triazol-CH)), 126.3 (C-1), 127.4 (C-2’ and -6’), 127.4 (C-4’), 128.5 
(C-3’ and -5’), 132.5 (C-10), 137.2 (C-1’), 137.9 (C-5), 149.6 (triazol-C), 156.7 (C-3). 
 
2.3.44. 3-Benzyloxy-16a-(4’-cyclopentyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-trien-
17a-ol (28b) 
Compound 20 (420.0 mg, 1 mmol) and cyclopentylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (2.5:97.5 v/v) to yield pure 28b (417 mg, 82%) as white crystals. Mp: 
197199 оC; Rf= 0.42 (ss B). (Found: C, 77.62; H, 7.85. C33H41N3O2 (511.70) requires C, 77.46; 
H, 8.08%). 
1H NMR (δ, ppm, CDCl3): 0.76 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.20 (s, 1H, 1”-
H), 3.66 (d, 1H, J = 5.0 Hz, 17-H), 4.29 (dd, 1H, J = 13.5 Hz, J = 5.5 Hz, 16a-H2), 4.62 (dd, 1H, 
J = 13.5 Hz, J = 9.5 Hz, 16a-H2), 5.04 (s, 2H, Bn-H2), 6.72 (s, 1H, 4-H), 6.78 (dd, 1H, J = 8.5 Hz, 
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J = 2.5 Hz, 2-H), 7.21 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (t, 1H, J = 7.0 Hz, 4’-H), 7.37 (t, 2H, J = 7.0 
Hz, 3’- and 5’-H), 7.43 (d, 2H, J = 7.0 Hz, 2’- and 6’-H). 13C NMR (δ, ppm, CDCl3): 17.3 (C-
18), 25.2 (2C), 26.1, 28.0, 29.1, 29.8 (2C), 31.3, 33.2, 36.8 (C-1”), 39.0, 42.4, 43.6, 46.4 (C-16a), 
47.2 (C-16), 50.6 (C-13), 70.1 (Bn-CH2), 79.0 (C-17), 112.4 (C-2), 115.0 (C-4), 126.3 (C-1), 
127.4 (C-2’ and -6’), 127.8 (C-4’), 128.5 (C-3’ and -5’), 133.0 (C-10), 137.5 (C-1’), 137.9 (C-5), 
156.9 (C-3). 
 
2.3.45. 3-Benzyloxy-16a-(4-cyclohexyl-1H-1,2,3-triazol-1-yl)methyl-estra-1,3,5(10)-trien-17a-ol 
(28c) 
Compound 20 (420.0 mg, 1 mmol) and cyclohexylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (2.5:97.5 v/v) to yield pure 28c (200 mg, 76%) as a white solid. Mp: 
223225 оC; Rf= 0.44 (ss B). (Found C, 77.82; H, 8.35. C34H43N3O2 (525.72) requires C, 77.68; 
H, 8.24%). 
1H NMR (δ, ppm, CDCl3): 0.75 (s, 3H, 18-H3), 2.84 (m, 3H, 6-H2, 1”-H), 3.64 (s, 1H, 
17-H), 4.37 (m, 1H, 16a-H2), 4.69 (m, 1H, 16a-H2), 5.03 (s, 2H, Bn-H2), 6.72 (d, 1H, J = 1.5 Hz, 
4-H), 6.78 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, 2-H), 7.22 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (t, 1H, J = 
7.0 Hz, 4’-H), 7.38 (t, 2H, J = 7.0 Hz, 3’- and 5’-H), 7.43 (d, 2H, J = 7.0 Hz, 2’- and 6’-H 
 
2.3.46. 3-Benzyloxy-16a-(4-phenyl-1H-1,2,3-triazol-1-yl)methyl-estra-1,3,5(10)-trien-17a-ol 
(28d) 
Compound 20 (420.0 mg, 1 mmol) and phenylacetylene (2 mmol, 0.22 ml) were used for the 
synthesis as described in Section 2.3. The crude product was chromatographed on silica gel with 
ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 28d (337 mg, 64%) as a white solid. Mp: 205206 
о
C; Rf= 0.46 (ss B). (Found C, 78.42; H, 7.32. C34H37N3O2 (519.68) requires C, 78.58; H, 7.18%). 
1H NMR (δ, ppm, CDCl3): 0.76 (s, 3H, 18-H3), 2.87 (m, 2H, 6-H2), 3.68 (d, 1H, J = 5.0 Hz, 17-
H), 4.41 (dd, 1H, J = 13.5 Hz, J = 5.5 Hz, 16a-H2), 4.69 (t, 1H, J = 13.5 Hz, 16a-H2), 5.04 (s, 2H, 
Bn-H2), 6.73 (s, 1H, 4-H), 6.79 (dd, 1H, J = 8.0 Hz, J = 2.0 Hz, 2-H), 7.22 (d, 1H, J = 8.0 Hz, 1-
H), 7.38 (m, 8H, 2’-, 3’-, 4’-, 5’- and 6’-H, 3”-, 4”- and 5”-H), 7.84 (d, 2H, J = 7.5 Hz, 2”- and 
6”-H), 7.89 (s, 1H, triazol-H). 13C NMR (δ, ppm, CDCl3): 17.1 (C-18), 26.0, 27.9, 29.8, 31.2, 
38.9, 42.2, 43.5, 46.4 (C-13), 47.0 (C-16), 50.8 (C-16a), 69.9 (Bn-CH2), 78.8 (C-17), 112.3 (C-2), 
114.8 (C-4), 120.7 (triazol-CH), 125.7 (C-2’ and -6’), 126.3 (C-1), 127.4 (C-2” and -6”), 127.8 
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(C-4’), 128.3 (C-4”), 128.5 (C-3” and -5”), 128.9 (C-3’ and -5’), 130.2 (C-10), 132.8 (C-1’), 
137.3 (C-1”), 137.9 (C-5), 147.1 (triazol-C), 156.7 (C-3). 
 
2.3.47. 3-Benzyloxy-16a-[4’-(4’’-nitro-benzoyloxymethyl)-1’H-1’,2’,3’-triazol-1’-yl]methylestra-
1,3,5(10)-trien-17a-ol (28e) 
Compound 20 (420 mg, 1 mmol) and propargyl 4-nitrobenzoate (2 mmol, 210 mg) were used for 
the synthesis as described in Section 2.3. The crude product was chromatographed on silica gel 
with ethyl acetate/CH2Cl2 (5:95 v/v) to yield pure 28e (610 mg, 98%) as a yellow solid. Mp: 
7577 оC; Rf= 0.45 (ss B). (Found C, 69.57; H, 61.32. C36H38N4O6 (622.71) requires C, 69.44; H, 
6.15%). 
1H NMR (δ, ppm, DMSO-d6): 0.66 (s, 3H, 18-H3), 2.71 (m, 2H, 6-H2), 3.57 (s, 1H, 16-
H), 4.29 (dd, 1H, J = 13.5 Hz, J = 8.5 Hz, 16a-H2), 4.47 (dd, 1H, J = 13.5 Hz, J = 8.5 Hz, 16a-
H2), 4.85 (d, 1H, J = 5.0 Hz, 17-H), 5.44 (s, 2H, Bn-H2), 6.65 (s, 1H, 4-H), 6.72 (d, 1H, J = 8.5 
Hz, 2-H), 7.14 (d, 1H, J = 8.5 Hz, 1-H), 7.29 (t, 1H, J = 7.5 Hz, 4’-H), 7.35 (t, 2H, J = 7.5 Hz, 3’- 
and 5’-H), 7.40 (d, 2H, J = 7.5 Hz, 2’- and 6’-H), 8.17 (d, 2H, J = 8.5 Hz, 3”- and 5”-H), 8.28 (s, 
1H, triazol H), 8.31 (d, 2H, J = 8.5 Hz, 2”- and 6”-H). 13C NMR (δ, ppm, DMSO-d6): 16.9 (C-
18), 25.6, 27.5, 28.4, 29.2, 31.1, 38.5, 39.8, 39.9, 43.2, 45.9 (C-16a), 46.2 (C-16), 53.4 (C-13), 
58.7 (linker CH2), 68.9 (Bn-CH2), 78.0 (C-17), 112.1 (C-2), 114.4 (C-4), 123.8 (C-2” and -6”), 
125.0 (triazol CH), 126.1 (C-1), 127.4 (C-2’ and -6’), 127.5 (C-4’), 128.3 (C-3’ and -5’), 130.6 
(C-3” and -5”), 132.3 (C-10), 134.7 (C-1’), 137.3 (C-5), 141.0 (C-1”), 150.2 (triazol C), 156.0 
(C-3), 163.9 (C=O). 
 
2.3.48. 3-Benzyloxy-16a-(4’-hydroxymethyl-1’H-1’,2’,3’-triazol-1’-yl)methylestra-1,3,5(10)-
trien-17-ol (28f) 
Compound 28e (220 mg, 0.5 mmol) was dissolved in methanol (10 ml) containing NaOCH3 (14 
mg, 0.25 mmol), and the solution was allowed to stand for 24 h. It was then diluted with water, 
and the precipitate separating out was filtered off and recrystallized from methanol to afford 28f 
(126 mg, 53%) as a white crystalline product. Mp: 8688 оC; Rf= 0.25 (ss B). (Found C, 73.68; 
H, 7.63. C29H35N3O3 (473.61) requires C, 73.54; H, 7.45%). 
1H NMR (δ, ppm, DMSO-d6): 0.68 
(s, 3H, 18-H3), 2.74 (m, 2H, 6-H2), 3.58 (brs, 1H, OH), 4.26 (t, 1H, J = 8.5 Hz, 16a-H2), 4.43 (dd, 
1H, J = 13.0 Hz, J = 7.0 Hz, 16a-H2), 4.51 (d, 2H, J = 5.0 Hz, linker H2), 4.85 (d, 1H, J = 4.0 Hz, 
17-H), 5.04 (s, 2H, Bn-H2), 5.13 (brs, 1H, OH), 6.68 (s, 1H, 4-H), 6.74 (d, 1H, J = 8.5 Hz, 2-H), 
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7.17 (d, 1H, J = 8.5 Hz, 1-H), 7.31 (d, 1H, J = 7.0 Hz, 4’-H), 7.37 (t, 2H, J = 7.0 Hz, 3’- and 5’-
H), 7.42 (d, 2H, J = 7.0 Hz, 2’- and 6’-H), 7.97 (s, 1H, triazol H). 13C NMR (δ, ppm, DMSO-d6): 
16.9 (C-18), 25.6, 27.5, 28.5, 29.2, 31.1, 38.5, 40.7, 43.2, 45.9, 46.2 (C-16), 47.9 (C-13), 50.6 (C-
16a), 55.0 (linker CH2), 68.9 (Bn-CH2), 78.0 (C-17), 112.1 (C-2), 114.4 (C-4), 122.7 (triazol 
CH), 126.1 (C-1), 127.4 (C-2’ and -6’), 127.6 (C-4’), 128.3 (C-3’ and -5’), 132.4 (C-10), 137.3 
(C-1’), 137.4 (C-5), 147.6 (triazol C), 156.0 (C-3). 
 
2.4. Determination of the antiproliferative activities 
The growth-inhibitory effects of the compounds were tested in vitro by means of the MTT 
assay against a gynecological panel containing two breast cancer cell lines (MCF-7, MD-MB-
231) and two cell lines isolated from cervical malignancies (HeLa, SiHa) [11]. All cell lines were 
obtained from the European Collection of Cell Cultures (Salisbury, UK). The cells were 
maintained in minimal essential medium supplemented with 10% fetal bovine serum (FBS), 1% 
non-essential amino acids and an antibiotic–antimycotic mixture (AAM). All chemicals, if 
otherwise not specified, were purchased from Sigma-Aldrich Ltd. (Budapest, Hungary). All cell 
lines were grown in a humidified atmosphere of 5% CO2 at 37 
o
C. For pharmacological 
investigations, 10 mM stock solutions of the tested compounds were prepared with dimethyl 
sulfoxide (DMSO). The highest applied DMSO concentration of the medium (0.3%) did not have 
any substantial effect on the determined cellular functions. Cells were seeded into 96-well plates 
(5000 cells/well), allowed to stand overnight under cell culturing conditions, and the medium 
containing the tested compounds at two final concentrations (10 or 30 µM) was then added. After 
a 72-hour incubation viability was determined by the addition of 20 µl 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/ml). The formazan crystals 
precipitated in 4 h were solubilized in DMSO and the absorbance was determined at 545 nm with 
an ELISA plate reader utilizing untreated cells as controls. The most effective compounds 
eliciting at least 60% growth inhibition at 10 μM were tested again with a set of dilutions (0.3−30 
µM) in order to determine the IC50 values by means of Graphpad Prism 4.0 (Graphpad Software; 
San Diego, CA, US). These promising compounds were additionally tested using nonmalignant 
murine fibroblasts (NIH-3T3) to obtain preliminary data concerning cancer selectivity of the 
tested molecules. Two independent experiments were performed with 5 parallel wells and 
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cisplatin (Ebewe GmbH, Unterach, Austria), an agent administered clinically in the treatment of 
certain gynecological malignancies, was used as reference compound. 
 
3. Results and discussion 
3.1. Synthetic studies 
 
 To prepare novel steroid triazoles via 1,3-dipolar cycloaddition, we chose the 3-methoxy- and 3-
benzyloxy-16-hydroxymethylestra-1,3,5(10)-trien-17-ol diastereomers (5–8 and 9–12). The 
synthesis strategy for the preparation of the starting diols (21–28) is illustrated in Scheme 1. The 
synthesis of steroidal 1,2,3-triazoles by CuAAC is outlined in Scheme 2. 
     Stereoselective tosylation of 5–8 and bromination of 9–12 gave 5b–8b and 9c–12c, 
respectively, which then underwent facile SN2 substitution with NaN3 in N,N-dimethylformamide 
to furnish the corresponding 16-azidomethyl compounds (13–16 and 17–20). 
 The 16-azido compounds were subjected to the azide–alkyne CuAAC reaction with different 
alkyl- and aryl-acetylenes. The azide–alkyne reactions of these compounds were carried out with 
CuI as catalyst in the presence of Et3N in CH2Cl2 under reflux conditions to obtain the required 3-
methoxy- and 3-benzyloxyestra-1,3,5(10)-trien-16-(1’,4’-substituted 1’,2’,3’)-triazolyl 
derivatives (21–24 and 25–28). 
 
 
3.2. Determination of the antiproliferative properties of the 16-triazolylmethyl diastereomers 
 
We have published recently that introduction of a substituted triazole moiety onto 
different positions of the estrane skeleton might increase the antiproliferative properties of 
estrone derivatives [12]. It was also established that the presence of certain alkyl or aralkyl 
protecting groups at the phenolic OH function is advantageous. Concerning that 16-
hydroxymethylene-17-hydroxy derivatives of estrone-3-methyl ether or 3-benzyl ether (5a‒12a) 
displayed substantial cytostatic potential against different types of breast cancer cell lines, these 
compounds might be suitable for directed modifications with the aim of developing potentially 
more active antiproliferative steroidal derivatives [13]. In the light of the above-mentioned recent 
observations, here we aimed to combine the substituted triazole and the 16,17-disubstituted 
estrone 3-ether moieties. The present study included an evaluation of the direct antiproliferative 
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capacities of the newly synthesized heterocyclic compounds (21af, 22af, 23af, 24af and 
25af, 26af, 27af, 28af). The antiproliferative activities were determined in vitro by means 
of MTT assays against human adherent cervical (SiHa, HeLa) and breast cancer (MCF-7 and 
MDA-MB-231) cell lines.  
 The antiproliferative activities of the newly synthesized heterocyclic compounds 
depended on the nature of the protecting group at the 3-hydroxy function and on the orientation 
of the substituents at C-16 and C-17. In general, the 3-methyl ethers (2124) exhibited weak 
antiproliferative action; none of them exerted any substantial effect at 10 M (Table 1). All 
diastereomers of the 3-benzyl ether series (2528) proved to be more potent in comparison with 
their 3-methyl ether counterparts (Table 2). This is in agreement with our earlier results [14]. 
Based on the substantial difference of the two groups, i.e. that of 3-methyl ethers and 3-benzyl 
ethers, it can be concluded that only the latter derivatives are promising from pharmacological 
point of view. 
Concerning the orientation of the substituents at position C-16 and C-17, the 16,17-
derivatives (25af) displayed outstanding growth-inhibitory properties. Two derivatives bearing 
similar cycloalkyl groups at position C-4’ displayed substantial selective antiproliferative action 
against the triple-negative breast cancer cell line MDA-MB-231 with IC50 values in the low 
micromolar range. It should be underlined  that 25b and 25c did not significantly influence the 
proliferation of other cell lines tested, including the non-cancerous fibroblast. Although both the 
4’-cyclohexyl (25c) and the 4’-phenyl derivative (25d) have six-membered substituents, their 
cytostatic behavior is completely different. This might be attributed to the different steric 
structure of the two rings (chair or planar) at C-4’. Compound 25d exerted potent 
antiproliferative action against all tested cell lines without any selectivity. The cis-16α,17α-3-
benzyl ethers (28a–f) were less potent than their β,β-counterparts (25a–f), except for 28d, which 
behaved similarly  to its diastereomer 25d. The trans-16β,17α-isomers (27a–f) exhibited activity 
exclusively on the breast cancer cell lines. Surprisingly, the tendency observed earlier (in the case 
of compounds 25a–f) concerning the nature of C-4’ substituent was not valid  here. Only 26a and 
26e inhibited cell growth markedly, but with no tumor selectivity. It’s worth mentioning that 
trans-16α,17β isomer 26c was the sole compound, which inhibited the proliferation of HPV 16+ 
squamous cell carcinoma SiHa, showing an IC50 value comparable with that of cisplatin. 
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In view of the cell lines, it should be noted that triple-negative breast cancer cell line MDA-MB-
231 proved to be the most sensitive and all calculated IC50 values were lower than that of the 
reference agent cisplatin (19.1 μM). 
Regarding the present and earlier results obtained for 16,17-disubstituted 3-benzyl ethers, it can 
be stated that introduction of a substituted triazolyl moiety onto the C-16 methylene group of the 
cis isomers proved to be advantageous. In the case of compounds 25b and 25c,  both the 
antiproliferative potential and the tumor selectivity were markedly improved. 
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Legends for Schemes and Tables 
Scheme 1 Reagents and conditions: (i) NaOMe, HCOOEt, anhydrous toluene, 50 °C; (ii) KBH4, 
MeOH; (iii) KOAc, CH3COOH, NaOMe/MeOH. 
 
Scheme 2 Reagents and conditions: (i) appropriate alkyne, TEA, CuI, CH2Cl2, 40 °C, 24 h; (ii) 
NaOMe, MeOH, 24 h. 
 
Table 1 Antiproliferative activities of compounds 21af, 22af, 23af and 24af 
 
Table 2 Antiproliferative activities of compounds 25af, 26af, 27af and 28af 
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Table 1 
Growth Inhibition, % ± SEM 
[calculated IC50 (μM)] 
Conc. 
(M) 
HeLa SiHa MCF-7 
MDA-MB-
231 
21 
a 
10 
30 
<20 
<20 
21.28±1.88 
28.71±2.20 
<20 
46.42±1.47 
<20 
<20 
b 
10 
30 
<20 
39.86±.38 
<20 
<20 
<20 
57.42±1.77 
<20 
29.88±1.57 
c 
10 
30 
<20 
40.22±1.02 
<20 
<20 
<20 
70.84±1.55 
<20 
37.96±1.55 
d 
10 
30 
<20 
44.16±0.48 
<20 
<20 
<20 
54.93±1.78 
<20 
38.28±1.84 
e 
10 
30 
<20 
37.18±1.65 
23.91±1.61 
54.72±0.48 
34.23±3.10 
76.26±0.72 
<20 
35.93±2.13 
f 
10 
30 
<20 
41.03±0.77 
28.06±1.99 
57.69±1.12 
29.45±1.67 
70.23±1.35 
<20 
34.81±2.88 
22 
a 
10 
30 
<20 
<20 
25.55±1.01 
34.78±2.47 
<20 
57.43±1.91 
<20 
<20 
b 
10 
30 
<20 
<20 
<20 
26.57±2.26 
<20 
67.59±1.65 
<20 
<20 
c 
10 
30 
<20 
<20 
<20 
29.90±2.59 
<20 
69.68±0.77 
<20 
<20 
d 
10 
30 
<20 
<20 
<20 
29.96±1.79 
<20 
70.75±1.05 
<20 
14.54±1.32 
e 
10 
30 
<20 
<20 
<20 
38.69±2.09 
<20 
63.12±2.14 
<20 
<20 
f 
10 
30 
<20 
<20 
<20 
37.79±1.04 
22.02±1.61 
50.94±1.55 
<20 
<20 
23 
a 
10 
30 
<20 
31.14±1.28 
<20 
<20 
<20 
28.72±0.93 
<20 
25.08±3.15 
b 
10 
30 
<20 
58.25±2.03 
<20 
<20 
<20 
48.01±1.31 
<20 
<20 
c 
10 
30 
<20 
<20 
30.97±2.69 
33.89±2.35 
<20 
<20 
<20 
<20 
d 
10 
30 
<20 
26.90±2.15 
<20 
<20 
<20 
63.27±0.82 
<20 
<20 
e 
10 
30 
<20 
<20 
<20 
37.53±3.00 
<20 
33.94±0.75 
<20 
28.19±0.96 
f 
10 
30 
<20 
26.61±0.57 
29.13±1.59 
43.85±3.32 
<20 
38.45±1.93 
<20 
43.85±3.32 
24 
a 
10 
30 
<20 
89.01±0.47 
<20 
<20 
<20 
78.65±0.78 
<20 
46.21±1.54 
b 
10 
30 
<20 
34.18±0.81 
<20 
<20 
<20 
31.07±2.36 
<20 
<20 
c 
10 
30 
<20 
49.11±0.55 
<20 
<20 
<20 
43.22±1.52 
<20 
<20 
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d 
10 
30 
<20 
42.13±1.66 
<20 
<20 
<20 
55.41±0.76 
<20 
<20 
e 
10 
30 
<20 
83.66±0.34 
<20 
42.06±2.50 
<20 
70.11±1.06 
<20 
50.27±2.00 
f 
10 
30 
<20 
84.77±1.18 
<20 
29.80±1.66 
22.34±2.06 
68.27±1.19 
<20 
47.74±1.21 
cisplatin 
10 
30 
42.61±2.33 
99.93±0.26 
[12.43] 
86.84±0.50 
90.18±1.78 
[7.84] 
53.03±2.29 
86.90±1.24 
[5.78] 
20.84±0.81 
74.47±1.20 
[19.13] 
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Table 2 
Growth Inhibition, % ± SEM 
[calculated IC50 (μM)] 
 
Conc. 
(M) 
HeLa SiHa MCF-7 
MDA-MB-
231 
NIH-3T3 
25  
a 
10 
30 
44.94±1.04 
52.45±2.39 
21.17±2.05 
66.23±0.86 
41.71±0.64 
64.32±0.56 
47.32±1.15 
71.49±0.75 
44.91±1.36 
91.28±0.50 
b 
10 
30 
 
51.49±3.62 
62.58±2.21 
 
49.36±1.69 
73.94±2.04 
 
44.58±1.50 
50.52±3.26 
 
93.00±0.26 
93.71±0.09 
[3.33] 
44.81±1.50 
59.09±0.73 
 
c 
10 
30 
54.70±1.88 
53.66±2.56 
49.58±2.11 
61.83±2.77 
44.04±3.32 
59.33±2.99 
77.13±1.07 
88.81±0.55 
[5.91] 
 
d 
10 
30 
 
64.14±0.86 
90.12±0.99 
[2.28] 
70.88±1.03 
94.14±0.29 
[4.05] 
73.41±1.22 
80.16±3.40 
[3.91] 
95.04±0.16 
95.60±0.06 
[3.65] 
95.60±0.25 
98.22±0.04 
[3.34] 
e 
10 
30 
<20 
92.12±0.25 
<20 
89.25±0.68 
41.63±2.83 
97.00±0.11 
21.96±0.73 
95.22±0.91 
 
f 
10 
30 
45.08±0.72 
39.39±0.49 
41.26±1.25 
52.60±1.31 
55.41±1.26 
62.52±0.67 
55.57±1.50 
88.92±0.99 
 
26  
a 
10 
30 
 
37.98±2.68 
96.56±0.11 
 
<20 
96.71±0.17 
 
72.42±2.19 
98.72±0.09 
[6.11] 
46.43±2.05 
97.96±0.17 
 
85.50±1.22 
97.63±0.12 
[5.97] 
b 
10 
30 
38.55±1.32 
43.97±2.23 
<20 
<20 
31.80±1.35 
84.44±0.71 
17.13±2.36 
37.72±2.28 
 
c 
10 
30 
36.30±1.45 
35.53±1.24 
<20 
<20 
24.95±2.15 
74.73±1.00 
<20 
<20 
 
d 
10 
30 
<20 
22.15±1.29 
<20 
<20 
47.25±1.78 
57.30±0.77 
45.55±2.63 
59.79±1.22 
 
e 
10 
30 
 
<20 
96.98±0.33 
 
<20 
96.91±0.14 
 
68.51±0.71 
99.12±0.07 
[6.53] 
89.24±0.70 
97.73±0.23 
[5.69] 
31.41±2.21 
99.01±0.05 
[11.75] 
f 
10 
30 
21.62±3.46 
30.79±2.92 
<20 
27.28±1.90 
29.14±2.06 
43.28±1.53 
40.46±2.98 
76.93±1.60 
10.00±1.01 
23.40±0.60 
27  
a 
10 
30 
24.26±2.63 
85.22±1.32 
34.00±1.43 
82.68±1.25 
58.38±3.20 
97.21±0.10 
56.24±0.98 
84.18±0.44 
25.56±2.21 
99.24±0.07 
b 
10 
30 
37.10±1.77 
52.08±2.08 
39.59±1.17 
69.54±1.24 
51.92±1.00 
65.12±1.91 
56.44±0.98 
71.81±0.96 
 
c 
10 
30 
 
38.89±2.60 
55.93±2.39 
 
64.05±1.24 
83.34±1.31 
[9.29] 
49.68±1.66 
61.26±1.72 
 
72.37±1.27 
85.81±1.04 
[6.74] 
13.99±1.79 
29.56±1.17 
 
d 
10 
30 
34.23±1.39 
47.74±0.78 
30.04±2.07 
39.96±2.34 
47.03±1.25 
42.43±1.69 
55.77±1.03 
57.71±1.00 
 
e 
10 
30 
<20 
99.06±0.09 
21.53±1.81 
96.91±0.06 
35.74±1.33 
98.50±0.93 
<20 
99.01±0.52 
 
f 
10 
30 
<20 
98.72±0.13 
24.65±1.46 
96.04±0.25 
25.50±2.93 
98.41±0.15 
24.79±2.20 
98.79±0.16 
 
28  
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a 
10 
30 
35.48±1.91 
63.44±1.79 
46.07±1.13 
69.86±0.55 
52.88±0.82 
73.39±0.74 
25.61±2.84 
52.16±2.52 
 
b 
10 
30 
39.75±2.45 
47.34±1.62 
<20 
<20 
43.51±1.85 
42.28±1.44 
44.86±0.93 
43.73±2.25 
 
c 
10 
30 
56.71±0.57 
58.21±0.73 
39.93±3.14 
31.15±2.86 
48.56±0.48 
49.93±1.33 
30.30±1.64 
31.60±3.08 
 
d 
10 
30 
 
74.18±1.15 
91.17±0.33 
[2.30] 
76.88±0.49 
87.39±0.86 
[4.14] 
75.97±0.89 
88.99±0.25 
[3.87] 
86.12±0.33 
90.72±1.00 
[3.89] 
70.18±1.15 
91.12±1.64 
[3.71] 
e 
10 
30 
27.42±2.16 
92.94±0.17 
<20 
91.91±0.23 
52.86±1.30 
96.38±0.07 
29.58±1.69 
94.09±0.43 
 
f 
10 
30 
30.97±1.02 
91.88±0.26 
39.85±1.24 
90.94±0.18 
50.60±0.65 
95.12±0.10 
31.89±2.92 
92.56±0.34 
 
cisplatin 
10 
30 
42.61±2.33 
99.93±0.26 
[12.43] 
86.84±0.50 
90.18±1.78 
[7.84] 
53.03±2.29 
86.90±1.24 
[5.78] 
20.84±0.81 
74.47±1.20 
[19.13] 
94.20±0.39 
96.44±0.17 
[3.23] 
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Scheme 1. Reagents and conditions: (i) NaOMe, HCOOEt, anhydrous toluene, 50 °C; (ii) 
KBH4, MeOH; (iii) KOAc, CH3COOH, NaOMe/MeOH 
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